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ABSTRACT
A common treatment for prostate cancer, which is the most common form of
cancer after skin cancer in Australian males, is androgen deprivation therapy (ADT).
However, ADT is associated with an array of adverse effects including reduced bone and
lean mass, loss of muscle strength, negative change in lipid profile, and increased risk of
cardiovascular disease (CVD) as well as diabetes, all of which can compromise physical
function and quality of life. Physical exercise has been suggested as a key lifestyle
intervention for this group of cancer patients as it has enormous potential to limit and
even reverse the effects of such treatment toxicities. This thesis is comprised of a review
of the literature and three experimental chapters examining the effects of androgen
deprivation therapy (ADT) and the role of exercise in ADT treated prostate cancer
patients. The review of literature provides a background to cancer, in particular prostate
cancer and the commonly reported side effects of treatment. The review identified gaps in
the literature that highlighted the need for well controlled and longer term experimental
studies to: 1) investigate the impact of androgen deprivation therapy duration on
cardiovascular and metabolic outcomes, and 2) investigate the effects of a long term
exercise intervention in reversing cardiovascular risk factors and unfavourable alterations
in the metabolic profile.
Study 1 examined the feasibility and safety of a maximal treadmill exercise test in
ADT treated prostate cancer patients as this was a key assessment of physiological
response to the exercise intervention. One hundred and twelve prostate cancer patients
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undergoing ADT took part in a physician supervised multistage maximal stress test (Bruce
protocol). Of these men, 85% were able to meet the criteria for the attainment of VO 2max
whilst three positive tests (3.2%) were observed. The three participants who recorded a
positive stress test were sent for further examination and subsequently cleared of any
serious issues. Apart from the relatively low VO2max (10-15th percentile), compared to
healthy age matched controls, the cardiovascular response to exercise is similar in this
cancer population. Maximal exercise testing in this population was demonstrated to be
feasible and safe providing a direct assessment of VO2max whilst treatment duration did
not appear to influence the cardiovascular responses to exercise.
Study 2 was a cross-sectional design comparing chronic versus acute ADT treated
patients to examine if therapy time exposure leads to additional risk factors for CVD and
metabolic toxicities in prostate cancer patients. One hundred and seven men undergoing
ADT for treatment of prostate cancer were stratified into two groups, either acute (<3
months) or chronic (>3 months) exposure. Chronic ADT exposure was associated with a
17% reduction maximal aerobic capacity (-0.4 L.min-1) and an 8% reduction in resting
metabolic rate (-147 kcal/24hr). The chronically exposed group also exhibited 8-22% lower
maximal strength values (chest press -5.9kg, seated row -3.9kg, leg press -27.5kg and leg
extension -12.2 kg) and a corresponding decrement in physical function variables ranging
from 9-16% (400m walk +24.9s, chair rise +2.0s, and stair climb +0.7s). Whilst not
significant, there was also a trend towards a decrease in lean mass of 3.5% (-2.1kg) and an
increase in fat mass of 6.5% (1.5kg) in the chronically suppressed group. ADT exposure did
in fact have a negative effect on CVD risk factors as well as physical function outcomes.
viii

Whilst the exact mechanisms remain unclear as to why these cardiovascular alterations
and physical function variables are further declining as treatment time progresses, it is
possible that factors other than those assessed in this study, such as reduced physical
activity levels, may have influenced the results.
Study 3 utilised a randomized controlled trial (RCT) study design to examine the
long-term effects (6 months) of a combined aerobic and resistance training intervention in
reducing or stabilizing CVD and diabetes risk factors in men receiving ADT. Participants
were randomly allocated to either an exercise (EX) group (n= 50) or a control (CON) group
(n= 48). The combined aerobic and resistance training program consisted of twice weekly
clinic based sessions at which the participants completed 20mins of aerobic activity (7090% maximal intensity) and 6 resistance based exercises targeting the major upper and
lower body muscle groups. In addition, participants were prescribed a home based
training program consisting of 110 minutes of aerobic activity. The control group were
instructed to adhere to their usual lifestyle and care routine. Body composition [lean
mass 1.1% (+0.8kg), fat mass -4.2% (-1.1kg) & body fat -3.8% (-1.1kg], muscular strength
[chest press 9.6% (+3.6kg), seated row 7% (+6.0kg), leg press 14.8% (+20kg) & leg
extension 19.4% (+10.2kg)], muscular endurance [chest press 49.4% (+5.0 reps) & leg
49.9% (+7.7 reps)] and 400m walk [-4.8% (-13s)] significantly improved (p<0.05) following
the exercise intervention. There was a trend [5% (0.1 L.min-1)] towards an increase in
maximal cardiorespiratory capacity with no change in other measures of physical function,
central blood pressure parameters, resting metabolic rate or hemodynamic profile. This is
the first study to demonstrate the effectiveness of a large scale long term multi-centre
ix

RCT exclusively in prostate cancer patients undergoing ADT. The extended duration of the
exercise intervention is thought to have led to the favourable adaptation in total fat mass
that has not previously been reported in this group of cancer patients. This trial further
substantiated the safety and efficacy of a combined aerobic and resistance training
intervention and provided support for structured exercise interventions to be considered
a key component of the overall course of treatment for men undergoing ADT for the
treatment of prostate cancer.
This research has demonstrated that: 1) maximal cardiorespiratory exercise testing
is safe and feasible in this population, 2) prolonged exposure to androgen deprivation
therapy (>3 months) has a negative impact on a number of cardiovascular, metabolic and
physical function outcomes, and 3) a combined aerobic and resistance training program
can be safely undertaken in men undergoing ADT and results in an array of benefits for
cardiovascular and metabolic outcomes as well physical function. As a result of these
findings, patients prescribed ADT for the treatment of prostate cancer should be
appropriately counselled as to the negative side effects commonly associated with this
form of treatment and be made aware of the safety and beneficial effects an
appropriately administered exercise intervention can have on reversing these adverse
alterations occurring throughout the course of treatment. Further, these specifically
designed exercise interventions should be commenced as soon as practically possible post
prostate cancer diagnosis and continue for the course of treatment and ideally beyond.
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CHAPTER 1

General Thesis Introduction

Introduction to prostate cancer
Prostate cancer is the most common form of invasive cancer in men and is the
second most common cause of cancer death in males (Jemal, et al., 2008; Welfare, 2011).
Prostate cancer is defined as a malignant tumour (carcinoma) of the prostate gland, a
common form of cancer in elderly men. In most men it progresses slowly over many years
and gives symptoms similar to those of benign enlargement of the prostate (Martin,
2010). Prostate cancer can be classified into different disease stages such as localised,
locally advanced and metastatic disease. Each year ~18,700 Australian men are diagnosed
and more than 3,000 die from the disease (Welfare, 2011). Age is the most common risk
factor for developing prostate cancer with 63% of cases occurring in men 65 years and
older (Ries, et al., 2008).

Testing & treatment options
The two most common tests for prostate cancer are the prostate specific antigen (PSA)
test and the digital rectal examination (DRE). The introduction of the PSA blood test has
led to much wider screening taking place resulting in earlier diagnosis and subsequently
extended treatment times. Men with prostate cancer are often faced with numerous
treatment options including various radiation therapy techniques, surgical approaches,
androgen deprivation therapy (ADT) or active surveillance (Nguyen, et al., 2011a). The
modality of treatment, particularly during the early stages of prostate cancer remains
controversial with a recent study by Wilt, et al. (2012) suggesting that when compared to
observation, radical prostatectomy did not reduce all-cause mortality or prostate cancer
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mortality in men with clinically localised cancer, diagnosed after PSA testing. This adds to
the body of literature supporting active surveillance as the preferred method of treatment
in men with localised prostate cancer, in particular those with low PSA or low risk disease
(Bill-Axelson, et al., 2011; Thompson, 2010; Wilt, et al., 2008).
As a result of the landmark work by Huggins & Hodges (1972; 1941) demonstrating that
testosterone is essential for the growth and development of prostate cancer, treatment
options often target the suppression of testosterone through several mechanisms.
Previously this was commonly achieved via bilateral orchiectomy although more recent
advances have led to the development of less invasive therapeutic castration methods
such as ADT in the form of gonadotropin releasing hormone (GNRH) agonists (Leuprolide
and Goserline) and antagonists (Abrelix). GNRH is a decapeptide hormone synthesised in
the hypothalamus and when GNRH is released it induces the anterior pituitary gland to
release luteinising hormone (LH). Luteinising hormone induces Leydig cells in the testes to
produce testosterone. GNRH agonists mimic GNRH and shuts down LH production (Choi &
Lee, 2011) whilst GNRH antagonists immediately block pituitary GNRH receptors. Despite
differing in actions, both GNRH agonists and antagonists result in suppressing
testosterone levels to castrated levels.
ADT can be used at different stages of the disease usually in combination with
other therapies. Approximately 50% of men with prostate cancer will receive ADT at some
point post diagnosis, with most exposed to this treatment for 2-3 years (Bolla, et al., 2002;
Heidenreich, et al., 2008; Meng, et al., 2002) as it offers improved efficacy when used with
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local therapy such as external beam radiation (Denham, et al., 2005). In the case of
localised prostate cancer a single modality treatment is often used although ADT has been
used as an adjuvant therapy to improve clinical outcomes (Meng, et al., 2002). Localised
advanced prostate cancer usually requires a multimodal approach such as surgery and
adjuvant radiotherapy, chemotherapy and ADT or radiotherapy and ADT (Dorff, et al.,
2011; Goharderakhshan, et al., 2000; Gravis, et al., 2013; Schulman, et al., 2000). ADT can
also be used as a salvage treatment in the case of a recurrence of the disease. In patients
with metastatic prostate cancer ADT is usually the first line of treatment (Choi & Lee,
2011).

ADT side effects
Although ADT has significant benefits for patients with prostate cancer, there are
also a number of reported side effects which can be broken into several sub-categories
including metabolic, body composition, physical function and quality of life alterations
(Alibhai, et al., 2010; Braga-Basaria, Muller, Carducci, Dobs, & Basaria, 2006b; Galvao, et
al., 2008b; Smith, et al., 2002a; Smith, et al., 2008). Metabolic complications include
insulin resistance, hyperglycemia, increased incidence of diabetes, dislipidemia and the
resultant metabolic syndrome (Braga-Basaria, et al., 2006a; Smith, et al., 2008). Closely
related to metabolic complications are body composition changes experienced when
undergoing ADT. Alterations include an increased abdominal circumference, increased fat
mass, reduced lean body mass and reduced bone mineral density (Galvao, et al., 2008b;
Smith, et al., 2002a; Smith, et al., 2008). Physical function has been reported to decline in
patients undergoing ADT (Alibhai, et al., 2010) largely due to reduced muscular strength
4

and endurance (Galvao, et al., 2008b). The reduced level of physical function is also closely
related to increased reported levels of fatigue (Herr & O`Sullivan, 2000). All side effects act
to reduce the patient’s quality of life. Recently a number of reviews have explored the
association between ADT and risk of cardiovascular disease (CVD). Several large
population based studies have reported positive correlations between ADT and both
cardiovascular morbidity and mortality (Keating, O'Malley, Freedland, & Smith, 2009;
Keating, O'Malley, & Smith, 2006; Levine, et al., 2010; Saigal, et al., 2007), however
controversy surrounds this association with Nguyen, et al. (2011b) finding in a pooled
analysis of RCT’s, that ADT use was not associated with an increased risk of cardiovascular
death but was associated with a lower risk of prostate cancer-specific mortality and allcause mortality. Blankfield (2012), however, has questioned the validity of the Nguyen et
al. (2011b) findings due to the possibility of bias in some of the studies reviewed, with the
time interval of ADT being less than the duration of the data collection period in 6 of the 8
studies. Blankfield (2012) has suggested that it is problematic to use such studies to detect
whether there is an association between ADT and cardiovascular death. Whilst there is
still controversy surrounding the association between ADT and cardiovascular disease and
mortality, interventions aimed at reducing CVD risk factors and metabolic toxicities should
still be explored.
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Strategies to counter the adverse treatment effects
Current treatments used to alleviate the side effects of ADT are predominantly
pharmaceutical in the form of anti-hypertensive medications, lipid lowering medications
and bisphosphonates (Smith, et al., 2011). Although these treatments target specific side
effects of ADT, they don’t improve physical function, fatigue or quality of life. Further
there are substantial costs associated with pharmacological interventions as well as the
issue of additional potential side effects of these medications (Smith, et al., 2011).
Research has shown positive effects of resistance training for the management of
treatment-related toxicities in terms of musculoskeletal health, quality of life, functional
performance and balance (Galvao, et al., 2006; Segal, et al., 2003b). Given that
cardiorespiratory fitness attenuates overall mortality risk with regard to CVD (Ekelund, et
al., 1988), it is thought that the addition of a suitable aerobic component to a resistance
training program could have greater effects on treatment-related side effects than
resistance training alone. Limited research has explored the role of a combined aerobic
and resistance training intervention on cardiovascular health endpoints in ADT treated
patients as a countermeasure to reduce cardiovascular and metabolic toxicities.
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Significance of the research
Prostate cancer is now the most common form of cancer after skin cancer in
Australian and American males (Jemal, et al., 2008; Sharifi, Gulley, & Dahut, 2005b; Siegel,
Naishadham, & Jemal, 2012). The use of ADT for prostate carcinoma has increased
extensively across all stages and histologic grades of prostate cancer in the past several
years (Cooperberg, Moul, & Carroll, 2005). The work contained within this thesis will
establish whether maximal exercise testing is feasible and safe in this population whilst
also identifying if the length of ADT exposure predisposes patients to additional CVD risk
factors and negative metabolic and physical function alterations. The role of exercise will
also be explored as a potential strategy to reduce risk factors associated with
cardiovascular and metabolic complications and may also reduce the incidence of comorbidities associated with androgen suppression (e.g. CVD, obesity, metabolic syndrome
and diabetes) as well as improving physical function. Further, the use of physical activity
may be a simple and cost effective strategy that provides similar benefits to
pharmaceutical interventions (e.g. cholesterol and blood pressure lowering, etc.) without
exposing patients to additional potential side effects and financial cost. Finally this work
will further refine position statements in the newly established field of exercise oncology
(Hayes, Spence, Galvão, & Newton, 2009; Rock, et al., 2012; Schmitz, et al., 2011).
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Purpose of the research
This thesis is comprised of interrelated studies examining the effects of androgen
deprivation therapy (ADT) and the role of exercise in ADT treated prostate cancer
patients. First, the aim is to investigate the feasibility and safety of maximal exercise
testing in this population (study 1). The aim of study 2 is to explore if therapy time
exposure leads to additional risk factors for CVD and metabolic toxicities in a crosssectional study design by comparing chronic versus acute ADT treated patients. The
purpose of study 3 is to examine the effects of exercise on reducing or stabilizing CVD and
diabetes risk factors in men receiving ADT for their prostate cancer in a randomized
controlled trial study design. Specifically, it is aimed to investigate the long-term effects (6
months) of exercise specifically designed to reduce CVD and diabetes disease progression
on the following endpoints: 1) cardiorespiratory function and maximal oxygen capacity, 2)
vascular function and blood pressure, 3) resting metabolic rate, 4) lipids and glycaemic
control, 5) body composition (lean mass and fat mass), and 6) physical and muscle
function.

8

Hypotheses
Study 1: It is hypothesised that maximal exercise testing will be a feasible and safe testing
method which will:
1. provide a useful pre-activity screening tool and a direct assessment of
cardiorespiratory capacity; and
2. provide descriptive data to demonstrate ADT treated prostate cancer patients
respond to maximal exercise in a similar way to healthy age-matched controls.
Study 2: It is hypothesised that there will be differences between chronic versus acute
ADT with chronic ADT exposure being associated with:
1. increased number of risk factors for metabolic syndrome in terms of blood
pressure, body composition, lipids and glucose metabolism;
2. decreased vascular compliance in terms of higher brachial and central blood
pressure; and
3. decreased overall physical function and muscular strength outcomes.
Study 3: Compared to the control (usual care) group, the effects of a 6-month combined
aerobic and resistance exercise program will:
1. increase cardiorespiratory capacity in terms of maximal oxygen capacity (VO2max);
2. reduce brachial and central systolic and diastolic blood pressure;
3. improve metabolic profile including lipids and glucose metabolism;
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4. improve body composition by increasing whole body and regional lean mass and
reducing whole body and regional fat mass as well as reducing abdominal obesity
(waist circumference) ; and
5. increase overall physical and muscle function.
Overall, these positive effects of the intervention are hypothesised to reduce the risk
factors for metabolic syndrome and cardiovascular disease in this population.
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Definitions of Terms
Prostate Cancer: a malignant tumour (carcinoma) of the prostate gland, a common form
of cancer in elderly men. In most men it progresses slowly over many years and gives
symptoms similar to those of benign enlargement of the prostate (Martin, 2010).
Prostate Specific Antigen: an enzyme produced by the glandular epithelium of
the prostate. Increased quantities are secreted when the gland becomes enlarged or
inflamed, and levels of PSA in the blood are significantly elevated in cancer of
the prostate. Although there is no clear ‘cut-off’ level for normality, over 4 ng/ml in the
blood is associated with a 20% increased risk of prostate cancer, even in patients with
normal-feeling prostates on rectal examination. Newer PSA assays can measure free PSA
and compare it to the total PSA in the blood. Low free:total PSA ratios indicate a greater
risk of prostate cancer and improve the discrimination between cancer and benign disease
in men with a PSA in the range 4–10 ng/ml. PSA levels tend to be much higher in
advanced prostate cancer and the rate of fall on treatment (e.g. after radical
prostatectomy or radiotherapy) is a good prognostic indicator of response (Martin, 2010).
Cardiovascular Disease: A disease affecting the heart or blood vessels. The cardiovascular
system includes the heart together with two networks of blood vessels – the systemic
circulation and

the pulmonary

circulation.

The cardiovascular system

effects

the

circulation of blood around the body, which brings about transport of nutrients and
oxygen to the tissues and the removal of waste products (Martin, 2010).
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Androgen Deprivation Therapy: A type of hormone therapy that acts to inhibit the action
of androgen, in this case testosterone. These act in the hypothalamic pituitary testicular
axis to inhibit the production of testosterone and or block testosterone receptors (Smith,
2001).

12
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ADT – Androgen Deprivation Therapy
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CHAPTER 2

Review of Literature
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Cancer introduction and common sites
Cancer is defined as any malignant tumour which arises from the abnormal,
purposeless and uncontrolled division of cells that then invade and destroy the
surrounding tissue (Martin, 2010). Cancer cases can be defined by locations that include
the oral cavity and pharynx, digestive, respiratory, bones and joints, soft tissue, breast,
genital, urinary, eye and orbit, brain and other nervous system, endocrine, lymphoma,
myeloma and leukaemia (Siegel, et al., 2012). The spread of cancer cells may occur via the
bloodstream or the lymphatic channels or across body cavities such as the pleural or
peritoneal spaces, thus setting up secondary tumours at sites distant from the original
tumour (Martin, 2010). Cancer is a major public health concern with 108,368 new cancer
cases diagnosed in Australia in 2007 and is expected to reach 150, 000 in 2020 (Welfare,
2011). This review will focus on some of the more common forms of diagnosed cancers
including breast, colorectal and prostate cancers.

Breast, colorectal and prostate cancers
Breast cancer is a malignant tumour of the breast, usually a carcinoma and in rare
instances a sarcoma (Martin, 2010). It is the most common form of invasive cancer in
women with approximately 12,670 cases in Australia in 2007, or 27% of all cancer
diagnoses (Welfare, 2011). Prostate cancer was the most commonly diagnosed cancer in
Australia in 2007 with 19,403 cases reported. As with breast cancer, prostate cancer is a
malignant tumour, although the location of the tumour originates in the prostate gland.
Prostate cancer is often a slowly progressing disease that gives symptoms similar to those
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of benign enlargement of the prostate. Prior to the introduction of the prostate specific
antigen test, many prostate cancer cases were not detected through clinical presentation
until the later stages of the disease where the tumour had invaded locally, possibly to
regional lymph nodes and metastasized (Martin, 2010). Colorectal cancer, commonly
known as bowel cancer includes tumour growth of the colon, rectum or small bowel and
was the second highest diagnosed cancer in Australia in 2007 (Welfare, 2011).
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Treatment options
The treatment of cancer is dependent upon several factors including the type of
tumour, the site of the primary tumour and the extent of the tumour spread. The most
common forms of treatment are active surveillance, surgery, radiotherapy and systemic
therapy. Increasingly, combinations of the main cancer treatment modalities listed above
are being used in the treatment of cancer with the type and stage of cancer determining
the timing and sequence of these treatment combinations (Dorff, et al., 2011; Kelly, et al.,
2012).

Active Surveillance
Due to the concern that prostate cancer screening has led to the diagnosis and
treatment of many cancers that would not have become life threatening (Draisma, et al.,
2003), active surveillance with curative intent is becoming an increasingly popular
alternative to immediate treatment (Soloway, et al., 2008). This form of treatment
involves monitoring low risk prostate cancer patients and only providing treatment if
higher risk features are detected during this time. This management strategy involves
serial PSA assessments, repeat biopsies and other tests intended to identify early forms of
progression (Klotz, 2012). This form of treatment has been associated with a prostate
cancer mortality rate of less than 3% 10 years post diagnosis, suggesting it as a safe and
reasonable option for men with low risk prostate cancer (Klotz, et al., 2010). The benefit
of this form of treatment is that patients are not exposed to unnecessary interventions
that result in physical and psychological complications.
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Surgery
Surgical interventions can be used to diagnose, treat and in some cases prevent
certain types of cancer. Surgery often refers to the surgical removal of the tumour and is
favoured when the cancer is in its early stages of progression and localised to a specific
area. Breast cancer surgery can take the form of either a mastectomy, involving the
removal of the entire breast tissue or breast conserving surgery such as a lumpectomy
which involves the partial removal of the breast tissue, as well as axillary lymph node
dissection and breast reconstructive surgery (McNeely, et al., 2012). In the case of
prostate cancer, the surgical intervention is referred to as a radical prostatectomy and
involves the removal of the prostate gland. A review of the Cancer of the Prostate
Strategic Urologic Research Endeavour (CaPSURE) registry has documented surgical rates
of approximately 50% in men with newly diagnosed localised disease (Cooperberg,
Broering, & Carroll, 2010). Studies have shown radical prostatectomy to provide an
excellent long term cancer control outcome in patients with localised disease (Lughezzani,
et al., 2012). Prostate cancer surgery may involve a standard radical prostatectomy or
nerve-sparing radical prostatectomy which represents the surgery of choice in all men
with normal erectile function and confined disease (Heidenreich, et al., 2011). Surgical
resection is still the cornerstone of curative therapy in colorectal cancer treatment despite
the introduction of non-operative management options. Surgical options include sphincter
sparing and non-sphincter sparing procedures depending upon the location and stage of
disease, and these can include local excision, radical dissection, bypass operations and
laparoscopic procedures (Kosinski, Habr-Gama, Ludwig, & Perez, 2012).
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Radiotherapy
Together with surgery and chemotherapy, radiotherapy plays an important role in
oncology, both in definitive and palliative aspects of treatment (Teh, Woo, & Butler,
1999). Since the discovery of X-rays in 1895, radiation has developed into a recognised
medical specialty with radiation oncology being recognised as a discipline in which health
and science professionals work together. The advances in imaging techniques,
computerized treatment planning systems, radiation treatment machines as well as
improved understanding of the radiobiology of radiation therapy has resulted in rapid
progress being made in this field (Baskar, Lee, Yeo, & Yeoh, 2012; Bernier, Hall, & Amato,
2004). Radiotherapy utilises ionizing radiation to control or kill cancerous cells and is used
in approximately 50% of all cancer survivors and contributes towards 40% of curative
treatment for cancer (Baskar, et al., 2012). Radiotherapy is typically delivered in small
doses over a 5 – 8 week period and is designed to damage the DNA of the exposed tissue
resulting in apoptosis (Heidenreich, et al., 2011). This therapy can either be external or
internal depending upon the chosen course of treatment (Baskar, et al., 2012). External
beam radiotherapy is the most common form of radiotherapy and relies upon an external
source of high energy x-rays targeted towards a specific region of the body. Internal beam
radiotherapy or brachytherapy involves the internal placement of short range radiation
sources to more specifically target the desired location and is often used in the treatment
of gynaecological and prostate malignancies (Baskar, et al., 2012). Intensity modulated
radiation therapy which became available in the late 1990’s is now a favourable method
to deliver radiation to the tumours as it has the ability to relatively spare the surrounding
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non-cancerous tissue through its more precise method of radiation delivery (Teh, et al.,
1999). Radiotherapy is often used in combination with other treatment modalities
including surgery, chemotherapy or immunotherapy. In the case of breast cancer, post
mastectomy radiotherapy reduces the incidence of local and regional recurrences by 5075% (Hortobagyi, 1998).

Systemic Therapy
Systemic therapy includes two of the most common forms of cancer treatment;
chemotherapy and hormone therapy. Chemotherapy is the use of chemicals to prevent or
treat cancer and can be administered either intravenously or orally in repeated courses 24 weeks apart over a 3-6 month period (Ayanian, et al., 2003; Du & Goodwin, 2001). It is
most commonly used in combination with other treatments for numerous types of cancer
as either a cure (destruction of cancer cells), to reduce the risk of a reoccurrence, to shrink
the cancer to either assist the primary treatment method and or to improve symptoms
and prolong life.
Hormonal therapies involve the manipulation of the endocrine system through
exogenous administration of specific hormones or pharmacological agents to inhibit the
production of certain hormones. Hormonal therapy is well established in the treatment of
breast and prostate cancer. Aromatase inhibitors are the standard hormonal therapy for
postmenopausal women with both early and late stage hormone sensitive breast cancer.
This form of treatment suppresses oestrogen levels in the body and slows the growth of
hormone sensitive breast tumours. Currently third generation aromatase inhibitors are
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being used by medical practitioners as they have been found to have superior results in
terms of disease free survival and time to recurrence when compared to the previous
method of treatment (Howell, et al., 2005).
Androgen deprivation therapy (ADT) has become one of the important advances in
the treatment of prostate cancer (Quon & Loblaw, 2010) and may be delivered in various
forms, all with the aim to block the predominant androgen, testosterone. (Shahinian, Kuo,
Freeman, Orihuela, & Goodwin, 2005b). ADT in the form of gonadotropin releasing
hormone (GNRH) agonists and antagonists are frequently used in the treatment of
prostate cancer with GNRH agonists (Leuprolide and Goserline) acting to gradually downregulate the pituitary for GNRH resulting in the inhibition of the secretion of
gonadotropins whilst the GNRH antagonists (Abrelix) immediately block pituitary GNRH
receptors achieving rapid therapeutic effects (Engel & Schally, 2007). Other hormonal
interventions targeting the suppression of androgens include adrenal ablating drugs
(Ketoconazole) which act on the adrenal gland to decrease androgen synthesis from
steroid precursors through the inhibition of cytochrome P450 enzymes. Androgen
receptor antagonists (flutamide, bicalutamide and nilutamide) act to inhibit androgen
receptor ligand-binding domain through competitive binding whilst 5α-reductase
inhibitors (finasteride) decreases the conversion of testosterone to dihydrotestosterone
through the inhibition of 5α-reductase (Sharifi, et al., 2005b).
ADT is used in a variety of settings including primary treatment, as adjuvant
therapy to radical therapy and in the setting of biochemical relapse (Alibhai, Gogov, &
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Allibhai, 2006). As a result ADT is the most widely used systemic treatment for prostate
cancer with almost 50% of men diagnosed with prostate cancer are expected to receive
ADT at some point during treatment (Keating, et al., 2009; Meng, et al., 2002).
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Treatment associated side effects
Surgery
The most common side effects or risks associated with surgical interventions are
surgical site infections (SSI). The level of risk for developing a SSI is dependent upon the
type of operation, comorbidities of the patient as well as perioperative therapy (Canavese,
et al., 1997; Xue, Qian, Yang, & Wang, 2012). Breast cancer surgery side effects are
typically related to the operative details (Canavese, et al., 1997; Xue, et al., 2012)
including cellulitis, flap necrosis, abscess, dehiscence and hematoma (McNeely, et al.,
2012). The rate of surgical site infections can range from 1% to 30% depending upon
numerous factors including the definition of a surgery site infection, nature of the
operation, follow up times, perioperative therapy and reporting institution (Canavese, et
al., 1997). These infections are major sources of postoperative morbidity and mortality. In
terms of prostate cancer related surgery side effects, radical prostatectomy is associated
with impaired urinary control (incontinence) and sexual complications (Boorjian, et al.,
2012; Michaelson, et al., 2008). Urinary incontinence is more common after surgical
therapy than after radiation therapy (Mirza, Griebling, & Kazer, 2011). Rates of erectile
dysfunction have varied from 10% to 100% (Akbal, Tinay, Simşek, & Turkeri, 2008) with
the large variance possibly due to differences in surgical techniques, population
demographics, timing of investigation and variations in baseline erectile function amongst
others (Mirza, et al., 2011). These side effects have been shown to negatively impact a
patient’s quality of life (Miller, et al., 2005). Colorectal cancer surgery side effects are
often associated with complications arising from the surgery itself and can include
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anastomotic complication such as bleeding, leaks, strictures and fistulas (Jung, et al.,
2008).

Radiotherapy
Radiotherapy is an important treatment in cancer patients and forms part of the
management of 40% of patients cured for their disease (Tubiana, 1992). Whilst significant
advances have been made in the past 2 decades due to improvements in engineering and
computing, radiotherapy related side effects are still common. These side effects are
commonly associated with the anatomical location of the radiotherapy fields (Ahmad,
Duke, Jena, Williams, & Burnet, 2012). Radiotherapy related side effects can generally be
classified as either early or late side effects with early side effects being reversible.
General side effects of radiotherapy, independent of location include; fatigue,
gastrointestinal issues, skin problems and loss of appetite. Fatigue is the most common
side effect with approximately 80% of patients on radiotherapy experiencing some form of
fatigue (Jereczek-Fossa, Marsiglia, & Orecchia, 2002). Whilst generally classified as an
early side effect peaking 2 weeks post radiotherapy and improving 4 weeks post
treatment, fatigue has been reported as a chronic, or late side effect in 30% of cases
(Jereczek-Fossa, et al., 2002).
The likelihood of specific side effects is dictated by the dose fractionation
schedule, site treated and any pre-existing comorbidities (Ahmad, et al., 2012). The
location specific side effects associated with radiotherapy can include breast oedema, fat
necrosis, breast fibrosis, lactation difficulty and in some instance bone fractures in breast
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cancer radiotherapy treatment (Yi, et al., 2009) whilst external beam or interstitial
radiation therapy in men with localised prostate cancer may lead to bowel, urinary and
sexual complications (Akbal, et al., 2008; Michaelson, et al., 2008). These location specific
side effects mentioned are all in addition to the general radiotherapy side effects detailed
above.

Systemic Therapy
Chemotherapy side effects are typically dependent upon the type of medication
used. Regardless of cancer type, fatigue is one of the most commonly reported side
effects of all chemotherapy treatments (Jacobsen, et al., 1999) and has the ability to
impair health related quality of life (Lindley, et al., 1992). As a result of the nature of
chemotherapy the immune system is often suppressed predisposing patients to numerous
illnesses and infections (Canavese, et al., 1997). In addition to these symptoms,
gastrointestinal issues (nausea and vomiting) have been reported to be experienced in
approximately 55% of patients whilst hair loss is another major side effect also
experienced by 55% of patients with baldness rates of approximately 3% (Canavese, et al.,
1997). Side effects can also be site specific with patients experiencing chemotherapy
induced peripheral neuropathy resulting from damage to or dysfunction of peripheral
nerves (Stubblefield, McNeely, Alfano, & Mayer, 2012).
Third generation Aromatase Inhibitors (AI) have been associated with an increased
risk of osteoporosis and/or fractures in large adjuvant breast cancer trials (Eastell, et al.,
2006). Furthermore, approximately 25% of postmenopausal women undergoing AI
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treatment report arthralgia, skeletal and muscle pain (Morales, et al., 2007) which can
limit the patient’s compliance to the treatment as well as negatively impacting their
quality of life over a prolonged period of time. Vasomotor symptoms such as hot flashes
are the more common side effects with Macquart-Mouline et al., (1997) reporting hot
flushes in 58% of patients undergoing a chemotherapy cycle whilst numerous other side
effects are also reported such as vaginal discharge, vaginal dryness and dyspareunia that
vary in prevalence (Macquart-Mouline, et al., 1997).
ADT has traditionally been used as a treatment during the latter stages of the
development of prostate cancer (e.g. the presence of metastases) (Moyad, 2005).
However, the development of the PSA blood test has meant that earlier detection of
prostate cancer is now possible through better screening, resulting in patients now
undergoing ADT in earlier stages of the disease with ADT now recognised as a primary
treatment method for prostate cancer (Keating, et al., 2009; Meng, et al., 2002). Although
ADT may improve prostate cancer survival, this widely employed treatment option is also
associated with a number of adverse effects relating to treatment toxicities (Chen &
Petrylak, 2005). The risks of co-morbidity related conditions are increased in this group of
cancer patients with side effects including reduced bone and lean mass, loss of muscle
strength, negative change in lipid profiles, vasomotor flushing, fatigue, and increased risk
of cardiovascular disease as well as numerous metabolic complications all of which can act
to compromise physical function and quality of life (Basaria, Muller, Carducci, Egan, &
Dobs, 2006; Galvao, et al., 2008b; Greenspan, et al., 2005; Shahinian, Kuo, Freeman, &
Goodwin, 2006; Sharifi, Gulley, & Dahut, 2005a; Smith, et al., 2002b). This array of side
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effects related to ADT affecting the musculoskeletal system and physiological function has
been previously described as “Androgen Deprivation and Sarcopenia-Related Disorders”
(Galvao, Taaffe, Spry, & Newton, 2007a).
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Cancer Related Cardiovascular Alterations
Chemotherapy
The presence of both cancer and cardiovascular disease is becoming more
prevalent due to our aging population and overall prevalence of risk factors associated
with CVD. This has meant that oncologists must now be aware of cardiovascular risks
associated with certain forms of treatment, to either avoid or prevent treatment-related
cardiotoxicities. In addition to the pre-existing cardiac risk factors, cardiotoxicities can also
be dependent upon the type of drugs used, dose and schedule employed, and the age of
patients as well as previous mediastinal irradiation (Sereno, et al., 2008). Specific
examples have been reported such as women who have been treated with chemotherapy
are reported to be more likely to experience subsequent cardiac disease when compared
with those not treated with chemotherapy (Shenoy, et al., 2011). However, these
cardiotoxicities associated with chemotherapy are in fact more related to the type of
chemotherapeutic chosen and dosage amounts, rather than the type of cancer being
treated. For example, certain chemotherapeutic drugs directly damage cardiomyocytes or
cause inflammation of the pericardium whilst others can affect the coagulation system
which can in turn result in cardiovascular and cerebrovascular ischemia as well as
endothelial dysfunction and hypertension (Albini, et al., 2010).

Radiotherapy
Early reviews, such as that presented by Cuzick et al. (1994) reported a 62%
increase in the incidence of cardiac death associated with radiotherapy for the treatment
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of breast cancer. However radiation techniques have since been refined and older
techniques utilising higher doses of cardiac radiation have been abandoned in favour of
computed tomography guided radiation treatment and has resulted in more precise
delivery of radiation and individualised treatment plans (Giordano, et al., 2005). As a
result, the mortality rate from ischemic heart disease associated with radiation therapy
has significantly decreased since the 1980’s (Giordano, et al., 2005). A recent report by
Darby, et al. (2013) has reported exposure of ionizing radiation to the heart during
radiotherapy for breast cancer increases the subsequent rate of ischemic heart disease in
a linear fashion by 7.4% per gray. Those with pre-existing cardiac risk factors are at a
greater risk from radiotherapy when compared to those with no apparent risk factors
(Darby, et al., 2013).

Combined Chemotherapy and Radiotherapy
Cancer treatment often takes the form of combination therapy involving a mixture
of chemotherapy, radiotherapy or surgery. Although highly successful, combination
therapy does predispose the patient to cardiovascular complications such as heart failure,
myocardial ischemia, hypertension, thromboembolism and arrhythmias (Yeh & Bickford,
2009). Combination therapy can often amplify cardiotoxicities, one such example is the
use of chemotherapy in combination with radiotherapy with this commonly used
combination therapy being associated with a higher rate of heart problems when
compared to either chemotherapy or radiotherapy alone (Albini, et al., 2010).
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Hormonal Therapy
Reviews exploring the association between cardiovascular risks and hormonal
therapy, in particular ADT, are becoming more common with reported metabolic
complications including increased abdominal circumference and obesity, dislipidemia,
insulin resistance and diabetes, hyperglycemia and metabolic syndrome (Alibhai, 2011;
Alibhai, et al., 2009; Collier, Ghosh, McGlynn, & Hollins, 2011; Jefferies, et al., 2011;
Punnen, Cooperberg, Sadetsky, & Carroll, 2011; Van Poppel & Tombal, 2011) which has
led the American Heart Association and American Cancer Society to issue a joint
statement acknowledging that ADT negatively affects traditional CVD risk factors and
discusses the possibility of an association with overall cardiovascular risk (Levine, et al.,
2010).
Recently, several large studies have provided important findings as to additional
risks and toxicities related to ADT by increasing risk of CVD and premature death
(D'Amico, et al., 2007a; Keating, et al., 2009; Keating, et al., 2006; Saigal, et al., 2007; Tsai,
D'Amico, Sadetsky, Chen, & Carroll, 2007; Van Hemelrijck, et al., 2010). Van Hemerlrijck et
al. (2010) conducted one of the largest population based studies (76, 000 prostate cancer
sufferers) utilising a data base for clinical epidemiological prostate cancer research
(PcBaSe, Sweden) confirming the increased relative risk of nonfatal and fatal CVD in all
men with prostate cancer, specifically those undergoing hormone therapy. Keating et al.
(2006) who used the Surveillance, Epidemiology, and End Results (SEER) database found
ADT use was associated with higher risks of incident diabetes, coronary heart disease,
acute myocardial infarction as well as sudden cardiac death. The authors also go further to
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report that short term ADT treatment was significantly associated with greater risks of
disease and the elevated risks persisted in men on longer term therapy (Keating, et al.,
2006). This raises the question as to how long a patient must be undergoing ADT before
experiencing treatment-related toxicities. Saigal and colleagues (2007) also using the SEER
database found that the risk of cardiovascular morbidity was increased within 12 months
of treatment when compared to similar men who did not receive ADT. Further, another
report by D’Amico, Renshaw, Loffredo and Chen (2007b) suggested that even short-term
ADT (3 months) was associated with increased risk of prostate cancer-specific mortality
and all-cause mortality at a similar rate to that seen at 6 months, suggesting that only 3
months of treatment is sufficient to elicit an adverse cardiovascular profile. Basaria and
colleagues (2008) indicate that short-term ADT can increase the risk of insulin resistance,
however, the resultant hyperinsulemia acts to maintain glucose within normal ranges and
it is not until the duration of ADT is extended (long-term ADT) that this compensatory
mechanism fails resulting in hyperglycaemia. A 5-year follow up of patients undergoing
hormonal treatment found the treatment was associated with a 20% higher risk of serious
cardiovascular morbidity (Saigal, et al., 2007), a finding that stresses that there are also
long-term side effects associated with this form of treatment. In more recent work and in
light of the work by Keating and colleagues (2009; 2006), Hu, et al. (2012) investigated the
risk of peripheral artery disease and venous thromboembolism associated with ADT use
and found there was in fact an increased risk of peripheral artery disease (adjusted hazard
ratio 1.16: 95% CI 1.12-1.21) and thromboembolism (adjusted hazard ratio 1.10: 95% CI
1.04-1.15) in an ADT treated cohort. A recent study by Jespersen, Nørgaard, and Borre
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(2013) has investigated the risk of cardiovascular disease including myocardial infarction
and stroke in prostate cancer patients undergoing ADT or orchiectomy and found that ADT
was associated with an increased risk of myocardial infarction and stroke. Whilst
orchiectomy and ADT result in comparable castration levels, a relationship between
orchiectomy and increased risk of cardiovascular disease was not evident. The authors
suggest that ADT could lead to a dysfunction in cardiac receptors regulating cardiac
contractile function which may play an important role in the cardiac pathology in men
receiving ADT. However, this relationship was not evident in men who received
orchiectomy treatment as opposed to pharmacological ADT.
The majority of literature supports an earlier report indicating that CVD is the most
common form of mortality in men with prostate cancer, and not the actual cancer itself
(Lu-Yao, Stukel, & Yao, 2004). As such, it is critical to develop strategies that could
ameliorate treatment adverse toxicities, in particular those related to the musculoskeletal
and cardiovascular systems (Keating, et al., 2006; Smith, 2002). Such is the importance of
these recent findings, a Science Advisory Statement from the American Heart Association,
American Cancer Society and American Urological Association has been released which
suggests there is a substantial amount of data demonstrating ADT adversely affects
traditional cardiovascular risk factors (Levine, et al., 2010). This association does however
remain controversial with Nguyen, et al. (2011b) reporting conflicting findings regarding
ADT and cardiovascular disease risk factors suggesting ADT is not associated with an
increased risk of cardiovascular death. With a large amount of the literature suggesting an
association between ADT and cardiovascular disease (D'Amico, et al., 2007b; Hu, et al.,
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2012; Keating, et al., 2009; Keating, et al., 2006; Saigal, et al., 2007; Tsai, et al., 2007; Van
Hemelrijck, et al., 2010) and Nguyen, et al. (2011b) reporting conflicting findings, it is
evident that more research in necessary to definitively establish the relationship between
ADT and cardiovascular disease.
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Cancer Related Metabolic Alterations
Breast & Colorectal
To date, very little research has investigated the metabolic outcomes associated
with breast or colorectal cancer treatments. Most research in this area has been
concerned with the link between metabolic alterations and the risk of developing cancer
rather than the metabolic outcomes associated with the treatment modality (Esposito,
Chiodini, Colao, Lenzi, & Giugliano, 2012; Rosato, et al., 2011). Such research has
suggested a modest link between impaired glucose metabolism and type 2 diabetes and
the rate of breast cancer incidence (Ehrmann-Josko, et al., 2006; Xue & Michels, 2007).

Prostate
Numerous metabolic complications have been linked to ADT including increased
abdominal circumference/obesity, insulin resistance, hyperglycemia, dislipidemia (Ribeiro,
Camara, Segre, Srougi, & Serrano Jr, 2010; Saylor & Smith, 2009; Smith, et al., 2002a) and
the resultant metabolic syndrome. Metabolic syndrome by definition refers to a clustering
of specific CVD risk factors whose pathophysiology appears related to insulin resistance
(Michaelson, et al., 2008). Metabolic syndrome is classified when patients meet three of
the following five criteria according to the Adult Panel III Criteria ("Executive Summary of
The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult
Treatment Panel III)," 2001); these being fasting plasma glucose level more than
110mg/dL, serum triglyceride levels >150mg/dL, serum high density lipoprotein less than
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40mg/dL, waist circumference greater than 102 cm and blood pressure of >135/80 mmHg.
Patients on anti-hypertensive and anti-lipid medications are also considered positive for
the respective criterion. This syndrome is most important because of its association with
the development of type II diabetes and CVD. In addition to the traditional contributing
risk factors, male hypogonadism has also been shown to be an independent risk factor in
the development of metabolic syndrome (Muller, Grobbee, den Tonkelaar, Lamberts, &
van der Schouw, 2005). An earlier report indicated that 50% of patients undergoing longterm ADT had metabolic syndrome (Braga-Basaria, et al., 2006a) with subsequent analysis
demonstrating abdominal obesity and hyperglycemia were responsible for these higher
prevalence rates.
Basaria and colleagues (2006) have shown that shorter term ADT patients tend to
have significantly higher levels of fasting glucose, insulin and leptin compared to healthy
age-matched controls whilst long-term ADT is associated with higher fasting levels of total
cholesterol, LDL cholesterol and non-HDL cholesterol than non-ADT prostate cancer men
or age-matched healthy controls (Braga-Basaria, et al., 2006b). A large cohort study has
demonstrated increased incidence of diabetes, coronary heart disease and sudden cardiac
death following ADT (Keating, et al., 2006)(Keating, 2009). Alibhai et al. (2009) have also
reported an increased risk of developing diabetes providing a link between glucose and
insulin control and ADT. Keating et al. (2006) first reported the increased risk of diabetes
in 2006 with more than one third of men receiving GnRH agonist use associated with an
increased risk of diabetes. A subsequent follow-up study found a statistically significant
increased risk of incident diabetes at a rate of 159.4 events per 1000 person years vs. 87.5
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events for prostate cancer patients not receiving ADT (adjusted hazard ratio 1.28)
(Keating, et al., 2009). Keating et al. (2009) were also the first to report a possible
association between ADT and the incidence of stroke, whilst this association was further
corroborated by Van Hemelrijck, et al. (2010) who investigated the absolute and relative
risk of cardiovascular disease in a Swedish based prostate cancer register (PCBaSe) and
found an increased relative risk of fatal and non-fatal CVD. Whilst the mechanisms
surrounding the association between ADT and the risk of stroke are unknown it is
postulated that it may result from similar physiological changes that underlie the risk of
coronary vascular disease, such as central obesity, lipid alterations and insulin resistance
(Keating et al., 2009).
It has been proposed that metabolic changes during ADT are in fact different from
those that present during classic metabolic syndrome. Smith et al. (2008) in a prospective
study found in contrast to the classic metabolic syndrome ADT treatment increases
subcutaneous fat mass, HDL cholesterol and adiponectin, but did not alter the waist: hip
ratio, blood pressure or C Reactive protein levels. These results suggest that ADT
treatment results in a pattern of metabolic alterations that are distinct from classic
metabolic syndrome (Smith, et al., 2008).

Body composition
Body composition alterations relating to cancer treatment are primarily associated
with hormonal therapy, in particular ADT for the treatment of prostate cancer. ADT is
frequently accompanied by prompt and often marked changes in body composition with
patients increasing body mass index and fat mass, reducing lean body mass and muscle
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strength and even developing osteoporosis (Galvao, et al., 2008b; Greenspan, et al., 2005;
Smith, et al., 2002a). Sarcopenic obesity is a term now used to describe the combination
of increased body weight in the form of adipose tissue and reduced muscle mass or
strength (Baumgartner, 2000; Zamboni, Mazzali, Fantin, Rossi, & Di Francesco, 2008).
Patients undergoing ADT have shown increases in fat mass of 9.4% to 11.0% in one year
with a concurrent decrease in lean body mass of 2.7% to 3.8% (Smith, et al., 2002b).
Consequently, men on ADT have shown a 5.5-fold increase in risk of being obese
compared to controls after adjusting for age (Chen, et al., 2002). The regional distribution
of fat in response to ADT has been explored in several studies, with Saylor and Smith
(2009) reporting that during ADT, fat accumulation is primarily subcutaneous fat whilst
intra-abdominal fat generally does not change significantly. In a recent study it was
reported that subcutaneous fat accounted for 94% of the observed 16.5% (±2.6%)
increase in abdominal fat area (Smith, et al., 2008). A similar finding was presented by
Galvao et al. (2008b) who found increases in fat accumulation at all regional sites
following 9 months of androgen deprivation, with greater changes seen for the limbs than
the trunk. This highlights one of the more concerning aspects of body composition, being
the limited amount of treatment time required to see negative alterations in fat mass.
Smith et al. (2001) reported significant increases in fat mass after only 3 months of ADT
whilst another study saw a 4.3% (±1.3%) increase in fat mass after only 12 weeks of
treatment (Smith, Lee, & Nathan, 2006) highlighting the dramatic changes occurring
during the early stages of treatment (Saylor & Smith, 2009).
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Insulin resistance is a metabolic abnormality that accompanies diabetes,
prediabetes and obesity and is a well-known risk factor associated with diabetes, CVD and
sudden death (Keating, et al., 2006; Saylor & Smith, 2009). Impaired insulin response as
well as hyperglycaemia have been shown to increase even after short-term ADT (Smith, et
al., 2006). Dockery et al. (2003) have observed a 63% increase in fasting serum insulin
after 3 months of ADT and Smith et al. (2001) have also reported higher insulin
concentrations despite unchanged plasma glucose, suggesting reduced insulin sensitivity
after only 3 months of ADT.
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Cancer and the Role of Exercise/ Physical Activity
Prevention
Whilst the terms exercise and physical activity are often used interchangeably in
the literature due to the fact they both have common elements, physical activity is
defined as any bodily movement produced by skeletal muscle that results in energy
expenditure whilst exercise is a sub section of physical activity and refers to planned,
structured and repetitive activity with the objective being improvement or maintenance
of physical fitness (Caspersen, Powell, & Christenson, 1985). Both exercise and physical
activity have been linked to the prevention of certain types of cancer, in particular breast
and colorectal cancer with recent evidence suggesting that similar preventative
mechanisms may exist for other forms of cancer (Key, Appleby, Barnes, & Reeves, 2002;
McTiernan, 2008; Thune & Furberg, 2001). In many cases the dose response relationship
of physical activity has been explored with research suggesting that exercise at a greater
intensity for longer periods of time produces greater reductions in cancer risks
(McTiernan, 2008; Thune & Furberg, 2001). As a result of these findings physical activity is
now being included in several health organisations published guidelines regarding
modifiable behaviours known to reduce risk of cancer (Kushi, et al., 2012; Lichtenstein, et
al., 2006).
Endogenous sex hormones have been found to be closely associated with the
aetiology of breast cancer (Key, et al., 2002). The theory behind the role of physical
activity and risk reduction is that physical activity may modulate the production,
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metabolism and excretion of these endogenous sex hormones thought to be responsible
for the development of breast cancer. In a review of approximately 170 observational
epidemiologic studies examining physical activity patterns and breast cancer, Friedenreich
and Cust (2008) reported that the average risk reduction was approximately 25%-35%
with a dose response relationship existing in the majority of studies analysed. The amount
required appears to be at least 30-60 minutes per day of moderate to vigorous intensity
physical activity to decrease cancer risk (Lee & Lee, 2003).
A meta-analysis by Samad et al. (2005) reported a significant protective effect
against colon cancer among physically active males and females, with another study
reporting increasing amounts of time spent undertaking recreational physical activity are
associated with substantially lower risk of colon cancer (Chao, et al., 2004). Whilst limited
research is available regarding the amount of physical activity required to decrease the
risk of colon cancer, early work by Lee, Paffenbarger, and Hsieh (1991) reported that men
who expended >1000 kcal.wk experienced half the colon cancer rates of their inactive
counterparts, with this amount of energy expenditure equivalent to at least 30 minutes of
moderate intensity physical activity 5 days per week. Whilst several biological mechanisms
have been hypothesised in an attempt to explain the association between physical activity
and risk of colorectal cancer, Samad and colleagues (2005) have proposed insulin
resistance and hyperinsulemia to be a unifying mechanism by which physical inactivity, as
well as other lifestyle factors surrounding insulin resistance, can be attributed to the
increased risk of colorectal cancer.
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The role of physical activity in reducing the risk of prostate cancer is unclear due to
inconsistent findings, with Friedenreich and Orenstein (2002) categorising the association
as probable according to the definitions developed and used in the World Cancer
Research Fund and American Institute for Cancer Research report on diet and cancer
prevention (WCRF/AICR, 2007). A large prospective study by Giovannucci et al. (2005)
reported no association between physical activity and overall prostate cancer risk,
however men aged 65 years or older who were undertaking vigorous activity for at least 3
hours per week were at the lowest risk of experiencing advanced and fatal cancers. The
authors also reported prostate cancer patients with high levels of physical activity were
less likely to be diagnosed with poorly differentiated cancers, suggesting that the role of
physical activity may only be applicable to advanced forms of cancer. Young- McCaughan
(2012) recently reviewed 22 studies published in the last 12 years with 12 of these studies
suggesting physical activity reduced the risk of prostate cancer whilst 9 found no
association and 1 showed an increased risk of prostate cancer. Overall it was reported that
there is a growing body of research suggesting physical activity does exert a protective
effect against the development of prostate cancer.
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Exercise interventions during cancer treatment
A summary of the exercise intervention studies undertaken during cancer
treatment sought to add to the previous reviews of Galvao and Newton (2005) and
Baumann, Zopf, and Bloch (2011) and is presented in Table 1. All cancer types were
included with the most commonly investigated cancers being of the breast and prostate.
Several studies were of mixed cancers and included gynaecological, colorectal,
haematological, lung, testicular, Hodgkin’s and non-Hodgkin’s lymphoma and oesophageal
cancers. Of the 39 studies included in Table 1, 24 included an aerobic only intervention, 6
included a resistance only intervention and 8 included a mixed aerobic and resistance
exercise intervention. The remaining study compared the effectiveness of an aerobic only
or resistance only intervention. Some form of intensity prescription was present in 30 of
the studies whilst 11 either reported no specific intensity (n=6) or allowed the participants
to self-select their desired intensity (n=5). The most common outcome measures for all
studies were physical function/ performance, physical fitness, fatigue, quality of life,
strength, body composition and psychological outcomes. To meet the inclusion criteria
studies must have employed an exercise intervention during the treatment stages of
cancer.
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70

Breast

46

Dimeo et al, 1997
(RT)

Breast

45

MacVicar et al, 1989
(RT)
Mock et al, 1997
(RT)
Breast, sarcoma,
carcinoma,
adenocarcinoma,
neuroblastoma

Breast

24

Winningham et al,
1989 (RT)

Breast

Leukaemia

Cancer Type

42

No. of
Patients
40

Winningham et al,
1988 (RT)

Cunningham et al,
1986 (RT)

Author (design)

Aerobic IT
(cycling)
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Aerobic IT
(cycling)
Aerobic (walking)

Aerobic IT
(cycling)

Aerobic IT
(cycling)

Intervention
Type
Resistance

Table 1. Exercise intervention studies during treatment

Frequency/
duration/ intensity
3-5x week/ 5 weeks
No specified
intensity
3x week, 20-30
mins/ 12 weeks
60-85% Max HR
3x week, 20-30mins/
12 weeks
60-85% Max HR
3x week/ 10 weeks
60-85% Max HR
4-5x week, 2030mins /6 weeks
Self-paced
Daily, 30 mins / 2
weeks
50% HR reserve

↑ 12-MWT 4%*
↓ Fatigue*
↓ symptom experience*
↓ MP (METS) 14%*
↓ Thrombopenia, neutropenia* &
hospitalisation duration*

↑ Lean tissue mass
↓ 0.5% Body Fat
↓ Skinfold sites
↑ VO2max 42%*

↓nitrogen balance
↔ creatine excretion
↔ Arm circumference
↓ Nausea*

Primary Outcomes

59

Dimeo et al, 1999
(RT)

Breast

Breast

Mock et al, 2001(RT) 52

Segal et al, 2001
(RCT)

123

Breast

72

Schwartz et al, 2001
(Non-randomised)

Stomach

35

Hodgkin’s lymph.,
non-Hodgkin’s
lymph., bronchial,
breast,
medullablastoma
Breast, lung
carcinoma,
seminoma,
adenocarcinoma,
Hodgkin’s lymph.
Breast

Na et al, 2000 (RT)

Schwartz et al, 1999, 27
2000 (RT)

5

Dimeo et al, 1997
(Non-randomised)

44

Aerobic (walking)
Home vs. non
home based

Aerobic (walking)

Aerobic (arm &
cycling
ergometer)
Aerobic (walking)

Aerobic (walking)

Aerobic IT
(cycling)

Progressive
Aerobic
(treadmill)

5x week 30mins /2
weeks
60% Max HR
3-4x week/ 8 weeks
Self-paced
accelerometers
5-6x week/ 6-24
weeks
Self-paced
5x week/ 26 weeks
50-60% VO2max

4x week 35mins/ 8
weeks
Self-paced
accelerometers

Daily/ 6 weeks
50% HR reserve

5x week, 30-35mins/
6 weeks
Lactate - 3mmol/L
80% Max HR

↑ 12-MWT 6%*
↓ Fatigue*
↓ Emotional distress*
↑ Physical function *
↔ QoL
↔ VO2max

↑ 12-MWT 15%
↓ Fatigue

↑ NKCA 28%

↑ 12-MWT 10.4%*
↓ Fatigue*

↓ Psychological distress*

↓ Lactate concentration 100%
↓ HR 18%
↑ Training distance 101%
↓ max performance 12%

155

24

66

Segal et al, 2003
(RCT)

Coleman et al, 2003
(Non-randomised)

Dimeo et al, 2003
(Non-randomised)

Courneya et al, 2003 102
(RCT)

40

Kolden et al, 2002
(Non-randomised)

Leukaemia,
Hodgkin’s lymph.,
non-Hodgkin’s
lymph., myeloma
Colorectal

Myeloma

Prostate (ADT)

Breast

45

Aerobic (walking)
Flexibility

Resistance (home
based 6
exercises)
Aerobic (home
based walking)
Aerobic (walking)

Resistance

Aerobic (walking,
cycling, stepping)
Resistance
Flexibility

3-5x week/ 16
weeks
65/75% Max HR

Daily/ ~2 weeks
70% Max HR

~6 months
Various frequency &
intensities

3x week/ 12 weeks
2 sets of 12
repetitions
60-70% 1RM

3x week/ 16 weeks
No specified
intensity

↔ QoL
↔ Cardiovascular capacity

↔ Walking speed
↓ Haemoglobin 6.7%*

↑flexibility 11%*
↑ VO2max 15.4%*
↑ Upper body strength 34.5%*
↑ Lower body strength 37%*
↓ Resting systolic BP 5%
↑QoL
↑ Upper body strength 42%*
↑ Lower body strength 36%*
↔ Body composition
↔ PSA
↓ Fatigue7.2%*
↑QoL4.4%*
↓ Lean body mass*

23

119

66

12

53

86

Adamsen et al, 2003
(Non-randomised)

Mock et al, 2004
(RT)

Windsor et al, 2004
(RCT)

Campbell et al, 2005
(RT)

Fairey et al, 2005
(RT)

Pinto et al, 2005
(RT)

Breast

Breast

Breast

Prostate

Leukaemia,
breast, colon,
ovary, testes,
cervix, Hodgkin’s
lymph, nonHodgkin’s lymph.
Breast

46

Aerobic (home
based walking,
cycling,
swimming)

Aerobic (walking,
cycling, low level
aerobics)
Muscle
strengthening
exercises
Aerobic (cycling)

Aerobic (home
based walking)

Aerobic (home
based walking)

Resistance
Aerobic (cycling)
Relaxation

↑Whole body strength 32.5%*
↑ VO2max 16%*
↔ QoL

3x week 15-35 mins/
15 weeks
70-75% VO2max
2-5x week ~1030mins/ 12 weeks
55-65% Max HR

↑ Physical activity levels 6.5%*
↑ 1- mile walk test performance
6.4%*

↑ NKCA 6.8%*
↔ neutrophil function

5-6x week 15↓ Fatigue 54%*
30mins/6 weeks to 6
months
50-70% max HR
3x week 30minutes
↔ in fatigue
60-70% Max HR
↑ fatigue in control group
↑ distance walked in intervention
group 13.2%*
2x week /12 weeks
↑ 12-MWT 32%*
Warm up, 10-20min ↑ Physical activity 104%*
exercise, cool down ↑QoL 16.5%
↔ in fatigue
& relaxation
60-75% Max HR

4x week/ 6 weeks
3 sets of 5-8
repetitions
60-100% Max HR
85-95% 1RM

10

70

21

Galvao et al. 2006
(Non-randomised)

Quist et al, 2006
(Non-randomised)

Monga et al, 2007
(RCT)

Prostate

Breast, ovary,
colon, testes,
cervix, lung,
oesophagus,
sarcoma,
rhinopharynx,
oral, Hodgkin’s
lymph, nonHodgkin’s lymph,
leukaemia,
myelomatosis,
meyelofibrosis

Prostate (ADT)

47

Aerobic
(treadmill)

Resistance (3
exercises)
Aerobic (cycling)

Resistance (12
upper and lower
body exercises)

High intensity: 3x
week 1.5hrs/ 6
weeks
Resistance 5-8 reps
at 85-95% 1RM
Aerobic 10 min 8595% Max HR
Low intensity 4x
week 0.5hrs/ 6
weeks
Massage 2x week
0.5hrs/ 6 weeks
Body awareness 1x
week 1.6hrs/ 6
weeks
Total: 9 hrs/ week
3x week 40mins/ 8
weeks
65% Max HR

2x weeks/ 20 weeks
6-12 RM for 2-4 sets
per exercise

↓ Fatigue 66.6%*
↑ QoL 5.3%*
↑ CV fitness 36%*
↑ Muscle strength 10.3%*

↑ Muscle strength & endurance
(40.5% - 96.3%)*
↑physical function & balance (7.4% 26.8%)*
↑Muscle thickness 15.7%*
↔lean body mass or fat mass
↑ Muscular strength 41.3%*
↑ VO2max 14.5%*
↑ Body mass 1%*
↓ Skinfolds 3%*

45

22

100

16

Schneider et al,
2007
(Non-randomised)

Chang et al, 2008
(RT)

Culos-Reed et al.
2009 (RT)

Hansen et al, 2009
(Non-randomised)

Prostate (ADT vs.
non ADT)

Prostate (ADT)

Leukaemia

Prostate, colon,
Hodgkin’s, lung,
bladder,
melanoma,
pancreas, rectal,
testes, throat

48

Resistance (high
force eccentric
leg cycle
ergometer)

Aerobic (home
based walking)
Resistance (light –
theraband)

Aerobic (home
based walking)

Aerobic
Resistance

↔ Cardiopulmonary function during
treatment group
↓ resting HR following treatment
group 7.4%*
↑ VO2max following treatment
group 16.4%*
↔ fatigue during treatment group
↓ fatigue following treatment group
33.9%
↑ 12 MWT 14.6%*
↓ fatigue 4.5%*

↑ physical activity 71%*
↓ blood pressure 6%
↓ waist 0.5% & neck 0.9%
circumference*
↔ QoL
3x week 12-15mins / ↑ quadriceps volume*
12 weeks
↑ isometric knee extension
strength*
RPE – somewhat
hard
↑ physical function*
↑ QoL
↑symptoms of fatigue

Suggested 3-5x
week/ 16 weeks
1x week 60min
group session

5x week 12 mins/ 3
weeks
Resting HR plus
30bpm

2-3x week 60mins/
12 weeks
Aerobic: 30-55% HR
Reserve
Resistance: 2 sets of
10 reps at RPE 3

Prostate
Prostate

66
33

Kapur et al, 2010
(RT)
Serda et al 2010
(Non-randomised)

Prostate (ADT)

57

Galvao et al. 2010
(RCT)

Prostate

121

Segal et al. 2009
(RCT)

49

Aerobic (home
based walking)
Resistance (10
upper and lower
body exercises)

Resistance (8
upper and lower
body exercises)
Aerobic

Aerobic group
(cycle, treadmill
& elliptical)
Resistance group
(10 exercises)

3x week 30mins/ 4
weeks
2x week/ 24 weeks
16 weeks –
supervised; 8 weeks
– unsupervised
8-12 reps 50-70% 8
RM

2x week/ 12 weeks
Resistance Exercise
– 6-12 RM for 2-4
sets per exercise
Cardiovascular
exercise – 15-20 min
65-80% Max HR

3x week/ 24 weeks
Resistance – 2 sets
of 8-12 repetitions
Aerobic – 70-75%
VO2peak

↓ Rectal toxicity 39.6%*
↓ Bladder toxicity 15.5%
↑ QoL 8.8%*
↑ Muscle strength 22.8-45.5%*
↑ Muscle endurance 57.7-61.4%*
↓ SBP 6.8%*
↓ BMI 1.6%, WHR 2%, waist 2.5%*

Aerobic
↔ aerobic fitness*
↓ fatigue 0 -12 weeks*
↑ Muscle mass 1.3%*
↑ Strength 11-31.5%*
↑ Physical function 6.4%*
↑ Balance3.2%*
↔ Cardiorespiratory fitness

Resistance
↑ QoL*
↑ Strength*
↓Triglycerides *
↓Body fat *
↑ Aerobic fitness*
↓ Fatigue 0 -24 weeks*

17

575

25

Newton et al, 2011
(Non-randomised)

Noble et al, 2012
(Non-randomised)

Quist et al, 2012
(Non-randomised)

Aerobic (home
based walking)
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Breast, colorectal, Aerobic
gynaecological,
Resistance
haematological,
lung & prostate
Lung
Aerobic (cycling)
Resistance (group
based 6
exercises)

Ovary

Home based 3x
week 20-40mins/ 6
weeks
Non reported
walking intensity

Aerobic: 10-15 mins
at 85-95% Max HR
Resistance:
3 sets of 5-8
repetitions at 7090%1RM

Group based 2x
week
1.5hrs/ 6 weeks

2x week 1hr/ 12
weeks
RPE 11-13

Group average 4x
week 30minutes
Duration dependent
upon treatment
time

↑ maximum work rate attained
16.8%*
↓ Submaximal HR response 3.7%,
systolic BP 3.8%and RPE 4.6%*
↑ VO2peak 6%*
↑ muscular strength 9-23%*
↔ QoL

No significance
Meaningful improvements in physical
function, symptoms, physical wellbeing & QoL

10

Breast

Aerobic
Resistance (bands
and weights up
to 2.3kg)

3x week 1hr/ 16
weeks
Non specified
intensity

↓ BMI 12.5%*
↔ tumour size
↔ C peptide
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Abbreviations: ↑ - increase; ↓ - decrease; ↔ - no change; HR – heart rate; NKCA – natural killer cell cytotoxic activity; QoL –
quality of life; BP –blood pressure; RM – repetition maximum; RPE – rating of perceived exertion; BMI – body mass index; IT –
interval training; METS – metabolic equivalents; MWT – minute walk test; ADT – androgen deprivation therapy; (RCT) – Randomised
Controlled Trial; (RT) – Randomised Trial;* statistically significant, MP: Maximal Physical Performance

Rao et al, 2012 (RT)

The earliest study published examining the role of exercise in cancer patients was
conducted by Cunningham et al. (1986) who initiated a resistance training program in
leukaemia patients receiving bone marrow transplant. Patients undertook a supervised
resistance training program either 3 times per week, 5 times per week or were assigned to
usual care. Body composition and muscle protein were assessed pre and post the 5-week
intervention. Body composition was assessed via skinfold and circumference whilst muscle
protein status and turnover was assessed via weekly nitrogen balance and creatinine, and
3 methylhistidine excretion. Although no differences were seen in body composition, the
two exercise interventions did maintain creatine status whilst the control group
significantly decreased, implying that the intervention may have spared muscle protein.
Winningham & MacVicar (1988) and Winningham, et al., (1989) were the first to employ
an aerobic based exercise intervention in cancer patients. In the first study (Winningham
& MacVicar, 1988) breast cancer patients undergoing chemotherapy were allocated for
10 weeks to either an aerobic cycle ergometer group (3x/week), a stretching and flexibility
group (1x/ week), or a usual care group. The primary endpoint was self-reported nausea.
The cycle ergometer group experienced significantly improved outcomes with regard to
symptoms of nausea when compared to the stretching and usual care groups, suggesting
that moderate aerobic exercise has the ability to provide an anti- nausea effect in patients
undergoing chemotherapy. Winningham et al (1989) and MacVicar, Winningham & Nickel
(1989) undertook a secondary analysis of the data examining functional capacity and body
composition. Functional capacity (VO2max) was significantly improved when compared to
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the control groups previously described. Body composition was assessed by way of
skinfold measurements and as such the specificity of the training program in this study
(aerobic exercise only), the relative increase in lean tissue mass may be attributed to the
decreased fat tissue. This is likely due to the limitations of this technique not measuring
muscle mass directly (Galvao & Newton, 2005).
Mock et al. (1997) had breast cancer patients undergoing chemotherapy complete
either a 4-5 day per week unsupervised home based walking program or usual care for 6
weeks. Intensity was self-selected but required participants to complete 20-30 minutes of
walking per session. Primary outcome measures were physical function, symptom
experience and fatigue. The home based walking group improved significantly in walking
distance as well as symptom experience and fatigue when compared to the control group.
The following series of studies conducted by Dimeo et al. (1997a; 1998; 1999) all
used mostly breast cancer patients receiving high dose chemotherapy and autologous
peripheral blood transplantation. The first of these studies investigated the effects of
supervised bed based (supine) interval training 30 mins a day for approximately 2 weeks
on physical performance, haematological indices and treatment complications. Compared
to the usual care group, the intervention group did not experience decrements in physical
performance to the same magnitude, experienced less pain and diarrhoea and shorter
periods of neutropenia and thrombopenia. The intervention group also spent on average
1.6 days less in hospital (Dimeo, et al., 1997a). This study suggested that physical activity
may partially preserve fitness during high dose chemotherapy. The second of this series
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of studies (Dimeo, et al., 1997b) had a similar group of cancer patients undergo supervised
treadmill walking 30-35 minutes daily for 6 weeks with a prescribed intensity set to elicit a
blood lactate level of 3 mmol/L. Results indicated that supervised treadmill walking led to
improvements in physical performance and haemoglobin levels which suggested exercise
could not only preserve physical function but actually increase physical function after high
dose chemotherapy. The final study of this series applied a similar intervention to that
used in the Dimeo et al. (1997b) investigation with the same type of population, however,
the key difference was the mode of exercise selected. Dimeo et al. (1999) in this study
utilised a supine cycle ergometer once per day that consisted of 30 minutes interval type
training to investigate the psychological impact of exercise. The exercise group
demonstrated reduced levels of psychological distress with no changes in fatigue levels at
the post intervention time point.
Schwartz (1999, 2000) conducted 2 studies to examine the influence of a home
based, self-paced walking program on breast cancer patients undergoing chemotherapy.
The 8-week intervention required participants to wear an accelerometer whilst walking 4
times per week for 8 weeks. As opposed to the usual care group, the walking group
significantly improved their physical performance, as demonstrated by a 10.4% increase in
the 12-minute walk test and also reported decreased levels of fatigue.
One of the first studies to employ an exercise intervention in patients with
stomach cancer was by Na, Kim, Kim, Ha & Yoon (2000) who employed a combination of
arm and cycle ergometers to evaluate the effects of exercise on the natural killer cell
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cytotoxic activity (NKCA). Patients exercised at 60% of maximal heart rate twice per day, 5
times per week for 2 weeks with blood samples collected at baseline, and day 7 and 14 of
the intervention. Post intervention (day 14) a significantly greater increase in NKCA was
observed in the exercise group (28%) compared to the control group (13%).
Schwartz et al. (2001) added to the earlier investigations (Schwartz, 1999, 2000) of
a home based self-paced walking program on breast cancer patients undergoing
chemotherapy. As a result of the same 8-week intervention used previously, functional
ability assessed by the 12-minute walk test increased 15% in the exercise group whilst the
control group declined by 16%. Exercise also reduced all four levels of self-reported
fatigue with a significant carry over effect of exercise on these fatigue scales. The series of
studies conducted by this group of authors all employed self-selected home based
exercise interventions. Despite their lack of laboratory based controls or supervision,
significant differences were still observed for functional capacity and reported levels of
fatigue. This self-selected home based intervention strategy was further explored in a pilot
study by Mock et al. (2001). This work expanded on their previous research also using
home based self-selected intensities in breast cancer patients (Mock, et al., 1997). Once
again, despite the apparent lack of direct supervision or specified intensity, the exercise
intervention led to significant improvements in physical performance as demonstrated by
increased distance in the 12-minute walk test. Fatigue and emotional distress were also
positively influenced as was quality of life. This series of studies, despite utilising relatively
simple unsupervised exercise interventions, were able to demonstrate significant
improvements in functional performance, fatigue and quality of life, providing
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encouraging signs for future researchers to explore the differences between home based
interventions and clinic or gym based interventions.
One such study to explore home based vs. non-home based interventions was
conducted by Segal et al. (2001) who implemented a randomised controlled trial
examining the effects of supervised gym based walking compared to unsupervised home
based walking 5 days per week for 26 weeks on breast cancer patients undergoing
adjuvant therapy. Results demonstrated an increased perceived physical functioning in
the exercising groups whilst the group not exercising at all (control group) reported a
decrease in perceived physical functioning, demonstrating a moderately large (and
clinically important) difference between the two groups. The authors concluded that
exercise has the ability to blunt some of the negative side effects of treatment, with selfdirected exercise an effective strategy to improve physical functioning.
One of the first studies to combine cardiovascular and resistance type training into
a single exercise intervention was conducted by Kolden et al. (2002). This pilot study also
included a flexibility component to the design. A 16-week program was designed for
breast cancer patients undergoing adjuvant therapy where they participated in group
exercise training delivered in a structure format 3 times per week. The feasibility and
health benefits were the primary desired outcomes of this pilot study. Results
demonstrated that structured group exercise training was feasible, safe and well
tolerated. The health benefits of the program were reported as an observed effect for
time for upper and lower body strength, predicted aerobic capacity, flexibility and resting
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systolic blood pressure. The authors highlighted the need for physical activity programs to
be included in comprehensive, complimentary treatment regimes for breast cancer
patients.
The first published study to investigate the effects of a resistance exercise
intervention in prostate cancer patients undergoing ADT was conducted by Segal et al.
(2003b). For 12 weeks participants underwent 3 days per week of whole body resistance
training. The resistance training program was designed to consist of two sets of 8 -12
repetitions at 60-70% of 1RM for 6 upper and 3 lower body exercises. Compared to the
control group, the resistance training group demonstrated reduced levels of fatigue as
well as improvements in quality of life and muscular fitness. Body composition did not
appear to be altered by the intervention. The lack of observed differences in the body
composition variables may be accounted for by the elementary assessment of body
composition used to measure changes in muscle and fat tissue. Sale (1988) has suggested
that the initial adaptations to a resistance training program are usually neural, with gains
in hypertrophy developing as the intervention continues. Given this was a 12-week
intervention, it is possible that the changes in strength were predominantly due to neural
alterations rather than muscle morphology (Galvao & Newton, 2005).
Coleman et al. (2003a; 2003b) had multiple myeloma patients undergoing high
dose chemotherapy and autologous peripheral stem cell transplantation undertake an
unsupervised home based aerobic and resistance training program for 12 weeks. The
resistance training component of the study design was included as it was thought that
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cancer patients who have skeletal muscle wasting may not obtain maximal benefit from
an aerobic only intervention.

As this was only a feasibility study with low subject

numbers, the only statistically significant end-point was lean body mass with no
differences observed in fatigue levels, aerobic capacity or any other body composition
outcomes.
Dimeo et al. (2003) employed a short term aerobic training program on a mixed
cancer population undergoing conventional or high dose chemotherapy. The intervention
involved daily treadmill walking at 70% of maximum heart rate with the primary endpoint
being physical performance. At the conclusion of the 2-week intervention no differences
were observed in physical performance, assessed by a sub-maximal stress test. It is likely
that the duration of the intervention was too short to elicit a significant alteration in
aerobic capacity. Despite the lack of change in physical performance, the authors
suggested

that

aerobic

training may

preserve

performance

during

intensive

chemotherapy.
Courneya et al. (2003) conducted a randomised controlled trial examining the
effects of an unsupervised aerobic exercise program on quality of life and cardiovascular
capacity in colorectal patients undertaking adjuvant therapy. The exercise intervention
involved participants undertaking 3-5 days of cardiovascular and flexibility activities per
week for 16 weeks. There were no differences observed between the exercise and control
groups for any of the study endpoints which included quality of life, cardiovascular
capacity, fatigue levels and body composition. The authors proposed that the lack of
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differences between groups may be due to the high levels of exercise in the control group,
where 51.6% of the control group exercised during the study period.
Adamsen et al. (2003) was the first study to employ a high intensity supervised
training program in a mixed cancer population. Aerobic interval training was prescribed at
60-100% of maximal heart rate whilst resistance exercise was performed at 85-95% of
1RM for 5-8 repetitions. The 6-week program resulted in a 32.5% increase in maximal
strength and a 16% increase in VO2max providing support for the proposal that cancer
patients can tolerate high intensity exercise programs.
As more preliminary studies (Dimeo, et al., 2003; Mock, et al., 1997; Mock, et al.,
2001; Schwartz, 1999, 2000; Schwartz, et al., 2001) reported the beneficial effects of
walking on physical function, Windsor et al. (2004) sought to strengthen the growing body
of literature by conducting a randomised controlled trial on men receiving radical external
beam radiotherapy for treatment of localised prostate carcinoma. The home based
moderate intensity walking program included 30 minutes of continuous walking, 3 days
per week for the duration of their radiotherapy treatment with primary endpoints being
fatigue and physical performance. The authors found that men in the control group
reported significant increases in fatigue from baseline to end of radiotherapy treatment
whilst the exercise group reported no such increases. The control group also reported a
slight reduction (although not statistically significant) in distance walked in the physical
function test whilst the exercise group significantly increased distance walked. It was also
concluded that men instructed to rest if they became fatigued during treatment (control
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group) demonstrated a slight deterioration in physical function and a significant increase
in fatigue. Although the program was home based and hence lacked direct supervision,
the exercise intervention still resulted in significant improvements in physical functioning
with no reported increases in fatigue levels.
Campbell et al. (2005) conducted a randomised controlled trial to examine the
effects of a supervised group exercise program on physical function, fatigue and quality of
life in women with breast cancer receiving adjuvant treatment. A 12-week intervention
had participants attend supervised exercise classes twice weekly and consisted of a
general warm-up, 10-20 minutes of various exercise (walking, cycling, low level aerobic,
muscle strengthening exercises etc.) and a cool-down period. The desired outcome of the
intervention was to have participants undertaking exercise at a moderate level for the
duration of the session. Although the physical work completed each week was quite low
(20-40 mins per week), the study still reported positive outcomes in the exercise group
with physical functioning and quality of life both improving as a result of the intervention.
There were slight changes in fatigue and satisfaction with life; however the relatively small
participant numbers as well as the previously mentioned relatively low dose of exercise
resulted in a lack of significant findings.
Fairey et al. (2005) focused their attention on blood immune function responses to
exercise on post-menopausal breast cancer patients where patients exercised on cycle
ergometers 3 times per week for 15 weeks. The primary endpoint was the change in NCKA
while secondary endpoints were the standard haematological variables. Exercise training
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did have a significant effect on change in NKCA with no significant changes in the standard
haematological variables. The small sample size combined with the use of peripheral
blood samples (as opposed to tissue biopsy samples) is thought to have influenced results.
Mock et al. (2004) sought to expand their previous work in breast cancer (Mock, et
al., 1997) with a multi-site randomised controlled trial to examine the effectiveness of a
home based walking program on fatigue and physical function. This same mode of
exercise was chosen as in their earlier work, however, this time participants were
instructed to exercise for 30 minutes, 5-6 times per week for the duration of their
treatment which was either 6 weeks for radiotherapy or 3-6 months for chemotherapy.
Upon initial analysis there were no differences in any of the endpoints, however this was
likely due to the fact that 39% of the control group exercised and 28% of the exercise
group did not. A secondary analysis considered exercise participation in the analysis and
found that moderate intensity home based walking exercise was effective in managing
fatigue levels during both radiation and chemotherapy treatments while physical function
was maintained during treatment.
Another home based randomised controlled trial was conducted by Pinto et al.
(2005) which had breast cancer patients build up to exercising 30 minutes per day, 5 days
per week for 12 weeks. Participants were encouraged to exercise at 55%-65% of
maximum heart rate, although heart rate was not recorded during the intervention. This
study differed to previous home based randomised controlled trials as it was primarily
concerned with the efficacy of the delivery of a home based program with the primary
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endpoint being physical activity levels during the intervention. The authors found that a
12-week intervention delivered via telephone successfully increased moderate intensity
physical activity levels and overall physical activity levels compared to the control group.
Galvao et al. (2006) employed a resistance training program in prostate cancer
patients undergoing ADT for the treatment of prostate cancer. The supervised resistance
training program consisted of 12 upper and lower body exercises set at an intensity of 612 repetition maximum completed twice per week for 20 weeks. Primary endpoints were
muscular strength and endurance, functional performance, balance and body
composition. As a result of the intervention participants increased muscular strength by
between 40% and 96% depending upon the site and muscular endurance was increased
115% for chest press and 167% for the leg press respectively. Significant improvements
were also seen in all functional performance tasks including usual walk test (14%), 6m
backward walk test (22%); chair rise (27%), stair climb (10%) and 400m walk (7.4%), and
balance improved by 7.8%. Whole body lean mass was also preserved whilst no changes
were reported in fat mass. This investigation demonstrated that resistance training is an
effective intervention strategy in preserving body composition and reducing treatment
side effects in men undergoing ADT for prostate cancer.
Quist et al. (2006) explored the role of a 6-week supervised high intensity
resistance and cardiovascular training intervention in a single intervention group design,
mixed cancer population undergoing chemotherapy. This work sought to expand on the
previous research of Adamsen et al. (2003) who also utilised a high intensity exercise
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intervention in a mixed cancer population. High intensity exercise training involved
participants undertaking a 90 min session 3 times per week involving a warm up, heavy
resistance training (3 exercises) and an aerobic fitness component. The aerobic
component consisted of 10 minutes of cycling at a workload equivalent to 85-95% of each
patient’s maximum heart rate. Low intensity training involved participating in 30 minutes
of relaxation type massage four times per week. Physical capacity and body composition
were the primary endpoints. The average increase in muscular strength was 41.3% whilst
aerobic fitness increased by an average of 14.5%. Body mass increased significantly (1%),
however, there was also a significant decrease in skin-fold measurements. Although only a
short term intervention, results demonstrated the program to be well tolerated with
beneficial outcomes for patients undergoing chemotherapy.
Monga et al. (2007) investigated the role of aerobic exercise on fatigue and quality
of life in prostate cancer patients undergoing radiotherapy. Participants undertook
supervised treadmill walking for 40 minutes 3 times per week for 8 weeks. Intensity was
set at 65% of heart rate reserve. Primary outcomes included cardiac fitness, fatigue,
functional status and well-being. Although the participant numbers were relatively low in
this study (21 participants) and the intervention only lasted 8 weeks, the results still
demonstrated a supervised aerobic intervention to be successful at improving
cardiovascular fitness (p<0.01), muscle strength (p<0.001) and quality of life (p=0.02) as
well as preventing fatigue (significant increase in control group p=0.04).
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Schneider et al. (2007) employed individualised exercise programs to determine
cardiopulmonary and fatigue alterations in male cancer survivors during various forms of
treatment, as well as following treatment of numerous forms of cancer.

Each

individualised program took into account the specific needs of each participant and
required participants to attend approximately 60 minutes of supervised exercise 2-3 days
per week for 6 months. Results were varied as is expected when employing individualised
exercise programs, with the authors suggesting that this is primarily due to where the
patient is on the cancer continuum. Regardless of where these patients were on the
cancer continuum, exercise appeared to be a safe and effective strategy to maintain or
improve physical and mental wellbeing.
Chang et al. (2008) conducted a hospital based randomised controlled trial to
examine the effects of a 3-week walking exercise program on fatigue related experiences
in leukaemia patients undergoing chemotherapy. Participants were required to walk 12
minutes per day, 5 days per week for 3 weeks. Sessions were supervised and intensity was
prescribed as resting heart rate plus 30 beats per minute. Primary outcomes were
measures of fatigue, 12-minute walking distance and psychological outcomes. As a result
of the intervention, the walking group reported significant time dependant changes in 12minute walking distance, lower levels of fatigue intensity and interference, symptom
distress, anxiety and depressive status when compared to the control group. This study
demonstrated that 60 minutes of moderate intensity aerobic exercise per week is
effective in not only maintaining patient’s energy levels but can also increase their
functional capacity by improving 12-minute walking distance.
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Culos-Reed et al. (2009) were the first to employ a combined aerobic and light
resistance based training program in men undergoing ADT for the treatment of prostate
cancer. The study was initiated to explore the effects a physical activity intervention
would have on physical activity behaviour, quality of life and fitness measures. The 16week intervention consisted of a home based aerobic and light resistance training
program and weekly group sessions. As the program was home based, participants were
encouraged to complete 3-5 sessions per week at a moderate intensity. Theraband’s
(rubberised bands) were provided for the resistance training component of the study. The
weekly group based session included an activity portion that was similar in design to the
home based program and included an additional 30 minutes of education/discussion
activity. As expected the physical activity group did increase their physical activity
behaviour by 71% whilst the control group decreased their activity levels by 13%. There
were small reported changes in neck (p=0.019) and waist (p=0.044) girths as well as blood
pressure (systolic p=0.004; diastolic p=0.0005); however these blood pressure
improvements were evident in both groups suggesting this was not a result of the
intervention. The high dropout rate (34%) combined with the relative lack of control in
specific doses of exercise and limited resistance type exercises meant there were no
significant findings for quality of life, fatigue or depression.
Hansen et al. (2009) compared high force eccentric resistance exercise in prostate
cancer patients either on or off hormone therapy. All participants underwent 12 weeks of
resistance exercise training using a recumbent cycle ergometer 3 times per week at a
‘somewhat hard’ perceived exertion for 12 – 15 minutes. Groups were based on ADT
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usage with quadriceps muscle volume, knee extension strength, functional mobility,
quality of life and fatigue compared between groups. The eccentric exercise intervention
was well tolerated with both groups deriving some benefits in strength and functional
mobility. Although underpowered due to being a pilot study (10 participants completed),
the authors reported encouraging signs that despite hormone related muscle function
deficits in men undergoing ADT, significant benefits in this group were still seen in
strength (p=0.01), functional mobility (p=0.03) whilst quality of life demonstrated a
clinically relevant change that did not meet statistical significance.
Segal et al. (2009) examined the effects of 24 weeks of resistance or aerobic
exercise training on fatigue, quality of life, physical fitness and body composition in men
with PCa receiving radiation therapy (~60% were also on ADT). The resistance training arm
of the study had participants exercise 3 times per week and perform two sets of 8-12
repetitions of 10 different exercises at 60-70% of their 1RM. The aerobic arm consisted of
training 3 times per week on a cycle ergometer, treadmill or elliptical trainer at an
intensity of 50-60% of their VO2peak for weeks 1-4 increasing to 70-75% for weeks 5-24.
The duration of the aerobic sessions commenced at 15 minutes and progressed 5 minutes
every 3 weeks until reaching 45 minutes. The authors found that both resistance and
aerobic type exercise mitigated fatigue over the short term with resistance training
providing longer term improvements. The resistance training arm reported significant
improvements in quality of life (p=0.015), muscle strength (p<0.01), triglycerides (p=0.036)
and body fat percentage (p=0.049). As expected aerobic training preserved aerobic
fitness, however so did resistance training. Whilst the intervention groups did not improve
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self-reported fatigue levels, the usual care group did report worsening fatigue during
treatment resulting in a significant difference between control and intervention groups.
Despite the well-controlled intervention, neither exercise mode prevented weight gain;
however resistance training did mitigate the increase in body fat commonly associated
with ADT.
Galvao et al. (2010) investigated the effects of a combined resistance and aerobic
exercise program in men undergoing ADT for prostate cancer. Participants undertook
supervised clinic based training twice per week for 12 weeks with primary endpoints being
whole body and regional lean mass with secondary endpoints of muscle strength and
function, cardiorespiratory capacity, blood biomarkers and quality of life. The resistance
training component of the study consisted of 4 upper body and 3 lower body exercises
progressing from 12 – 6 RM for two to four sets per exercise as well as abdominal
crunches. The aerobic component of the study consisted of 15-20 minutes of aerobic type
exercise at 65-85% of maximal heart rate. Despite a relatively brief exposure to the
intervention, participants recorded improvements in muscle mass of 0.8kg (p=0.047),
muscular strength for the leg press of 31kg (p<0.001) and 3kg for the chest press
(p=0.018), physical function as reported by a 0.3 second improvement in 6m usual walk
(p=0.024) and a 4.1 second improvement in 6m backwards walk (p=0.039) as well as a
borderline improvement in balance of 8.7 points (p=0.061). The exercise intervention did
lead to a borderline improvement in predicted cardiorespiratory capacity as shown by a
mean group difference of 7 seconds (p=0.018); however the relatively low dose of aerobic
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exercise (30-40 minutes per week) likely contributed to the lack of significant difference
between groups.
Kapur et al. (2010) retrospectively analysed acute toxicity data from a previous
study (Windsor, et al., 2004) to assess the impact of aerobic exercise on acute rectal and
bladder morbidity during treatment.. The authors reported a positive association with the
severity of radiation induced acute rectal toxicity scores (Radiation Therapy Oncology
Group/European Organisation for Research and Treatment of Cancer 0-4 point scoring
criteria). There was a lack of any beneficial association between exercise and bladder
toxicity scores; however it is thought that this could be attributed to the confounding
effect of lower urinary tract symptoms reported by patients at the start of treatment.
Therefore bladder symptoms could not be solely attributable to radiation therapy.
Serda et al. (2010) explored the role of exercise as a complementary treatment in
prostate cancer patients undergoing radiotherapy. The exercise intervention lasted for a
total of 24 weeks with the first 16 weeks being supervised whilst the remaining 8 weeks
unsupervised. The two 90-minute exercise sessions per week consisted of 1-2 sets of 8-12
repetitions at 50-70% of 8RM for 10 selected exercises. As a result of the intervention
there was a significant improvement in muscular endurance which was more evident in
the lower limbs. The authors concluded that the improvement in quality of life was likely
due to the improvement in functional and physical capacity.
Another walking based intervention was conducted by Newton et al., (2011) who
recruited ovarian cancer patients undergoing chemotherapy. The program was home
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based and individualised to each participant based on their pre intervention assessment of
physical functioning and level of physical activity. Primary outcomes were physical
function assessed by the 6-minute walk test, self-reported distress, symptoms and quality
of life. This pilot study reported that the majority of the 17 participants completed
exercise 4 days per week at a moderate intensity for 30 minutes. Participating in the
walking intervention was associated with improvements in physical functioning, physical
symptoms and ovarian cancer specific quality of life. The lack of a control group was a
limitation to the study, whilst the small sample size also meant that some changes did not
reach statistical significance.
The impact of supervised exercise programs on physical capacity and quality of life
in mixed cancer populations was recently investigated by Noble et al. (2012). This large
scale intervention (305 participants completed pre and post testing) consisted of a 24
session program, completed twice weekly for 12 weeks. Each session consisted of both
aerobic and resistance training exercise for a total of 1 hour. Intensity was broadly set at
between 11 and 13 on the RPE (6-20) scale for both aerobic and resistance exercises.
Primary outcomes assessed were changes in physical function at a sub maximal work rate
as well as body mass index and quality of life. The authors reported a significant increase
(10.8 Watts, p<0.001) in the maximum work rate attained and significant decrease (4 bpm
p<0.001) in the heart rate response, systolic blood pressure (6mmHg, p<0.001) and RPE (1,
p<0.001) at a sub-maximal level. Quality of life was also significantly improved following
the intervention.
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Quist et al. (2012) was the first study to assess the safety and feasibility of a
combined aerobic and resistance intervention in inoperable lung cancer patients
undergoing chemotherapy. This pilot study employed a 6-week intervention consisting of
a supervised structured exercise and relaxation training program. Each supervised session
was 90 minutes in duration and consisted of 10 minutes of light stationary cycling (60-90%
maximum heart rate), strength training for 3 sets of 5-8 repetitions (70-90% 1RM) and
aerobic interval training for 10-15 minutes (85-95% of maximum heart rate). The home
based component consisted of walking and relaxation exercises for approximately 20-40
minutes 3 times per week. Primary endpoints were VO2peak, muscular strength and
physical function. This study showed significant improvements in aerobic capacity, muscle
strength, functional capacity and emotional wellbeing. Despite the intervention there was
no significant improvement in general quality of life or lung capacity. The authors
concluded that this type of combined aerobic and resistance exercise intervention was
safe for patients with advanced stage lung cancer.
A pilot study by Rao et al. (2012) employed a ‘bootcamp’ style exercise
intervention which involved breast cancer patients complete both aerobic training and
resistance exercises. The type of training employed was a circuit style of training where
participants completed activities such as jumping jacks, running in place, arm and leg work
using exercise balls, bands and weights up to 2.3kg. Prescribed duration was 48 sessions
completed 3 times per week as either one on one or group exercise sessions depending
upon personal preference. Primary outcomes were a number of biomarkers including Ki67 in the actual tumour, insulin-like growth factor 1(IGF-1) and C peptide as well as body
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mass index. This supervised exercise program was found to have decreased body mass
index which may lead to lower Ki-67 levels and improved survival.

Physical activity and Post Cancer Survival
Studies are emerging to support the link between physical activity and improved
survival rates in cancer patients. A recent study by Chen et al. (2011) evaluated the
association between exercise post breast cancer diagnosis and total mortality and
recurrence. After accounting for quality of life, clinical prognostic factors and other
covariates, exercise during the first 36 months post diagnosis did have a beneficial impact
on total mortality and recurrence rates. These findings are in addition to several other
large scale prospective studies that have also found women who engage in higher levels of
physical activity are at a lower risk of dying from breast cancer (Holick, et al., 2008;
Holmes, Chen, Feskanich, Kroenke, & Colditz, 2005). Similar findings are also reported for
colorectal survivors with several large prospective studies reporting physical activity has
improved disease specific survival, in particular for patients with stage II and III colon
cancers (Haydon, Macinnis, English, & Giles, 2006; Meyerhardt, et al., 2006). As with both
breast and colorectal cancers, physical activity has also resulted in beneficial outcomes for
prostate cancer survivors. Kenfield et al. (2011) conducted a prospective study assessing
physical activity with total and prostate cancer specific mortality with their findings similar
to those presented for other cancer survivors. Men who were physically active, in
particular those engaging in 9 MET h/wk or greater of physical activity had a 33% lower
risk of death from any cause and a 35% lower risk of prostate cancer specific death, after
adjusting for other risk factors for mortality and pre-diagnosis physical activity levels.
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Ballard-Barbash, et al. (2012) conducted a systematic review of 45 articles relating
to physical activity, cancer survival and biomarkers potentially related to cancer survival.
The authors reported there was consistent evidence from 27 observations studies that
physical activity is associated with reduced all cause, breast cancer specific and colon
cancer specific mortality. Whilst no associations between physical activity and other types
of cancers were present, this is likely due to the lack of insufficient evidence in the form of
randomised controlled trials in other cancer types.
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Background and justification for choice of intervention
Reduced levels of physical activity and increased levels of fatigue are commonly
reported in prostate cancer patients treated with ADT (Galvao, et al., 2008c) which in turn
reduces functional capacity. Reductions are seen in cardiorespiratory endurance, upper
and lower body strength and endurance, and physical components of quality of life
(Alibhai, et al., 2010; Basaria, et al., 2002; Galvao, et al., 2008c) which lead to inhibiting
activities of daily living as well as the previously established risks of CVD. Exercise has been
shown to be effective for improving surgical outcomes, reducing symptom experience,
managing side effects, improving psychological health, maintaining physical function and
reducing fat gain and muscle and bone loss in cancer patients (Newton & Galvão, 2008).
Studies in the past have used aerobic exercise (Segal, et al., 2009), resistance exercise
(Segal, et al., 2003b; Segal, et al., 2009), or a combination of aerobic and resistance
exercise (Galvao, et al., 2010). Exercise programs have also differed in method of delivery
with some home based (Culos-Reed, et al., 2009) whilst others are group based in a clinic
setting (Galvao, et al., 2006; Galvao, et al., 2010).
Resistance exercise improves muscle strength and function and has been shown to
be an effective intervention against sarcopenia (Frontera, Meredith, O'Reilly, Knuttgen, &
Evans, 1988). This exercise mode also leads to improvements in functional capacity and
quality of life whilst reducing disability in individuals with and without CVD (Hunter,
McCarthy, & Bamman, 2004; Williams, et al., 2007). In prostate cancer patients
undergoing treatment, studies have shown positive effects of resistance exercise on
reducing musculoskeletal treatment side effects, decreasing fatigue, and improving quality
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of life, (Galvao, et al., 2006; Segal, et al., 2003a) despite a compromised hormonal profile
(Galvao, et al., 2008a). Segal and colleagues (2003b) had patients complete resistance
exercises 3 times per week for 12 weeks and reported upper and lower body muscular
fitness improvements of 42% and 32%, respectively, whilst Galvao et al. (2006) had
patients undergo resistance exercise 2 times per week for 20 weeks and reported
significant improvements in upper body muscular strength (chest press 40%, seated row
42%), lower body strength (leg press 96%), functional performance (400m walk 7.4%, stair
climb 10.4%, chair rise 27%) and balance (7.8%).
Improvements in muscle mass, such as those seen by Galvao et al. (2010) are
important not just in terms of mobility and functional performance but also in assisting
glucose disposal (Ferrara, Goldberg, Ortmeyer, & Ryan, 2006). Muscle stimulates insulin
sensitivity and accounts for up to 80% of insulin dependent glucose uptake (DeFronzo, et
al., 1981).

Numerous clinical studies have shown resistance training to lower the

percentage of glycosylated haemoglobin and increase glucose disposal as well as
favourably impact cardiovascular disease risk factors in elderly individuals (Holten, et al.,
2004; Zanuso, Jimenez, Pugliese, Corigliano, & Balducci, 2010). Srikanthan & Karlamangla
(2011) conducted a cross-sectional analysis of the National Health and Nutritional
Examination Survey III data to investigate the possible correlation between relative
muscle mass and insulin resistance and prediabetes. After adjusting for age, ethnicity, sex
and generalised and central obesity, the authors found for every 10% increase in skeletal
muscle index (skeletal muscle mass relative to total body mass) was associated with an
11% reduction in insulin resistance and a 12% relative reduction in pre-diabetes. This
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correlation was stronger in non-diabetic patients (Srikanthan & Karlamangla, 2011) and
was not just limited to the lower, sarcopenic end of the muscle mass distribution in the
population, suggesting that increases in muscle mass, even above average levels was
associated with additional protection against insulin resistance and diabetes.
Studies employing aerobic training only interventions have primarily utilised breast
cancer patients, with promising outcomes reported in physical function, fatigue mitigation
and quality of life (Campbell, et al., 2005; Mock, et al., 1997; Pinto, et al., 2005). Of the
aerobic intervention studies in prostate cancer patients, radiotherapy has been the most
common treatment modality (Monga, et al., 2007; Windsor, et al., 2004) with one study
utilising ADT treated prostate cancer patients (Segal, et al., 2009). Segal et al. (2009)
reported beneficial effects of the aerobic training for both fatigue mitigation and
maintenance of aerobic fitness.
With regard to non-cancer patients, it is well established that cardiorespiratory
fitness attenuates the mortality risk associated with metabolic syndrome in healthy men,
independent of body mass (Katzmarzyk, Church, & Blair, 2004) indicating that
cardiorespiratory fitness is of greater importance than body mass per se. High
cardiorespiratory fitness levels have also been found to attenuate the increased arterial
stiffness in patients with metabolic syndrome (Young Sae at al., 2010). Increases in arterial
stiffness, independent of age and blood pressure have been reported in men receiving
ADT (Dockery, et al., 2003; Dockery, Rajkumar, Agarwal, Waxman, & Bulpitt, 2000; Smith,
et al., 2001) highlighting the need for prescribed aerobic exercise programs focused on
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improving cardiorespiratory fitness to offset the metabolic related treatment toxicities in
ADT treated patients.
Although there are studies that have investigated the effects that resistance
training programs and aerobic training programs have on prostate cancer patients
undergoing treatment, very few have utilised a combined aerobic and resistance training
intervention with prostate cancer patients undergoing ADT. Culos-Reed et al (2009) was
one of the first studies to attempt to employ a combined aerobic and resistance training
program in ADT treated prostate cancer patients, however the study was a low intensity
home based intervention and hence lacked the control of a laboratory based intervention.
This apparent lack of control may have been the reason for a lack of statistically significant
differences. Galvao et al. (2010) was the first group to conduct a clinic based supervised
randomised controlled study to evaluate the combined effects of a resistance and low
volume aerobic exercise program in men undergoing ADT. Galvao et al. (2010) reported
favourable changes in total body and regional lean mass as well as improvements in
muscular strength and functional performance outcomes. Cardiorespiratory capacity only
showed borderline improvement but this was thought to be a result of the low level of
aerobic exercise prescribed. Participants undertook 30 – 40 minutes of aerobic exercise
per week, which is well below 150 minutes recommended by the American Heart
Association for good health. However, the promising aspect of this study was that despite
the low dose of aerobic exercise prescribed, borderline changes were still seen in
cardiorespiratory capacity.
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A combined supervised aerobic and resistance training program was selected to
expand upon the original work of Culos-Reed, et al. (2009) and Galvao, et al. (2010)
through a clinic based randomised control trial employing a larger aerobic training
component than has been previously used in combined aerobic and resistance training
programs.
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Background of Study Measures
Cardiorespiratory Fitness Assessment
Maximal oxygen intake or VO2max is the maximum amount of oxygen that an
individual can utilise during intense or maximal exercise and when measured under
maximal exercise is considered the gold standard measurement of cardiorespiratory
capacity (Mitchell, Sproule, & Chapman, 1958). This was chosen as a primary outcome
measure as it has been shown to be a stronger predictor of overall mortality than selfreported physical activity levels (Byun, et al., 2011) which have been used in previous
studies. Blair and colleagues (2001) suggest there is an inverse gradient across categories
(medium, low and high) of cardiorespiratory fitness for risk of fatal and non-fatal health
outcomes. The authors also reported that the dose response gradient for health-related
outcomes is steeper when a direct assessment of cardiorespiratory fitness is used as
opposed to self-reported physical activity levels (Blair, et al., 2001). Segal et al. (2009) is
one of the very few studies to have utilised a direct assessment of cardiorespiratory
capacity in cancer patients, in this case prostate cancer patients undergoing radiotherapy
(~60 on ADT). No serious adverse events arose as a result of maximal exercise testing in
the Segal, et al. (2009) study. The association between cardiorespiratory fitness and risk of
cardiovascular disease is well established (Katzmarzyk, et al., 2004) and given the
heightened risk of developing cardiovascular disease as a result of ADT for the treatment
of prostate cancer (Collier, et al., 2011; Levine, et al., 2010) it was thought a direct
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assessment of cardiorespiratory fitness would be an important component of the testing
battery.

Resting Metabolic Rate Assessment
A major side effect of ADT is the loss of skeletal muscle mass due to suppression of
testosterone (Galvao, et al., 2008b). This loss of lean mass not only affects functional
performance and muscle strength but can also impact resting energy expenditure or
resting metabolic rate (RMR). Fat-free mass has been shown to be a major determinant of
basal or resting metabolic rate as muscle mass is responsible for approximately 30% of
resting energy expenditure and protein turnover as well as 70% of body cell mass
(Ravussin, Lillioja, Anderson, Christin, & Bogardus, 1986). This reduction in muscle mass
combined with decreased levels of physical activity can reduce total energy expenditure in
elderly adults, which can result in other complications such as abdominal fat accumulation
and hence increased risk factors for CVD (Cunningham, 1991; Rosito, et al., 2008). Buscemi
(2007) has reported that a low resting metabolic rate is associated with metabolic
syndrome and given there is a heightened risk of developing metabolic syndrome in
prostate cancer patients undergoing ADT, the ability to quantify potential changes in
resting metabolic rate may assist in understanding the relationship between exercise, ADT
and energy expenditure. Galvão et al. (2008b) reported large reductions in whole body
and regional lean mass with concomitant increases in fat mass following 36 weeks of ADT
suggesting that reduced lean mass may compromise basal metabolic rate and hence
energy expenditure. Although a study by Reis et al. (2009) failed to find any differences in
resting energy expenditure in ADT patients, possibly due to their small sample size, they
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did identify a significant increase in carbohydrate oxidation and a decrease in lipid
oxidation suggesting the way energy is utilised is in fact influenced by ADT. This alteration
in lipid oxidation is likely due to the suppression of testosterone as previous studies have
shown supplemental testosterone therapy increases lipid oxidation in healthy aging men
with low testosterone levels (Frederiksen, Hojlund, Hougaard, Brixen, & Andersen, 2012).
Resting metabolic rate testing has been included in the two experimental chapters of this
thesis to determine if the preservation of lean mass in patients receiving ADT through
resistance training may assist in maintaining resting and total energy expenditure and
possibly reduce risk factors associated with CVD.

Central Blood Pressure Assessment
Techniques have now been developed to noninvasively assess central blood
pressure, focussing on arterial stiffness and autonomic function (Zhang, et al., 2013). The
ability to assess central blood pressure in this population is important as although it is not
known exactly how androgens interact with the cardiovascular system, recent studies
have shown men undergoing ADT experience decreases in systemic arterial compliance,
which is reflected in an increase in aortic stiffness, independent of age and blood pressure
(Dockery, et al., 2003; Dockery, et al., 2000; Smith, et al., 2001). This arterial compliance
or ‘elasticity’ is increasingly regarded as a surrogate marker for CVD (Dockery, et al.,
2000). Smith et al. (2001) have reported that hypogonadism results in a rise in the
augmentation of central arterial pressure suggesting considerable arterial stiffening. The
authors suggested that testosterone has a direct role in modulating blood flow and vessel
resistance in medium and large arteries which may also contribute to the increased
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cardiovascular mortality following temporary ADT. This proposal is further supported by a
recent study that used transdermal testosterone replacement in hypogonadal men
(unrelated to ADT) to exert a rapid, and partial favourable effect on pulse wave velocity
(Yaron, et al., 2009).

Body Composition Assessment
Dual energy X-ray absorptiometry (DEXA) is now a widely used method of
assessing fat mass, bone mineral-free lean mass and bone mineral mass in clinical
research. DEXA utilises X rays at two energy levels that pass through body tissue providing
an accurate and reliable measurement of total body composition whilst also allowing for
site specific regional analysis including upper and lower limb and trunk analysis (Shih,
Wang, Heo, Wang, & Heymsfield, 2000). Body composition alterations are well established
adverse effects of ADT (Galvao, et al., 2008b; Haseen, Murray, Cardwell, O'Sullivan, &
Cantwell, 2010) with the term sarcopenic obesity now commonly used to describe the
concomitant increases in body weight and reduced muscle mass and strength
(Baumgartner, 2000). These body composition changes have the ability to alter resting
energy expenditure and metabolic variables as well as contributing to the increased risk of
cardiovascular disease. The addition of this outcome will aid in the understanding of ADT
associated body composition alterations in response to a combined six month aerobic and
resistance training program and seek to explore the related changes in other measured
variables.
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Strength and Endurance Assessments
One repetition maximum (1RM) strength testing, which is the maximal amount of
weight that can be lifted in a single repetition, dates back as far as 1955 and has been
found to be a reliable assessment of maximal strength (Hoeger, Hopkins, Barette, & Hale,
1990). 1RM testing has been conducted extensively in our laboratory with similar
populations (Galvao, et al., 2006; Galvao, et al., 2010; Galvao, Taaffe, Spry, & Newton,
2007b; Peiffer, et al., 2010) without the presence of any serious adverse events. This view
is further supported by Shaw et al. (1995) who has previously reported 1RM testing to be
a safe and acceptable tool used to evaluate strength in elderly populations. Muscular
endurance, reported as the maximal number of repetitions performed at 70% of 1RM has
also been used previously in our laboratory (Galvao, et al., 2006; Galvao, et al., 2008b)
with similar populations without the presence of any serious adverse events.
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Physical Function Assessments
Tests of physical function were performed to provide objective functional
measures of strength and endurance. This battery of tests has been used extensively in
our laboratory (Galvao, et al., 2006; Galvao, et al., 2008b; Galvao, et al., 2010; Galvao, et
al., 2008c; Peiffer, et al., 2010) and have reported coefficients of variations for the chair
rise test, 6 meter backwards walk test and 400 meter walk test of 5.6%-6.7%, 9.4% and
2.5% respectively (Galvao, et al., 2006). In addition to providing objective functional
measures of strength and endurance, lower extremity function, assessed in the current
series of studies by the sit to stand test and stair climb have been previously shown to be
highly predictive of subsequent disability in older individuals (Guralnik, Ferrucci,
Simonsick, Salive, & Wallace, 1995).
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Implications of literature review - Conclusion
It is becoming increasing evident that physical activity and exercise play a key role
in the various stages of cancer. Physical activity has been shown to reduce the likelihood
of several types of cancer, in particular breast and colorectal cancer (Key, et al., 2002;
Thune & Furberg, 2001). This review has extensively explored the role of exercise during
treatment for cancer as a method of reducing certain toxicities of the treatment including
fatigue, quality of life and psychological distress whilst also exerting positive influences on
muscular strength and endurance, physical function and body composition. Research is
also emerging in support of the link between physical activity and improved survival rates
in cancer patients demonstrating the far reaching effects of physical activity and exercise
across the entire cancer continuum.
Exercise interventions during cancer treatment date back to 1986 (Cunningham, et
al., 1986) and since then have involved different cancer populations including breast,
colorectal, prostate and mixed populations whilst the interventions have included aerobic
exercise, resistance training or a combination of both. The interventions have also varied
in terms of settings with some being gym or laboratory based whilst others have been
home based. Numerous psychological and physiological endpoints have been used with
the most common being fatigue, quality of life, physical fitness and function, muscular
strength and endurance and body composition. Investigators have most commonly used
breast cancer patients with study results varying due to the differences in settings and
psychological and physiological endpoints.
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Whilst exercise interventions in breast cancer patients during treatment have been
numerous, there are only limited studies that have attempted to explore the role of
exercise in prostate cancer patients undergoing ADT. Of the six interventions conducted
whilst patients were undergoing ADT, three were resistance only interventions (Galvao, et
al., 2006; Hansen, et al., 2009; Segal, et al., 2003b), two were combined aerobic and
resistance interventions (Culos-Reed, et al., 2009; Galvao, et al., 2010) whilst the
remaining study compared aerobic and resistance exercise interventions (Segal, et al.,
2009). Of the two combined aerobic and resistance interventions, one of these was a
home based intervention (Culos-Reed, et al., 2009) and the other was a short term (12
weeks) intervention (Galvao, et al., 2010). The majority of previous studies investigating
the effects of exercise on cancer patients during therapy have been either 12 weeks
duration or less and whilst several have lasted 16 weeks very few have extended beyond
this. This has been predominantly due to the nature of the treatments lasting 12 weeks or
less (Baskar, et al., 2012; Heidenreich, et al., 2011). However, as ADT treatment may last
several months up to several years, little is known about the long term effects of exercise
during longer duration ADT. There are currently no long- term randomised controlled
trials investigating the effects of a combined aerobic and resistance training intervention
during ADT for the treatment of prostate cancer. Baumann, et al. (2011) in a recent
review have highlighted the need for further randomised controlled trials with high
methodological quality to be conducted to establish evidenced-based recommendations
for prostate cancer patients.
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Conclusion
A complex relationship exists between prostate cancer, ADT, metabolic factors,
physical fitness and the subsequent risk of cardiovascular disease. There is now an
abundance of literature suggesting ADT does in fact adversely affect traditional CVD risk
factors; however the timing of the onset of these risk factors and other related side
effects still needs to be explored. The timing of the onset of these risk factors has
implications on the scheduling of exercise interventions and associated time course
responses to exercise during ADT treatment. Long term clinical trials are required to
investigate interventional strategies that not only reduce the CVD risk factors associated
with ADT but also other treatment related toxicities such as fatigue and quality of life.
Although current research supports the positive psychological outcomes (e.g.
improvements in quality of life), questions remain how specific physiological outcomes
such as cardiorespiratory function, vascular function, blood pressure, lipids and glycemic
control would adapt following a combined aerobic and resistance training exercise
intervention. Based on current recommendations from the American College of Sports
Medicine (1998) to incorporate both aerobic and resistance exercise to enhance
cardiovascular and musculoskeletal function in healthy older adults and more recently in
cancer survivors (ACSM, 2010), a similar approach should be tested in a long term
randomised controlled trial in prostate cancer patients on ADT.
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CHAPTER 3

Feasibility and safety of maximal exercise testing in men receiving
androgen deprivation therapy for prostate cancer
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INTRODUCTION
Exercise is being increasingly established as a key adjuvant therapy in clinical
oncology with a growing body of literature providing strong evidence that exercise is well
tolerated, safe, and can mitigate several common treatment related side-effects (Jones &
Alfano, 2013). As a growing number of cancer patients begin to undertake structured
exercise programs (Baumann, et al., 2011; Jones & Alfano, 2013) it is necessary to
determine the safety and feasibility of formal exercise testing in clinical settings as it is
becoming increasingly used as a screening tool and for exercise prescription purposes
(Jones, et al., 2007a). Given that many cancer patients are older (Yancik, 2005), combined
with the potential adverse cardiovascular effects of certain cancer treatments (Albini, et
al., 2010), the risk of cardiovascular disease is often elevated in these populations (Albini,
et al., 2010; Jones, et al., 2007b; Keating, et al., 2009) highlighting the need for thorough
screening prior to commencing an exercise program.
Pre-exercise screening will often include a series of questions designed to identify
individuals with signs or symptoms of underlying disease. These questionnaires may be
used in addition to detailed medical history and physical examination (Balady, et al.,
1998). Further screening often involves cardiopulmonary exercise testing which provides
an objective determination of an individual’s cardiorespiratory fitness and baseline
parameters for training intensities as well as accurate screening for cardiac, pulmonary
and physical limitations (Balady, et al., 1998).
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When cardiopulmonary testing is used during incremental exercise with
continuous gas exchange it provides the only way of assessing maximal oxygen
consumption directly. Maximal oxygen uptake as assessed in a graded exercise test is the
greatest amount of oxygen that can be consumed while performing dynamic exercise
involving large muscle groups and is considered to be the gold standard in assessing
cardiopulmonary fitness and exercise capacity (Fletcher, et al., 2001). Whilst the
assessment of peak exercise during a graded exercise test may be subjective due to the
motivation of the patient, the collection of expired gas can provide an objective measure
of maximal exercise capacity (Cohn, 1999). The inclusion of electrocardiography (ECG) can
be applied as both a diagnostic and screening tool (Steins Bisschop, et al., 2012). The use
of ECG monitoring during a graded exercise test allows for the non-invasive measurement
of the heart’s ability to respond to stress in a controlled environment and aids in the
diagnosis of coronary artery disease and estimating prognosis for cardiac outcomes
(Sharma, Kohli, & Gulati, 2012). Whilst traditional exercise stress tests are primarily
concerned with ST segment changes indicative of myocardial ischemia, the addition of
exercise capacity, heart rate and blood pressure responses all enhance the diagnostic and
prognostic value of the exercise test (Sharma, et al., 2012).
Given that androgen deprivation therapy (ADT) for the treatment of prostate
cancer has been associated with an increased risk of cardiovascular disease (Keating, et
al., 2009; Levine, et al., 2010; Saigal, et al., 2007), a comprehensive cardiovascular
screening battery, including clinical exercise testing, may be necessary prior to the
commencement of an exercise program, particularly if the patient is sedentary or has
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identified risk factors. To date, no study has investigated the safety and feasibility of
maximal exercise testing, including ECG, expired gas, heart rate and blood pressure
responses in men undergoing ADT for the treatment of prostate cancer. As such, this
study seeks to determine the feasibility and safety of maximal exercise testing in prostate
cancer patients by reporting descriptive data from maximal exercise tests as well as
reporting any adverse events and exercise abnormalities. From this it may be determined
if ADT treated prostate cancer patients respond differently to maximal exercise when
compared to the available data from healthy age-matched controls. Further, this study will
examine if maximal exercise testing with expired gas and ECG monitoring is a necessary
screening tool in this population.
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METHODS
Subjects were recruited by invitation of their attending specialist physician. One
hundred and twelve prostate cancer patients (age 42 – 89 years) receiving ADT for their
treatment (duration 4.3 ± 4.9 months) underwent a physician supervised multistage
maximal stress test utilising the Bruce protocol (Bruce, 1971) on a motorised treadmill.
The Bruce protocol is a widely used incremental exercise testing protocol consisting of
three minute stages commencing at 2.7km/h and a 10% incline. The speed and incline
increase with each stage with participants encouraged to continue until volitional
exhaustion (Bruce, 1971). Participants in this study were recruited for the purposes of
undertaking a large scale exercise intervention study (Newton, et al., 2009), and as such
the exclusion criteria applied to the intervention study (Chapter 5) also applied to the
current study. The exclusion criteria included the presence of an acute illness or any
musculoskeletal, cardiovascular or neurological disorder that could inhibit exercise
response or adaptation or put the participant at risk from exercising. All participants
obtained medical clearance from their general practitioner and completed a detailed
health history questionnaire. This study protocol was approved by the University Human
Research Ethics Committee and all participants signed informed consent documentation
prior to any data collection.
Participants were continuously monitored with a 12-lead ECG system (CardioDirect
12S, Irvine, CA) at rest, during the maximal exercise test and during recovery. During the
maximal exercise test the subject’s expired gases were collected (Parvo Metabolic
Measuring System, Sandy, UT) to measure their maximal oxygen uptake (V
VO2max).
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V O2max was determined to be the point at which the highest V O2 value was recorded
over an averaged 30s period. All subjects were instructed to exercise until volitional
exhaustion or they experienced signs or symptoms necessitating the termination of the
test which included: 1) chest pain, 2) ischemic ECG changes, or 3) an abnormal blood
pressure response. A plateau in oxygen consumption was used as qualification for
achieving VO2max. In the absence of a plateau, a secondary criteria was a Respiratory
Exchange Ratio (RER) >1.1. If the subject was unable to achieve a plateau or RER values
>1.1 their data were excluded from the presentation of maximal values. The coefficient of
variation for VO2max (repeated maximal exercise tests) is approximately 4% (Howley,
Bassett, & Welch, 1995). V O2max is presented as an absolute value and relative to body
mass as well as metabolic equivalent of task (METS), where 1 MET is equivalent to 3.5 ml
O2.kg.min-1. The duration of the maximal exercise test is presented as minutes: seconds.
Systolic and diastolic blood pressure was assessed via manual auscultation using a
mercury column sphygmomanometer and appropriate-sized cuff pre-test whilst in the
standing position on the treadmill, during the last minute of each stage and 3 minutes
post cessation of exercise.

Positive Test Criteria
A positive (abnormal) test was defined as 1) any significant ECG change indicative
of ischemia during exercise or recovery, or 2) the development of exercise induced bundle
branch block. A significant ECG change was defined as ≥0.1mV of horizontal or downsloping ST-segment depression ≥ 80 milliseconds after the J-point (as compared to the
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level of the PQ interval) (Gibbons, et al., 1997). ST segment changes toward the isoelectric
line were not considered positive, regardless of the magnitude of change. If the baseline
ECG revealed a J-ST segment depression of >0.05mV, then ‘double criteria’ (an additional
0.2mV) of ST depression was required with the appropriate horizontal or down-sloping
morphology to qualify as a positive test (Jones, et al., 2007a). All cases were interpreted
by the same supervising physician.
For further analysis, participants were stratified into two groups: 1) patients receiving ADT
<3 months (acute ADT) or 2) patients receiving ADT ≥3 months (chronic ADT) to determine
if additional ADT exposure does influence the physiological responses to maximal exercise.
Several studies have reported negative metabolic changes after short-term (3 months)
ADT (Dockery, et al., 2003; Smith, et al., 2001; Smith, et al., 2006), suggesting an acute
exposure to ADT may be sufficient to elicit an adverse cardiovascular profile and hence
alter the physiological response to exercise.
Body weight and height were measured using standard anthropometric measures.
Body weight was measured to the nearest 0.1kg using a digital scale (AND TB: 200), whilst
height was measured to the nearest millimetre using a wall mounted stadiometer (SECA
700, Brooklyn, NY). Body mass index (BMI, kg/m2) was calculated as body mass (kg)
divided by height (m) squared. Whole body fat was assessed by dual energy X-ray
absorptiometry (DEXA, Hologic Discovery A, Waltham, MA).
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Statistical Analysis
Data analyses were performed using the Statistical Package for Social Sciences
version 18.0 software (PASW, Chicago, IL). Standard descriptive statistics were used to
describe subject characteristics. Differences between groups VO2max were examined
using Student’s independent t test while blood pressure and heart rate responses were
examined using 2 x 4 mixed model analysis of variance procedures. All tests were twotailed and an alpha level of 0.05 was applied as the criterion for statistical significance.
Data were assessed for normality using the Kolmogorov-Smirnov test. Results are
reported as the mean ± standard deviation.
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RESULTS
Subject characteristics
One hundred and twelve participants were tested for the purposes of this study.
Of the one hundred and twelve, ninety five participants (85%) met the criteria for
attainment of VO2max. The characteristics for the one hundred and twelve participants
are presented in Table 2. Mean ADT duration was 2.0 ± 0 months and 7.1 ± 6.2 months for
the acute and chronic groups, respectively. There were no significant differences between
groups for any descriptive characteristics. A borderline difference was observed (p=0.053)
for body fat %.
Table 2. Subject characteristics including age, testosterone, height, body mass, body mass
index and aerobic fitness (n=112).
Variable

Mean ± SD

Acute ADT

Chronic ADT

Mean

Mean ± SD

Mean ± SD

Difference

n=60

n=52

(95% CI)

P Value

Age (years)

68.8 ± 9.3

67.6 ± 9.0

69.9 ± 9.6

-2.3 (-6.1, 1.6)

0.254

Testosterone
(mmol/L)

1.4 ± 2.6

1.3± 1.5

1.5 ± 3.4

-0.2 (-1.2, 0.8)

0.651

Height (cm)

172.4 ± 6.5

172.1 ±
6.6

172.9 ± 6.4

-0.8 (-3.7, 2.1)

0.589

Body Mass (kg)

84.0 ± 13.6

84.3± 13.2

83.7 ± 14.2

0.7 (-5.1, 6.4)

0.822

Body Mass Index
(kg.m2)

28.0 ± 3.9

28.2 ± 3.8

27.8 ± 4.0

0.4 (-1.4, 2.1)

0.678

27.3 5.2

26.4 5.1

28.3 5.2

-1.9 (-4.0, 0.1)

0.053

Body Fat %
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Adverse events and abnormal ECG responses.
Of the ninety-five participants who achieved VO2max, three positive tests (3.2%)
and ninety-two negative tests (96.8%) were observed. Two positive tests were due to ST
segment depression while the remaining positive test was due to right bundle branch
blockage. There were no positive events in the seventeen participants who failed to meet
the criteria for VO2max. The three participants who recorded a positive stress test were
sent for further examination. All three participants were cleared of any serious issues
precluding them from participating in an exercise intervention. One participant had their
maximal exercise test postponed due to poorly controlled blood pressure (>200mmHg
systolic or 110mmHg diastolic) but returned at a later date to safely complete the test.

Cardiorespiratory fitness
The cardiorespiratory fitness data are presented in Table 3. Combined relative
VO2max for all participants was 24.7 ± 6.0 ml.kg.min-1 (range 13.7 – 45.2 ml.kg.min-1).
There was a significant difference in cardiorespiratory fitness between the acute and
chronic groups with a significantly higher value in the acute group relative to body mass
(P=0.020), as an absolute value (p=0.035) or in corresponding metabolic equivalents
(P=0.020). Whilst not statistically significant (P=0.080), the acute group was able to
complete an additional 59 seconds of the exercise stress test.

Heart rate and blood pressure response to exercise
Heart rate increased significantly (P<0.001) from baseline (93±13 bpm) to the end
of stage one (119±17 bpm), stage two (136±18 bpm) and VO2max (155±18 bpm). There
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was no time by group interaction (P=0.378) between acute and chronic groups during the
test with acute and chronic groups increasing heart rate by 76±17 bpm and 73±12 bpm,
respectively. There were also no significant difference observed between groups for heart
rate recovery after 3 minutes of low intensity active recovery with values of 46±13 bpm
and 43±19 bpm for the acute and chronic groups, respectively.
Systolic blood pressure increased significantly (P<0.001) from baseline (145±18
mmHg) to the end of stage one (188±28 mmHg) and stage two (205±28 mmHg). There
was no time by group interaction (P=0.941) between acute and chronic groups during the
test with acute and chronic groups increasing systolic blood pressure by 62±24mmHg and
63±27mmHg, respectively. Combined diastolic blood pressure did not increase
significantly (p=0.857) from baseline during the graded exercise test nor did mean arterial
pressure (p=0.344). Further, there was no time by group interaction (p=0.492) between
acute and chronic groups for either diastolic blood pressure or mean arterial pressure
during the test.
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Table 3. Maximal Exercise Testing Data
Variable

All

Acute ADT

Chronic ADT

Mean

P

Participants

Mean ± SD

Mean ± SD

Difference

Value

n=112

n=60

n=52

Between
Groups (95% CI)

Resting Data
Heart Rate

83 ± 13

82 ± 11

84 ± 16

-2 (-8, 3)

0.819

SBP (mmHg)

145 ± 18

144 ± 19

146 ± 16

-2 (-9, 5)

0.609

DBP (mmHg)

87 ± 10

86 ± 10

85 ± 11

1 (-3, 6)

0.547

MAP (mmHg)

106 ± 11

105 ± 11

105 ± 12

0 (-5, 5)

0.940

Heart Rate

119 ± 17

118 ± 17

121 ± 16

-3 (-11, 3)

0.873

SBP (mmHg)

188 ± 28

188 ± 28

188 ± 30

0 (12,12)

0.991

DBP (mmHg)

87 ± 11

86 ± 11

86 ± 14

0 (-5, 5)

0.974

MAP (mmHg)

120 ± 14

118 ± 22

118 ± 25

0 (-10, 10)

0.967

Heart Rate

136 ± 18

135 ± 18

137 ± 19

2 (-11, 6)

0.869

SBP (mmHg)

205 ± 28

205 ± 29

205 ± 29

0 (14, 14)

0.999

DBP (mmHg)

89 ± 12

87 ± 11

90 ± 13

-4 (-9, 2)

0.226

MAP (mmHg)

127 ± 15

123 ± 25

128 ± 17

-5 (-15, 5)

0.302

Submaximal Data
Stage 1

Stage 2
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Maximal Data
Heart Rate

155 ± 18

157 ± 17

152 ± 18

5 (-2, 13)

0.158

SBP (mmHg)

208 ± 30

206 ± 30

209 ± 30

-3 (-15, 10)

0.684

DBP (mmHg)

88 ± 12

87 ± 11

90 ± 13

-3 (-8, 2)

0.214

MAP(mmHg)

128 ± 15

126 ± 14

129 ± 17

-3 (-9, 4)

0.377

1.18 ± 0.09

1.17 0.09

1.19 0.07

-0.02 (-0.06,

0.131

RER

0.01)
VO2max

24.7 ± 6.0

26.1 6.0

23.2 5.8

2.9 (0.5, 5.3)

0.020

VO2max (L.min-1)

2.1 ± 0.9

2.3 1.1

1.9 0.6

0.4 (0.1, 0.7)

0.035

VO2 (METS)

7.1 ± 1.7

7.5 1.7

6.6 1.6

0.8 (0.1, 1.5)

0.020

Maximal Test

8:06 ± 2:43

8:33 2:46

7:34 2:36

0:59 (-0:07,

0.080

(ml.kg.min-1)

Duration (min)

2:05)

Recovery Data
(3min post)
Heart Rate

111 ± 17

113 ± 18

108 ± 17

5 (-4, 13)

0.303

SBP (mmHg)

178 ± 31

177 ± 31

179 ± 32

-2 (16, 12)

0.785

DBP (mmHg)

83 ± 11

81 ± 11

84 ± 14

-3 (-9, 2)

0.218

MAP(mmHg)

114 ± 16

113 ± 15

116 ± 18

-3 (-10, 4)

0.415

Note: SBP; Systolic blood pressure, DBP: Diastolic blood pressure, MAP; Mean arterial
pressure, RER; respiratory exchange ratio, METS; metabolic equivalent
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DISCUSSION
This study examined the feasibility and safety of maximal treadmill exercise in
prostate cancer patients undergoing ADT. This study demonstrated that 85% of the
participants were able to meet the criteria established for the achievement of VO 2max. In
terms of participant safety, three positive tests (3.2%) were observed while one test was
postponed due to poorly controlled blood pressure. Although three positive tests were
observed, further examination revealed no underlying issues that would preclude the
individual from commencing an exercise program. The test postponed due to poorly
controlled blood pressure was conducted at a later date without issue. This demonstrates
that maximal exercise testing in this population appears to be a relatively safe and feasible
assessment tool to be used for both screening and exercise prescription purposes.
In this study, ADT treated prostate cancer participants VO2max of 24.7 ± 6.0
ml.kg.min-1 fell within the 10th – 15th percentile for age-matched (60-69y) men according
to the American College of Sports Medicine Guidelines for Exercise Testing and
Prescription (Thompson, Gordon, & Pescatello, 2010), however, peak blood pressure
response of 208±30/ 88±12 mmHg closely corresponded to the age- and sex-predicted
maximal mean blood pressure response of 197±24/ 84±12 mmHg reported by Daida,
Allison, Squires, Miller, and Gau (1996) using the Bruce treadmill protocol. The maximal
heart rate value of 155±18 bpm falls between the two most common maximal heart rate
formulas of 220-age (151 bpm) (Fox, Naughton, & Haskell, 1971) and 208 – 0.7 x age (159
bpm) (Tanaka, Monahan, & Seals, 2001). This suggests that aside from the relatively low
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VO2max values recorded in this study (10 -15th percentile), the cardiovascular response to
exercise is similar in this cancer population to that of healthy age-matched individuals.

Acute vs. chronic ADT exposure
When comparing acute and chronically suppressed ADT participants’ physiological
responses to the maximal exercise test, VO2max was the only variable significantly
differentiating the groups with a mean difference of 0.4 L.min -1 (95% CI 0.1, 0.7). The
difference in VO2max remained significant even when reporting relative to body mass with
a mean difference of 2.9 ml.kg.min-1 (95% CI 0.5, 5.3). It is not known why these
differences occurred between the two groups. One possible reason may be due to the
reduction of physical activity levels after cancer diagnosis. While not measured in the
present study, physical activity has been shown to decline from pre-diagnosis levels in
cancer patients (Courneya & Friedenreich, 2007; Irwin, et al., 2003) and could result in a
reduction of cardiac output and oxidative capacity (Jones, Eves, Haykowsky, Freedland, &
Mackey, 2009; Steins Bisschop, et al., 2012). Both heart rate and blood pressure
responded similarly pre, during and post-test regardless of the duration of ADT exposure,
as did heart rate recovery. With regard to the ECG responses, all three positive tests were
in the acute ADT exposure group, however, due to the small number of positive tests no
conclusion can be drawn as to the likelihood of a positive test being related to duration of
ADT exposure.
In a recent review, Steins Bisschop, et al. (2012) examined the safety and feasibility
of cardiopulmonary exercise testing in cancer patients which included one prostate cancer
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study. Twenty studies describing 1158 patients were deemed to meet the review eligibility
criteria and of the twenty studies only eleven reported whether adverse events occurred.
Of the eleven studies it was reported that adverse events only occurred in 1% of all tests,
however the low incidence may be due to the fact that only 55% of the studies reviewed
utilised ECG monitoring procedures. The relatively low rate of positive tests in the current
study is also similar to previous work in clinical non-cancer populations (ATS/ACCP, 2003).
In an extensive review conducted by Fletcher, et al. (1995) the risk of death and life
threatening complications during maximal exercise testing was reported to be 0.5 per 100,
000 tests in healthy individuals while in patients with cardiovascular disease this rate rises
to 2-5 per 100, 000 tests. As a result of these findings it appears that the risk of an adverse
event in maximal exercise testing appears to be dependent upon the extent of underlying
disease (Jones, et al., 2007a).
Given ADT has been associated with an increased risk of cardiovascular disease
(Keating, et al., 2009; Levine, et al., 2010; Saigal, et al., 2007) it is recommended that
prostate cancer patients undergo a thorough screening process prior to commencing an
exercise intervention. Further, maximal exercise testing with gas exchange provides an
objective measure of maximal aerobic capacity which can form the basis of aerobic
exercise prescription and accurately assess the effectiveness of the exercise intervention.
Given the relatively low number of positive tests and subsequent clearance of any serious
cardiac complications in this study, this early evidence suggests that risk of adverse events
is relatively low in this population and certainly no higher than age-matched apparently
healthy individuals.
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As the priority is to get more men with prostate cancer to exercise and not to
create barriers to participation as a result of expensive equipment and additional staffing
requirements, an exercise stress test is strongly recommended but should not be a
requirement prior to commencing an exercise program.
Whilst the findings of this study are promising, several limitations need to be
considered when interpreting the results of this study. The sample size of this study is
relatively low making it difficult to detect group differences in acute and chronic ADT
responses. Selection bias does exist in this study due to the nature of recruitment. All
participants who underwent the maximal exercise test were recruited for the purposes of
participating in a randomised controlled trial investigating the effects of an exercise
intervention on reducing treatment-related side effects in men receiving therapy for
prostate cancer (Newton, et al., 2009). As such the exclusion criteria applied to the
intervention study was required to be met in order to complete the maximal exercise test.
The small amount of positive tests observed, although promising from a safety aspect,
does make it difficult to detect group differences. Larger sample size studies are required
to definitively determine if ECG monitoring is a necessary part of screening prior to
participating in exercise in this population.

Conclusion
Maximal treadmill exercise testing in prostate cancer patients undergoing ADT was
demonstrated to be feasible and safe with 85% of participants able to achieve the criteria
established for achievement of VO2max and only 3.2% of participants recording a positive

103

test. ADT treated prostate cancer patients responded similarly to a maximal graded
exercise test regardless of ADT time exposure. This study provides preliminary evidence to
suggest a relatively low risk of adverse events exists when ADT treated prostate cancer
patients undergo maximal exercise. Whilst an exercise stress test provides a valuable
screening tool and is useful for exercise prescription purposes, it should not create an
additional barrier to participation in an exercise program.
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CHAPTER 4

Cardiovascular capacity, resting metabolic rate, vascular function,
body composition and physical function in men undergoing acute
and chronic androgen deprivation: a cross-sectional investigation
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INTRODUCTION
Androgen deprivation therapy (ADT) has become a widely used treatment for
prostate cancer (Heidenreich, et al., 2011). Previously, ADT was reserved for patients with
bone metastases (advanced stages), however, since the early 1990’s ADT has become
more prevalent in locally advanced prostate cancer with improved disease free and overall
survival rates reported (Bolla, et al., 2002; Shahinian, Kuo, Freeman, Orihuela, & Goodwin,
2005a). Although ADT has been highly successful in terms of improving prostate cancer
survival rate, there are an increasing number of studies reporting associations between
ADT and treatment related toxicities, such as reduced bone and lean mass, loss of muscle
strength, negative changes in lipid profiles, and increased risk of cardiovascular disease
(CVD) as well as numerous metabolic complications all of which can act to compromise
physical function and quality of life (Basaria, et al., 2006; Galvao, et al., 2008b; Greenspan,
et al., 2005; Shahinian, et al., 2006; Sharifi, et al., 2005a; Smith, et al., 2002b). Given the
successful outcomes of this treatment, ADT is often commenced in men with early stage
prostate cancer (Chodak, 1998) with treatment at times extended over several years
(Michaelson, et al., 2008).
Treatment time can affect the likelihood and severity of certain treatment-related
toxicities. For example, early work by Smith, et al. (2001) reported that increased arterial
stiffness and adverse body compositional changes were associated with increasing insulin
concentrations after only 6 months of ADT treatment which suggested a reduced insulin
sensitivity. In terms of metabolic adaptations, Dockery, et al. (2003) reported an increase
in serum insulin levels after only 3 months of ADT exposure. Alibhai et al. (2010) recently
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investigated physical function and quality of life changes in men undergoing ADT at
various time points. The authors reported declines in physical function, grip strength and
self-reported physical function when compared with controls; secondary findings
indicated ADT users had worsening role physical function, bodily pain and vitality. The key
finding of this study was that these reductions in physical function and quality of life were
apparent within the first 3 months of ADT initiation.
Basaria et al., (2006) have investigated the metabolic implications of long-term
ADT and found men receiving >12 months ADT developed insulin resistance and
hyperglycaemia, independent of age and BMI. Long term ADT has also been associated
with frank diabetes and metabolic syndrome (Basaria, 2008) whilst Saigal and colleagues
(2007) found 24% of men undergoing ADT experienced a cardiovascular event within 1-4
years of starting treatment versus 18% in a matched group of men not receiving ADT.
The current study was initiated to determine if risk factors for CVD are associated
with subsequent cycles of therapy providing further support for lifestyle interventions to
be part of the treatment plan for men undergoing ADT. In addition to CVD risk factors,
muscle function and physical performance measures were determined given the impact of
ADT on age-related loss of muscle strength and function and the paucity of research in this
area. Therefore, the aim of this cross-sectional study was to investigate if therapy time
exposure is associated with additional risk factors for CVD, metabolic treatment relatedtoxicities and physical function by comparing acute versus chronic ADT-treated patients.
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METHODS
Participants
Subjects were recruited by invitation of their attending specialist physician. One
hundred and seven men undergoing treatment for prostate cancer involving ADT with no
formal regular exercise training (undertaking structured aerobic or resistance training less
than two times per week) within the previous 3 months were recruited for this study. All
participants had been hypogonadal for a period of at least 2 months prior to testing.
Exclusion criteria included the presence of an acute illness or any musculoskeletal,
cardiovascular or neurological disorder that could inhibit or put them at risk from
exercising. As this cohort were also recruited for the purposes of partaking in an exercise
intervention (Chapter 5), the participants were informed that they were required to be
able to walk 400 m and to undertake upper- and lower-body exercises. All participants
obtained medical clearance from their general practitioner and completed a detailed
health history questionnaire. This study protocol was approved by the University Human
Research Ethics Committee and all participants signed informed consent documentation
prior to any data collection.

Protocol
Participants were stratified into two groups: 1) patients receiving ADT <3 months
(acute ADT) or 2) patients receiving ADT ≥3 months (chronic ADT), based upon recent
findings of Alibhai, et al. (2010) and Smith, et al. (2006). Alibhai, et al. (2010) indirectly
assessed cardiorespiratory endurance and upper extremity strength and reported these
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outcomes were negatively affected within 3 months of starting ADT whilst Smith, et al.
(2006) have previously investigated insulin sensitivity during ADT and have reported that 3
months of treatment significantly increased fat mass and decreased insulin sensitivity.
Given that inclusion criteria required participants to be hypogonadal for a period of 2
months prior to the commencement of testing, the acute group were tested within 8-12
weeks of initiating androgen deprivation therapy. Subjects performed a familiarisation
session to reduce any learning effect gained throughout baseline testing. The battery of
tests were completed over a 2-day period and included cardiorespiratory capacity, body
composition, blood pressure and arterial stiffness, blood collection, muscle strength and
endurance, and physical function.

Cardiorespiratory Capacity:
Participants performed a standardised progressive maximal walking test (Bruce
Protocol) on a motorized treadmill supervised by a physician. During this test, the
subject’s expired gases were collected (Parvo Metabolic Measuring System, Sandy, UT) to
measure their maximal oxygen uptake (V·O2max). V·O2max was determined to be the point at
which the highest V·O2 value was recorded over an averaged 30s period. All subjects were
encouraged to achieve maximal exertion. A plateau in oxygen consumption was used as
qualification for achieving VO2max, in the absence of a plateau, a secondary criteria was a
Respiratory Exchange Ratio (RER) >1.1. If the subject was unable to achieve plateau or an
RER value >1.1 their data were excluded from the analysis. Although not measured in this
laboratory the coefficient of variation for repeated maximal exercise tests is
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approximately 4% (Howley, et al., 1995). V· O2max is presented as an absolute value and
relative to body mass as well as metabolic equivalent of task (METS). The average time of
the test is also reported.
The electrocardiogram (ECG) was recorded using a 12-lead monitoring system
(CardioDirect 12S, Irvine, CA) and blood pressure was measured during the last minute of
each 3-minute stage via manual auscultatory technique. The coefficient of variation for
the measurement of systolic and diastolic blood pressure is 5.7% and 5.3%, respectively
(Marshall, 2004).

Body Composition:
Body weight and height were measured using standard anthropometric measures.
Body weight was measured to the nearest 0.1kg using a digital scale (AND TB: 200), whilst
height was measured to the nearest millimetre using a wall mounted stadiometer (SECA
700, Brooklyn, NY). Body mass index (BMI, kg/m2) was calculated as body mass (kg)
divided by height (m) squared. Whole body as well as regional fat and lean tissue mass
was assessed by dual energy X-ray absorptiometry (DEXA, Hologic Discovery A, Waltham,
MA). Measurements of whole body, upper limb, lower limb, and trunk lean and fat mass
and percentage body fat were derived from the whole body scan. Appendicular skeletal
muscle (ASM) was calculated by combining upper extremity lean mass and lower
extremity lean mass. In our laboratory, the coefficient of variation involving duplicate
scans with repositioning are less than 1% for body composition variables (Galvao, et al.,
2006). Circumference measures were taken at standardised sites (Thompson, et al., 2010)
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including the waist, hip, arm and calf and reported to the nearest 0.1 mm.

Resting Metabolic Rate
On the same day following the DEXA scan, resting metabolic rate (RMR) was
measured via respiratory gas analysis over a period of 20 minutes with a 5-minute period
used for analysis. The period selected was based upon the analysis of oxygen consumption
with a coefficient of variation of <10%. Using standardised procedures, the subject was
completely rested in a darkened room for 10 minutes prior to the mouthpiece being fitted
for the 20 minute collection period (Compher, Frankenfield, Keim, & Roth-Yousey, 2006).
Resting metabolic rate was presented as kcals per 24hrs as well as kcals/ 24hrs relative to
total body mass (kcals/kg/24hr) and total lean mass (kcals/lean kg/24hrs). A previous
study investigating the intra-individual variations in resting metabolic rates have reported
a coefficient of variation of 2.9% (Soares & Shetty, 1986).

Blood Pressure and Arterial Stiffness:
A validated oscillometric device (HEM-705CP, Omron Corporation, Japan) was used
to record brachial blood pressure at the dominant arm in triplicate (O'Brien, Mee, Atkins,
& Thomas, 1996). This is presented as peripheral diastolic blood pressure, peripheral
systolic blood pressure and peripheral mean arterial pressure. Central (ascending aortic)
blood pressure and indices of arterial stiffness were determined by pulse wave analysis
using the SphygmoCor version 6.1 software (AtCor Medical, Sydney, Australia). This is
presented as central diastolic blood pressure, central systolic blood pressure and central
mean arterial pressure. Radial artery pressure waveforms were captured at the right arm
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by applanation tonometry using a high fidelity micromanometer (SPC-301, Millar
Instruments, Houston, Texas, USA). A generalised transfer function was applied to the
radial artery waveform in order to obtain the central pressure waveform at the ascending
aorta. This method has been validated against invasive techniques for determination of
central blood pressure (Karamanoglu, O'Rourke, Avolio, & Kelly, 1993; Pauca, O'Rourke, &
Kon, 2001) whilst the augmentation index (AIx) is a marker of systemic arterial stiffness
and presented as the ratio of augmentation to central pulse pressure, expressed as a
percentage (Safar & London, 2000; Williams, et al., 2006). Variability has been previously
reported as 0.3 mmHg for central systolic pressure and 1.5% for augmentation index.
Carotid to radial pulse wave velocity was measured by collecting arterial pressure
waves at both the carotid and radial locations. The surface distance between the two
locations was measured and the pressure wave transit time was calculated using a foot of
the wave to foot of the wave method. The reported coefficient of variation for forearm
(radial) pulse wave velocity is 2.9% whilst the brachial pulse wave velocity coefficient of
variation is 7.7% (Nottin, et al., 2006).
Participants were instructed to undertake no strenuous physical activity for 24 hrs
and fast for 12 hours prior to the test. Participants were completely rested for 30 minutes
prior to the test (RMR testing was conducted immediately prior). Participants were also
asked to maintain similar dietary patterns in the 2 days prior and any medications were
recorded.
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Metabolic Profile:
Venous blood samples (2 x 8.5 ml) were drawn from the antecubital vein to assess
markers of cardiovascular disease and diabetes. Full blood analysed for haemoglobin A1C
whilst the remaining blood was separated and the serum and plasma analysed for
testosterone, insulin, PSA, triglycerides, LDL cholesterol, HDL cholesterol, total cholesterol,
and glucose. Participants were asked to maintain similar dietary patterns prior to the
blood tests. All blood variables were analysed commercially by accredited Australian
National Association of Testing Authorities laboratories (Pathwest Laboratory Medicine,
WA).

Muscle Strength and Endurance:
As mentioned above, subjects were familiarized to all assessment procedures
during their familiarisation session. Dynamic concentric muscle strength for the chest
press, seated row, leg press and leg extension exercises was measured using the onerepetition maximum (1-RM) method as previously used with a similar population (Galvao,
et al., 2006). The coefficient of variation in our laboratory for 1RM measures performed
approximately 1 week apart is 2.2-7.5% (Peiffer, et al., 2010). Muscular endurance was
assessed using the maximal number of repetitions performed at 70% of 1-RM for the
chest press and leg press exercises representing upper and lower body muscle endurance,
respectively (Galvao & Taaffe, 2005). Reported coefficients of variation for the chest and
leg press muscular endurance are 6.3% and 6.8%, respectively (Galvao, et al., 2006;
Peiffer, et al., 2010).
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Physical Function:
A battery of tests were used to assess functional performance and are similar to
those used previously with a similar population (Galvao, et al., 2006). The tests were
performed in triplicate (except for the 400-m walk which was performed once) with
sufficient recovery time between trials. The best performance on each test was used in
the analyses.
Repeated chair rise - participants were seated with their arms folded across their
chest and rose to a standing position without using their hands for support and then
returned to a seated position as fast as possible, with the outcome being the time taken to
perform this task 5 times. Timing was started from the command ‘go’ and the total time
required to complete all 5 cycles was recorded with a handheld stopwatch. The coefficient
of variation for the repeated chair rise in our laboratory is 5.6%-6.7% (Galvao, et al., 2006).
Stair climb - participants were instructed to climb a flight of stairs (11 steps at 16
cm height per step) as fast as possible, without using the handrail. Time to complete the
stair climb was recorded using a handheld stopwatch with the tester standing at the top of
the flight of stairs. The coefficient of variation in our laboratory for the stair climb is 4.8%
(Galvao, et al., 2006).
6-meter backward tandem walk - as a test of dynamic balance, participants
covered a 6 meter distance walking backwards with one foot being placed directly behind
the other so the heal of one foot and the toes of the other foot were touching. Time to
complete the task was determined using electronic timing gates positioned at 0 and 6
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meters (Kinematic Measurement System, Fitness Technology, SA Australia). The
coefficient of variation for the 6-meter backwards walk test is 9.4% (Galvao, et al., 2006).
6-meter usual and fast walk- Participants were assessed for their usual walking
pace explained to them as the pace they would usually walk whilst carrying out everyday
activities. The fast paced walk required participants to cover the 6 meters at their
maximal walking pace. Times were recorded using the same method as the 6-meter
backwards tandem walk (Kinematic Measurement System, Fitness Technology, SA
Australia). The coefficients of variation in our laboratory for the usual and fast walk are
5.6% and 6.7%, respectively (Peiffer, et al., 2010).
400 meter walk – Participants were required to walk 400 meters, consisting of 10
laps out and back over a 20 meter straight path at a pace as fast as they could maintain for
the distance of the test. Time taken to complete the test was recorded via a handheld
stopwatch, reported to the nearest second. The coefficient of variation for the 400 meter
walk test is 2.5% (Galvao, et al., 2006).
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Statistical Analysis:
Data analyses were performed using the Statistical Package for Social Sciences
version 18.0 software (PASW, Chicago, IL). Normality of the data were assessed using the
Kolomogorov-Smirnov test. The analyses included standard descriptive statistics and
Student’s independent sample t tests. A chi square test was used to determine differences
in metabolic syndrome variables between groups. All tests were two-tailed and an alpha
level of 0.05 was applied as the criterion for statistical significance. Results are reported as
the mean ± standard deviation.

116

RESULTS
Subject Characteristics
One hundred and seven participants were tested for the purposes of this study.
Combined participant characteristics are presented in Table 4. Subject characteristics
separated for the acute and chronic ADT exposure groups are presented in Table 5.

Table 4. Subject characteristics including age, height and body composition variables
(n=107).
Variable

Mean ± SD

Range

Age (years)

68.6 ± 8.8

42.0 – 89.0

Height (cm)

172.4 ± 6.3

156.0 – 186.0

Body Mass (kg)

84.0 ± 13.7

59.0 – 146.2

Body Mass Index (kg.m2)

28.5 ± 4.15

20.2 – 43.2

Waist Circumference (cm)

99.5 ± 12.5

64.0 – 151.0

Waist to Hip Ratio

1.00 ± 0.1

0.62 – 1.25
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There were no significant differences in any of the subject characteristics between the
acute and chronic ADT exposure groups.
Table 5. Subject characteristics including age, height and body composition variables for the acute
and chronic ADT exposure groups.

Variable

Acute ADT

Chronic ADT

Mean Difference

Mean ± SD

Mean ± SD

(95% CI)

n=57

N=50

Age (years)

67.6 ± 8.9

69.9 ± 9.7

-2.3 (-5.9, 1.3)

0.395

Height (cm)

172.2 ± 6.4

172.7 ± 6.3

-0.5 (-3.2, 2.1)

0.648

Body Mass (kg)

85.7± 13.6

83.4 ± 14.0

2.3 (-3.1, 7.8)

0.105

Body Mass Index
(kg.m2)

28.9 ± 4.3

28.0 ± 3.9

0.9 (-0.7, 2.4)

0.215

Waist
Circumference (cm)

99.2 ± 12.1

100.3 ± 12.9

-0.9 (-5.5, 3.9)

0.737
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Body Composition
Body composition variables for the two groups are provided in Table 6. No differences
were observed in lean tissue mass or fat mass between the two groups.
Table 6. Body composition and bone mass variables for acute and chronic androgen
deprivation groups
Variable

Acute ADT

Chronic ADT

Mean Difference

P Value

Mean ± SD

Mean ± SD

(95% CI)

Lean Mass

60.1 ± 7.5

58.0 ± 8.6

2.1 (-1.0, 5.2)

0.184

Upper Limb

6.7 ± 1.6

6.5 ± 1.3

0.2 (-0.4, 0.7)

0.484

Lower Limb

18.7 ± 2.4

18.0 ± 2.7

0.7 (-0.3, 1.6)

0.173

Trunk

30.2 ± 4.2

29.3 ± 4.8

0.9 (0.8, 2.6)

0.316

Appendicular

25.6 ± 3.3

24.5 ± 3.9

1.1 (-0.3, 2.5)

0.112

Fat Mass

23.1± 7.3

24.6 ± 8.3

-1.5 (-4.5, 1.4)

0.307

Upper Limb

2.6 ± 0.8

2.7 ± 0.8

-0.1 (-0.4, 0.2)

0.653

Lower Limb

6.8 ± 2.3

7.7 ± 2.3

-0.9 (1.7, 0.3)

0.058

Trunk

12.4 ± 4.5

12.9 ± 5.8

-0.5 (-2.5, 1.5)

0.627

26.4 5.1

28.3 5.2

-1.9 (-4.0, 0.1)

0.053

Lean tissue mass
(kg)

Skeletal Muscle
Fat mass (kg)

Body fat %
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No differences were observed in any of the girth values measured between the acute and
chronic groups (Table 7.).

Table 7. Girth values for selected regions for acute and chronic androgen deprivation
groups
Variable

Acute ADT

Chronic ADT

Mean Difference

Mean ± SD

Mean ± SD

(95% CI)

Waist Circumference

99.2 ± 12.1

100.3 ± 12.9

-0.9 (-5.5, 3.9)

0.737

Hip Circumference

99.8 ± 7.6

100.4 ± 7.2

-0.5 (-3.4, 2.3)

0.702

Arm Circumference

29.9 ± 3.2

29.6 ± 3.0

0.3 (-0..9, 1.4)

0.659

Calf Circumference

36.5 ± 2.8

36.1 ± 2.7

0.4 (-0.7, 1.4)

0.508
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Cardiorespiratory Capacity
There was a significant difference in cardiorespiratory fitness between the two groups
(Table 8). Maximal oxygen consumption was significantly higher in the acute group when
presented in absolute terms (L.min-1) (p=0.035) and relative terms (ml.kg.min-1) (p=0.020).
Corresponding metabolic equivalents were also significantly higher in the acute group
(p=0.02). Whilst test duration was not statistically significant, the acute group exercised
for an additional 54 seconds.
Table 8. Maximal exercise capacity values as determined from the exercise stress test for
acute and chronic androgen deprivation groups
Variable

Acute ADT

Chronic ADT

Mean Difference

P Value

Mean ± SD

Mean ± SD

(95% CI)

VO2max (L.min-1)*

2.3 ± 1.0

1.9 ± 0.6

0.4 (0.1, 0.7)

0.035

VO2max

26.1 ± 6.0

23.2 ± 5.8

2.9 (0.5, 5.3)

0.020

VO2 (METS)*

7.5 ± 1.7

6.6 ± 1.6

0.9 (0.1, 1.5)

0.020

Test duration (mins)

8.5 ± 2.8

7.6 ± 2.6

(0.9 (-0.1, 2.1)

0.080

(ml.kg.min-1)*
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Resting Metabolic Rate
There was a significant difference observed in resting metabolic rate between the two
groups with the acute group recording a significantly higher (p=0.005) resting metabolic
rate and relative to body mass resting metabolic rate (p=0.017) then the chronic group
(Table 9). Whilst not statistically significant (p=0.079) resting metabolic rate relative to
lean body mass was 1.3 kcal/lean kg/24hr higher in the acute group.
Table 9. Resting metabolic rate for acute and chronic androgen deprivation groups.
Variable

Acute ADT

Chronic ADT

Mean Difference

Mean ± SD

Mean ± SD

(95% CI)

Resting Metabolic Rate
(kcal/24hr)

1795 ± 256

1647 ± 236

147 (46, 249)

0.005

Relative Total Body Mass
Resting Metabolic Rate
(kcal/kg/24hr)

21.5 ± 3.0

20.0 ± 2.6

1.5 (0.3, 2.7)

0.017

Relative Lean Body Mass
Resting Metabolic Rate
(kcal/lean kg/24hr)

30.5 ± 3.2

29.2 ± 4.1

1.3 (-0.2, 2.9)

0.079
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Central Blood Pressure
No differences were observed between groups in any of the central or peripheral blood
pressure variables. Further, there were no differences observed between groups in central
augmentation pressure (Table 10).
Table 10. Hemodynamic and pulse wave analysis parameters for acute and chronic
androgen deprivation groups

Variable

Peripheral SBP
(mmHg)
Peripheral DBP

Acute ADT

Chronic ADT

Mean Difference

P Value

Mean ± SD

Mean ± SD

(95% CI)

150.9 ±

149.0 ± 19.4

1.9 (-5.8, 9.6)

0.624

85.6 ± 12.1

84.5 ± 10.4

1.1 (-3.4, 5.6)

0.626

108.4 ±

107.2 ± 12.8

1.2 (-4.3, 6.7)

0.669

138.7 ± 20.2

0.4 (-7.7, 8.5)

0.922

86.8 ± 12.3

85.5 ± 10.6

1.3 (-3.2, 5.8)

0.571

108.9 ±

107.2 ± 12.8

1.7 (-4.1, 7.5)

0.557

83.5 ± 13.0

86.5 ± 13.9

-3.0 (-8.3, 2.3)

0.261

15.4 ± 8.2

16.7 ± 9.6

-1.3 (4.8, 2.1)

0.445

19.9

(mmHg)
Peripheral MAP
(mmHg)
Central SBP (mmHg)

15.0
139.1 ±
21.1

Central DBP (mmHg)

Central MAP
(mmHg)
Peripheral

16.1

Augmentation Index
(%)
Central
Augmentation
Pressure (mmHg)
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Augmentation Load

Central

14.3 ± 5.0

14.6 ± 4.9

-0.3 (-2.3, 1.6)

0.732

140.4 ±

144.4 ± 19.6

-4.0 (-11.3, 3.3)

0.281

10.0 ± 1.8

0.0 (-0.6, 0.7)

0.983

Augmentation Index

17.8

Pulse Wave Velocity

10.0 ± 1.4
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Muscular Strength & Endurance
The chest press (p=0.013), seated row (p=0.022), leg press (p=0.007) and leg extension
(p<0.001) were all significantly higher in the acute group compared to the chronic group
(Table 11, Figure 1). There were no significant differences observed for upper or lower
body muscular endurance.
Table 11. Maximal strength and endurance values for acute and chronic androgen
deprivation groups

Variable

Acute ADT

Chronic ADT

Mean Difference

Mean ± SD

Mean ± SD

(95% CI)

Chest Press 1RM (kg)*

39.9 ± 12.2

34.1 ± 12.0

5.9 (1.3, 10.5)

0.013

Seated

47.4 ± 8.1

43.5 ± 9.4

3.9 (0.6, 7.2)

0.022

Leg Press 1RM (kg)*

137.8 ± 60.6

110.3 ± 42.7

27.5 (7.8, 47.3)

0.007

Leg Extension (kg)*

55.3 ± 16.9

43.1 ± 17.4

12.2 (5.6, 18.7)

<0.001

Chest Press 70% 1RM

10.0 ± 3.0

9.3 ± 3.7

0.7 (-7.4, 2.2)

0.326

16.5 ± 7.6

16.0 ± 7.4

0.5 (-3.3, 4.3)

0.794

Row

1RM

P Value

(kg)*

(reps)
Leg Press 70%1RM
(reps)

*Note: 1RM = one repetition maximum; reps = number of repetitions
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Figure 1. Maximal strength and endurance values for acute and chronic androgen deprivation
groups

* Denotes significant different between acute vs. chronic ADT exposure, p<0.05.
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Physical Function
The acute group performed the 400m walk significantly (p=0.023) faster than the chronic
group (Table 12, Figure 2). The acute group also performed the chair rise (p=0.014) and
stair climb (p=0.016) significantly faster than the chronic group. No significant differences
were observed in any of the 6m walk times.
Table 12. Physical Function values for acute and chronic androgen deprivation groups

Variable

Acute ADT

Chronic ADT

Mean Difference

Mean ± SD

Mean ± SD

(95% CI)

261.9 ± 38.3

286.8 ± 66.2

-24.9 (-46.3, -3.5)

0.023

Chair rise (s)*

12.7 ± 3.4

14.7 ± 4.7

-2.0 (-3.6, -0.4)

0.014

Stair climb (s)*

5.0 ± 1.3

5.7 ± 1.9

-0.7 (-1.4, -0.1)

0.016

6m normal pace

4.8 ± 0.8

5.0 ± 0.8

-0.2 (0.6, 0.1)

0.121

6m fast pace walk

4.1 ± 0.6

3.6 ± 0.6

0.5 (-0.8, 1.8)

0.481

6m backwards

19.2 ± 7.4

20.6 ± 7.0

-1.4 (-4.2, 1.4)

0.316

400m walk (s)*

P Value

walk

walk
*Denotes significant difference (p<0.05)
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Figure 2. Physical Function values for acute and chronic androgen deprivation groups

* Denotes significant difference between acute vs. chronic ADT exposure, p<0.05.
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Metabolic Profile
No differences were observed between the acute and chronic ADT groups in any of the
blood markers analysed (Table 13).
Table 13. Blood markers for acute and chronic androgen deprivation groups

Variable

Acute ADT

Chronic ADT

Mean Difference

P Value

Mean ± SD

Mean ± SD

(95% CI)

HbA1C (%)

6.4 ± 3.7

6.1 ± 1.0

0.3 (-0.8, 1.3)

0.638

Testosterone (pg.mL-1)

1.3± 1.5

1.5 ± 3.4

-0.2 (-1.2, 0.8)

0.651

Prostate Specific

1.2 ± 1.7

1.4 ± 2.6

-0.2 (-1.1, 0.7)

0.659

Insulin (mU/L)

11.2 ± 6.7

9.2 ± 4.3

2.0 (-0.3, 4.2)

0.085

Triglycerides (mmol/L)

1.3 ± 0.6

1.4 ± 0.7

-0.1 (-0.3, 0.1)

0.393

LDL cholesterol

2.8 ± 0.9

2.9 ± 1.0

-0.1 (-0.5, 0.3)

0.575

1.3 ± 0.4

1.4 ± 0.4

-0.1 (-0.3, 0.1)

0.269

4.7 ± 1.1

4.9 ± 1.0

-0.2 (-0.6, 0.2)

0.287

Glucose (mmol/L)

5.5 ± 1.1

5.9 ± 1.9

-0.4, (-1.0, 0.2)

0.216

C Reactive Protein

2.9 ± 3.3

2.5 ± 2.0

0.4 (-0.7, 1.5)

0.469

Antigen (ng.mL-1)

(mmol/L)
HDL cholesterol
(mmol/L)
Total cholesterol
(mmol/L)

(mg/L)

129

Metabolic Syndrome Variables
According to National Cholesterol Education Program Adult Treatment Panel III, 20.3% of
the acute group and 13.5% of the chronic group were classified as having metabolic
syndrome (Table 14). There were no differences observed between groups for any of the
metabolic syndrome criteria.
Table 14. Percentage of acute and chronic androgen deprivation groups that met the
individual metabolic syndrome criteria and overall metabolic syndrome criteria.
Variable

Acute ADT

Chronic ADT

Mean ± SD

Mean ± SD

16.9%

17.3%

0.998

20%

21.3%

0.874

Serum HDL

20.3%

17.3%

0.815

Waist circumference

39.0%

39.2%

0.994

Hypertension

86.4%

75%

0.093

Meeting <3/5 criteria

20.3%

13.5%

0.337

Fasting plasma glucose
Serum triglyceride
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P value

DISCUSSION
This study examined the difference between acute (<3 months) and chronic (>3
months) androgen deprivation exposure with a variety of cardiovascular, musculoskeletal
and metabolic parameters with the aim of determining if additional therapy time
exposure results in additional cardiovascular disease risk factors or metabolic treatment
related toxicities. This study further sought to explore the effects of therapy time
exposure on physical function. Following post screening and baseline testing participants
were divided into two groups according to time on ADT. A 3-month cut-off for acute and
chronic exposure was defined based upon recent work by Alibhai (2010) as well as several
other studies that have attempted to explore similar outcomes (Dockery, et al., 2003;
Smith, et al., 2006).
Both groups were similar in terms of age, height and body mass. Although not
statistically significant, the chronic androgen deprivation group did have on average 2.1kg
less lean body mass and 1.5kg more fat mass. Whilst neither of these body composition
alterations were significant, it is thought that the combined effect of less lean mass and
more fat mass may be a clinically meaningful difference with regard to functional
performance and metabolic risk factors. In a recent review, Haseen et al. (2010) described
the changes in body composition including body weight, BMI, body fat % and declines in
lean muscle mass in response to ADT. Using pooled data, Haseen et al. (2010) reported
relative mean changes in fat mass of 7.7% (95% CI 4.3%, 11.2%) and fat free mass of -2.8%
(CI -3.6%, 2.0%) in prostate cancer patients undergoing ADT regardless of treatment time
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(3-24 months). Whilst in the present study there was a trend towards greater fat mass
accumulation and reduction in lean mass in the chronically suppressed group when
compared to the acute group, the lack of significant differences is likely due to the
negative alterations in body composition occurring earlier in treatment. Smith (2001) has
reported significant reductions in lean mass after only 1 month of ADT with a follow-up
study revealing 80% of the observed changes in fat and lean mass were evident at 6
months (Smith, et al., 2008). Negative body composition alterations appear to occur after
only a relatively brief exposure to ADT, with longer duration treatment resulting in a
greater amount of fat mass accumulation and loss of lean mass.
To date, no study has used a maximal exercise protocol to directly assess
cardiorespiratory fitness in men undergoing ADT for the treatment of prostate cancer. Our
findings demonstrate there are differences in cardiorespiratory capacity between short
and long term androgen deprivation with the acute group exhibiting significantly higher
maximal oxygen consumption values compared to the chronic group, even when
expressed relative to body mass. The acute group VO2max was 21% higher than the
chronically exposed group, which has important implications when considering low levels
of cardiorespiratory fitness have been associated with a markedly increased risk of
premature death from all causes and in particular, cardiovascular disease in all
populations (Laukkanen, et al., 2010). Conversely, an increase in cardiorespiratory fitness
is associated with a reduced risk of cardiovascular disease (Barlow, et al., 2012). Whilst
not significant, the acute group was able to complete an additional 54 seconds of exercise
when compared to the chronically suppressed group, reflecting the significantly higher
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VO2max values. No differences were observed in any of the blood pressure parameters
between the acute and chronic groups.
Therapy time exposure does appear to influence resting energy expenditure with
the acutely suppressed group reporting a significantly greater resting metabolic rate when
compared to the chronically suppressed group. The majority of studies indicate that fat
free mass plays a major role in the variance in resting metabolic rate amongst individuals
(Cunningham, 1991; Weinsier, Schutz, & Bracco, 1992), with more recent research
suggesting that both fat free mass and fat mass are significant contributors to resting
metabolic rate (Johnstone, Murison, Duncan, Rance, & Speakman, 2005). Whilst no
significant differences in any body composition values were reported between the acute
and chronically suppressed groups, it is likely that the combined effects of the nonsignificant differences in lean body mass (2kg) and fat mass (1.5kg) contributed to this
significant reduction in resting energy expenditure in the chronically suppressed group.
Therapy time exposure does appear to affect muscular strength with the acutely
suppressed group reporting significantly higher strength values than the chronically
suppressed group. This was the case for both upper (chest press and seated row) and
lower (leg press and leg extension) body strength. The greater strength reported in the
acutely suppressed group as accompanied by a greater level of physical function with the
400m walk, chair rise and stair climb all being performed significantly faster compared to
the chronically suppressed group. Whilst Alibhai et al. (2010) have previously observed
declines in physical function in this group of men, the declines generally occurred within 3
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months of initiation of ADT and then remained stable. In contrast, our current findings
indicate that further physical function declines are associated with longer duration ADT.
When exploring cardiovascular disease risk factors, metabolic syndrome has been
widely used as a surrogate marker for cardiovascular disease. In our study, 20.3% of the
acute group and 13.5% of the chronic group met the National Cholesterol Education
Program Adult Treatment Panel III criteria for metabolic syndrome. These values are lower
than the 55% of ADT treated prostate cancer patients previously reported by BragaBasaria (2006a) to have metabolic syndrome but similar to non-ADT treated prostate
cancer patients (22%) and control group (20%) reported in the same study (Braga-Basaria,
et al., 2006a). Whilst on average, neither group met three of the necessary five criteria,
increased waist circumference and hypertension did appear to be the two most common
cardiovascular risk factors present in both groups, demonstrating these risk factors are
present irrespective of treatment duration.
Whilst not measured in the present study, physical activity levels are known to
exert large influences on aerobic fitness and functional performance. Previous research in
breast cancer patients has demonstrated that physical activity levels are significantly
reduced following cancer diagnosis and during treatment (Demark-Wahnefried, et al.,
1997; Irwin, et al., 2003) and that these reductions in physical activity negatively alter
energy balance. It is possible that in the current study physical activity levels were reduced
following diagnosis and either continued to decline as treatment time progressed or the
side effects associated with declining physical activity levels did not present until later in
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treatment which may have contributed to the differences observed in aerobic fitness,
resting metabolic rate and potentially physical function outcomes.

Conclusion
In summary, we found that chronic ADT exposure (>3 months) was associated with
reduced cardiorespiratory capacity, resting metabolic rate, muscular strength and physical
function when compared to those only exposed to ADT for a relatively short amount of
time (<3 months). The exact mechanisms remain unclear as to why these cardiovascular
alterations and physical function variables are further declining as treatment time
progresses although it is thought that physical activity levels, which were not measured in
this study, may have influenced the results. Although there was a trend towards
alterations in lean body mass and fat mass, the lack of significant differences seen in body
composition variables may be attributed to the fact that these negative alterations were
occurring after only a relatively brief exposure to ADT treatment. These findings suggest
that prolonged exposure to ADT for the treatment of prostate cancer is associated with
negative alterations to numerous cardiovascular and physical function outcomes.
Resistance training programs should be designed to offset the potential loss of lean
muscle mass and muscular strength whilst aerobic training should target preserving, or
even increasing cardiorespiratory fitness given the association between aerobic fitness
and cardiovascular disease risk. These interventions should remain a priority for the
entirety of the expected treatment duration.
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CHAPTER 5

A 6-month randomized controlled trial of exercise in prostate
cancer patients receiving treatment: effects on cardiorespiratory
capacity, physical function, vascular function and resting
metabolic rate.
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INTRODUCTION
Exercise interventions are increasingly being used in cancer survivor programs
given their effectiveness in maintaining or even reversing toxicities relating to the
treatment being undertaken. In the case of patients undergoing ADT for the treatment of
prostate cancer a number of adverse side effects are directly attributable to the
treatment, due to the lack of testosterone (Galvao, et al., 2008b). Side effects include
reduced bone and lean mass, loss of muscle strength, negative change in lipid profiles, and
increased risk of cardiovascular disease (CVD) as well as numerous metabolic
complications (Basaria, et al., 2006; Galvao, et al., 2008b; Greenspan, et al., 2005;
Shahinian, et al., 2006; Sharifi, et al., 2005a; Smith, et al., 2002b). Although exercise is
being increasingly used in prostate cancer patients (Baumann, et al., 2011), very few RCT’s
exist that have attempted to assess the effectiveness of a prescribed exercise program
aimed at targeting the negative side effects associated with ADT. Further, no long term
RCT’s have used a combination of resistance exercises and appropriate dosage of aerobic
activity prescribed for overall health and improving aerobic fitness set down by the
American College of Sports Medicine (ACSM) and the American Heart Association (AHA)
(Nelson, et al., 2007; Schmitz, et al., 2011).
The recent ACSM roundtable discussion paper on exercise guidelines for cancer
survivors (Schmitz, et al., 2011) utilised evidence categories set down by the National
Heart, Lung, and Blood Institute (NHLBI, 1998) to categorise the strength of previous
research studies. When categorising the strength of studies reporting aerobic benefits in
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prostate cancer studies, only 3 ‘evidence category A’ (overwhelming data from
randomised controlled trials) studies have used ADT only populations. Of these three
studies, one was a home based intervention consisting of walking, stretching and light
theraband exercises at a non-specified intensity (Culos-Reed, et al., 2009) whilst the other
two studies were primarily strength oriented (Galvao, et al., 2006) or used a low level of
aerobic exercise prescription (Galvao, et al., 2010). The promising aspects of the latter two
studies (Galvao, et al., 2006; Galvao, et al., 2010) was that beneficial aerobic outcomes
were observed despite not specifically adhering to a targeted aerobic training program.
Consequently, this raises the question as to what gains can be made when specifically
targeting aerobic fitness concurrently with resistance training?
Both of the primary muscle strength based studies by Galvao et al. (2006; 2010)
were also categorised as evidence category A by the ACSM roundtable as was the work of
Segal (Segal, et al., 2003b) who also used a primarily resistance based training program.
This research provided further rationale to adopt a similar resistance training program in
the present study whilst adding an aerobic component to the study design. Of the
remaining outcomes assessed in the present study, the ACSM has classified body
composition and physical function as category B evidence (few RCT’s exist or they are
small and inconsistent), suggesting randomised clinical trials are required to clarify the
effects of an exercise program in this population.
The current study sought to expand the original work of Galvao and colleagues
(2010) who have previously used a similar protocol to that presented, albeit over a shorter
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time period (12 weeks). Despite only being exposed to a relatively brief exercise program,
Galvao et al. (2010) found significant improvements in muscle mass, strength, physical
function and balance in hypogonadal men when compared to the usual care group. This
previous study found no improvements in aerobic capacity, although this is likely due to
the relatively low dose of aerobic exercise prescribed. Given the increased incidence of
cardiovascular and metabolic diseases associated with ADT, it was important in the
current study to implement an intervention that focussed on attempting to improve the
maximal aerobic capacity of the participants. The protective effect provided by increasing
levels of maximal aerobic power has been highlighted in large population based studies
(Blair, et al., 1995; Ekelund, et al., 1988; Erikssen, 1986). Therefore, the present study
would be strengthened by supplementing the original aerobic training prescribed in the
Galvao et al. (2010) investigation with additional aerobic training sessions. The weekly
accumulated aerobic volume was prescribed to meet the 150 min/wk guideline as set
down by numerous health organisations, namely the American College Sports Medicine
and American Heart Association recommendation (Haskell, et al., 2007). The intervention
was expanded to six months duration as opposed to the 12 weeks used by Galvao et al.
(2010) to investigate what further adaptations would occur with an additional 3 months
exposure to the intervention, as well as to assess the adherence to a longer, multi-centre
based exercise program.
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METHODS
Participants
This study was a parallel group randomised control trial comparing a combined
aerobic and resistance training program to a usual care (control) program. One hundred
and fifty five men undergoing treatment for prostate cancer involving ADT with no formal
regular exercise (undertaking structured aerobic or resistance training less than two times
per week) within the previous 3 months were recruited by invitation of their attending
specialist for this study. All participants had been hypogonadal for a period of at least 2
months prior to testing and expected to remain hypogonadal for the period of the
intervention. Exclusion criteria included the presence of an acute illness or any
musculoskeletal, cardiovascular or neurological disorder that could inhibit or put them at
risk from exercising. The participants were informed that they were required to be able to
walk 400 m and to undertake upper- and lower-body exercises. Those entering the study
undertook a series of familiarisation sessions and baseline measurements prior to
randomization to either 1) aerobic and resistance exercise group or 2) usual care (control
group) for 6 months. The study protocol received human ethics approval from the Edith
Cowan University Ethics Committee. All participants obtained medical clearance from
their general practitioner and completed a detailed health history questionnaire in
addition to written informed consent. The participant flow through the trial is presented
in Figure 1.
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Figure 3. Consort Flow diagram of participant randomisation including enrolment,
intervention, allocation, follow-up and data analysis
264 participants referred by Oncologists/Urologists

Excluded (n=108)
x Not interested (n=26)
x No GP consent (n=15)
x Location/ travel issues (n=10)
x Bone metastases (n=9)
x Undergoing structured exercise (n=8)
x Could not walk 400m (n=2)
x Work commitments (n=6)
x Other (n=32)

Baseline testing/ randomised (n=155)

Allocated to group not
involved in this study (n=57)

Allocated to Exercise Group (n=50)

Allocated to control group (n=48)

Lost to follow-up (n=7)
x Due to illness/ death (n=2)
x Bone metastases (n=1)
x Voluntary withdrawal/ no reason (n=4)

Lost to follow-up (n=15)
x Did not return for post testing (n=13)
x Ineligible for post testing (n=2)
x Due to illness/ death (n=1)
x Bone metastases (n=1)

Analysed (n=43)

Analysed (n=33)
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Exercise Intervention:
The combined aerobic and resistance (EX) training participants took part in a
combination of clinic and home based training for 6 months. The clinic based component
consisted of twice weekly sessions to undertake the resistance training component of the
intervention and included 40 minutes of the weekly aerobic intervention component. The
additional 110 minutes of aerobic training to make up the required weekly 150 minutes of
aerobic activity was completed at home each week and documented in their training log.
The usual care control group (CON) was instructed to maintain their normal physical
activity and dietary routine.
The clinic based sessions were approximately 60 – 75 minutes in duration
(including the warm-up and cool-down periods) and were conducted at 5 different sites
across the Perth metropolitan area in Western Australia depending on the participant’s
location of residence (Joondalup, Mt Lawley, Nedlands, South Lake & Mandurah). Sessions
commenced with a 5-minute warm-up comprising various low-level aerobic activities
using a treadmill, cycle ergometer or elliptical trainer, as well as static stretching.
Participants were instructed to perform an equal number of warm-up sessions on each
ergometer.
The resistance training regime included 6 exercises that targeted the major upper
and lower body muscle groups which were the chest press, seated row, lat pull-down, leg
press, leg extension and leg curls. These exercises have been previously utilised in a
number of exercise intervention studies (Galvao, et al., 2006; Galvao & Taaffe, 2005;
Newton, et al., 2002; Taaffe, Duret, Wheeler, & Marcus, 1999). The rest period between
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sets was 1-2 minutes. To ensure the progressive nature of the training program,
participants were encouraged to work past the specific repetition maximums (RMs)
prescribed. The resistance was increased by a 5-10% increment for the next set or training
session if the participants were able to perform more repetitions than the RMs specified
during a set. Intensity was systematically manipulated on a 4-week cycle from 6-12 RM
(e.g. the maximal weight that can be lifted 6 to 12 times) using 1-4 sets per exercise (Table
15).
Table 15. Resistance training progression overview
Weeks

Sets

Repetitions

1-4

2

12

5-8

3

10

9-12

3

8

13-16

4

6

Each clinic based session included 20 minutes of aerobic exercise completed prior
to the resistance training component using an equal amount of various modes including
walking or jogging on a treadmill, cycling and rowing on a stationary ergometer, as well as
exercising on an elliptical trainer. The target intensity was set at 70%-90% of each
participant’s individualised heart rate at VO2max which was monitored with individual
heart rate monitors (Polar F3, Polar Electra Oy, Finland) provided for each participant and
recorded at the completion of the session. The same intensity (70%-90%) was also used
for the prescription of the 110 minutes of home based aerobic activity to meet the
required 150 min/wk.
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The criterion for the clinic based exercise program was to design optimal stimulus
to the cardiorespiratory and neuromuscular systems whilst maximizing compliance and
retention. All exercise sessions were conducted in small groups of up to 10 participants,
with participants exercising under direct supervision of an Accredited Exercise Physiologist
to ensure correct technique and to minimize the risk for injury. Each session concluded
with a 5-minute cool-down period of lower intensity aerobic and stretching activities.
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Measurements:
Primary and secondary endpoints were identical to those in the previous cross
sectional study (Chapter 4) and took place at baseline and 6 months (end of intervention).
Briefly, these measurements included cardiorespiratory capacity as assessed by maximal
oxygen uptake (VO2max), lean tissue mass and fat mass by DXA, selected girth
measurements by anthropometry, resting metabolic rate via respiratory gas analysis with
fat and carbohydrate oxidation determined from measurements of oxygen consumption,
blood pressure by a validated oscillometric device (HEM-705CP, Omron Corporation,
Japan) and reported as both central and peripheral systolic, diastolic and mean arterial
blood pressure values along with central and peripheral augmentation pressures. The
metabolic profile was externally analysed utilising standardised industry techniques for
haemoglobin AIC, testosterone, insulin, PSA, LDL cholesterol, HDL cholesterol, total
cholesterol, and glucose. Muscular strength was assessed using the one- repetition
maximum (1-RM) method while muscular endurance was reported as the maximum
number of repetitions performed at 70% of 1-RM for the chest press and leg press
exercises with an additional variable presented as muscular endurance relative to baseline
1RM. This required the participant to complete as many repetitions as possible for the
original baseline 1RM and the more recently established post intervention 1RM. Physical
function was assessed using a battery of tests that included the repeated chair rise, stair
climb, 6-meter walks and the 400 meter walk.
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Statistical Analysis:
Data analyses were performed using the Statistical Package for Social Sciences
version 18.0 software (PASW, Chicago, IL). Normality of the data were assessed using the
Kolomogorov-Smirnov test. The per protocol analyses included standard descriptive
statistics and independent samples t tests. Between group differences for the variables
collected pre and post intervention were examined using a 2 x 2 mixed model analysis of
variance. The differences between the change scores for the independent variables
between groups pre and post intervention are reported as treatment effects. All tests
were two-tailed and an alpha level of 0.05 applied as the criterion for statistical
significance. Results are reported as the mean ± standard deviation.
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RESULTS
Ninety-seven participants undertook baseline testing. Combined mean age was 69
± 9 years and a mean ADT treatment duration of 4.3 ± 4.7 months. Forty-eight participants
were randomly assigned to the CON group whilst 50 participants were randomised to the
EX group. Baseline subject characteristics are shown in Table 16.
There were no differences for age, height, body mass, waist circumference or ADT
treatment duration between the EX and CON groups.
Table 16. Subject baseline characteristics
Variable

Control

Exercise

(n=47)

(n=50)

Age (years)

69.4 ± 8.9

69.3 ± 9.4

Height (cm)

170.0 ± 11.9

172.8 ± 6.7

Body Mass (kg)

89.3 ± 15.5

84.8 ± 16.1

Waist Circumference (cm)

103.7 ± 12.0

102.8 ± 15.8

3.9 ± 3.9

4.8 ± 5.4

ADT duration (months)
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Attrition Rate
At the 6-month time point 33 out of the original 48 participants remained in the
CON group whilst 43 of the original 50 participants remained in the EX group. As
presented in Figure 3, 7 participants in the EX group discontinued the intervention, due to
voluntary withdrawal (n=4), bone metastases (n=1) and illness/death (n=2). The CON
group had 15 participants not complete post testing. Of these withdrawals, 13 did not
return for follow-up testing whilst 2 were ineligible for testing due to bone metastases
(n=1) and illness (n=1). The attrition rate for the CON group was 31% whilst the attrition
rate for the EX group was 14%. Overall attrition rate for the study was 22%.
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Body Composition
There was a significant group by time interaction present for total lean mass (p=0.050),
total fat mass (p=0.043), trunk fat (p=0.003) and body fat percentage (p=0.006) (Table17).
The differences occurred in EX for total lean mass while fat mass, trunk fat and body fat
percentage increased in CON with no change in EX. No significant interaction was
observed for upper lean mass, lower lean mass, appendicular skeletal muscle mass or
whole body mass. A time effect was present for lower limb lean mass (p=0.040) and whole
body mass (p<0.001).
Table 17. Body composition variables for the CON and EX group pre and post intervention
Variable
Lean tissue mass (kg)
Total Lean Mass*
Pre
Post
Difference Score
Upper Limb
Pre
Post
Difference Score
Lower Limb
Pre
Post
Difference Score
Appendicular Skeletal
Muscle
Pre
Post
Difference Score

Control

Exercise

Treatment
effect (95% CI)

P Value

0.050
58.7 ± 6.1
58.6 ± 5.9
-0.1 ± 1.4

59.4 ± 8.6
60.1 ± 8.6
0.7 ± 1.9

0.8 (0.4, 1.6)
0.245

6.7 ± 1.0
6.7 ± 1.0
0.0 ± 0.2

6.8 ± 1.2
6.9 ± 1.3
0.1 ± 0.5

0.1 (-0.9, 3.4)
0.996

18.2 ± 2.2
18.3 ± 2.3
0.1 ± 0.7

18.8 ± 3.0
19.0 ± 2.9
0.2 ± 0.7

0.1 (-0.3, 0.3)
0.603

24.9 ± 3.1
25.0 ± 3.2
0.1 ± 0.9

25.7 ± 4.0
26.0 ± 4.1
0.3 ± 1.0
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-0.2 (-0.3, 0.6)

Fat mass (kg)
Total Fat Mass*
Pre
Post
Difference Score
Trunk*
Pre
Post
Difference Score
Whole body mass (kg)
Pre
Post
Difference Score
Body Fat %*
Pre
Post
Difference Score

0.043
25.7 ± 6.0
27.2 ± 6.5
1.5 ± 1.7

24.1 ± 9.9
24.5 ± 9.0
0.4 ± 2.5

14.2 ± 3.8
14.9 ± 3.9
0.7 ± 0.9

13.2 ± 6.6
13.0 ± 5.9
-0.2 ± 1.6

-1.1 (-2.1, -0.3)
0.003
-0.9 (-1.6, -0.3)
0.097

86.5 ± 12.3
88.4 ± 12.3
1.9 ± 2.7

85.7 ± 17.0
86.5± 16.4
0.8 ± 2.6

-1.1 (-2.3, 0.2)
0.006

29.2 ± 3.6
30.3 ± 3.8
1.1 ± 1.3

27.2 ± 6.0
27.2 ± 5.9
0.0 ± 1.8

* denotes significant group x time interaction
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-1.1 (-1.9, -0.3)

There were no significant group by time interactions for waist, hip, arm, or calf
circumferences (Table 18).
Table 18. Circumference measurements for the CON and EX group pre and post
intervention
Variable
Waist Circumference
Pre
Post
Difference Score
Hip Circumference
Pre
Post
Difference Score
Arm circumference
Pre
Post
Difference Score
Calf Circumference
Pre
Post
Difference Score

Control

Exercise

Treatment
effect (95% CI)

P Value
0.673

103.7 ± 10.2
104.3 ± 10.5
0.6 ± 3.15

99.7 ± 13.2
99.7 ± 12.9
0.0 ± 3.3

-0.6 (-2.1, 0.8)
0.452

101.5 ± 6.4
102.7 ± 6.3
1.2 ± 4.8

99.0 ± 8.1
100.3 ± 9.0
1.3 ± 4.75

0.1 (-2.1, 2.3)
0.065

30.3 ± 2.8
30.4 ± 2.7
0.1 ± 1.4

29.4 ± 2.8
30.1 ± 2.7
0.7 ± 1.4

0.6 (-0.1, 1.3)
0.396

36.8 ± 2.6
36.8 ± 2.6
0.0 ± 1.0

36.3 ± 2.5
36.5 ± 2.6
0.2 ± 1.0
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0.2 (-0, 0.7)

Cardiorespiratory Capacity
There was no significant group by time interactions present for any of the
cardiorespiratory capacity variables measured. Although not significant (p=0.095),
absolute VO2max (L.min-1) increased by 5% with a moderate effect size of 0.6 (Cohen,
1988) in the EX group whilst the CON group did not change (Table 19, Figure 4).
Table 19. Maximal exercise capacity values as determined from the exercise stress test for
the CON and EX group pre and post intervention
Variable

Control

Exercise

Treatment effect
(95% CI)

VO2max (L.min-1)
Pre
Post
Difference Score
VO2max (ml.kg.min-1)
Pre
Post
Difference Score
VO2max (METS)
Pre
Post
Difference Score
VO2max duration
(mins)
Pre
Post
Difference Score

P Value
0.095

1.95 ± 0.35
1.94 ± 0.35
-0.01 ± 0.20

2.05 ± 0.56
2.16 ± 0.55
0.11 ± 0.22

0.10 (-0.1, 0.2)
0.169

23.0 ± 4.5
22.6 ± 4.9
-0.4 ± 2.1

24.7 ± 6.2
25.4 ± 5.7
0.7 ± 3.1

-1.1 (--0.5, 2.9)
0.171

6.6 ± 1.3
6.5 ± 1.4
-0.1 ± 0.6

7.1 ± 1.8
7.3 ± 1.6
0.2 ± 0.9

0.3 (-0.1, 0.8)
0.239

7.7 ± 2.6
8.4 ± 2.7
0.7 ± 1.9

8.3 ± 2.3
9.6 ± 2.1
1.3 ± 1.6
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0.6 (-0.5, 1.8)

Figure 4. Maximal exercise capacity variables effect size

Note: 0.2 Small effect, 0.5 moderate effect, 0.8 large effect (Cohen, 1988)
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Resting Metabolic Rate
There was no significant group by time interactions present for resting metabolic rate
when presented as kilocalories per day or fat oxidation or carbohydrate oxidation (Table
20).
Table 20. Resting metabolic rate for the CON and EX group pre and post intervention
Variable

Control

Exercise

Treatment effect
(95% CI)

Resting Metabolic
Rate (kcal/24hr)
Pre
Post
Difference Score
Fat Oxidation
(mg/min)
Pre
Post
Difference Score
Carbohydrate
Oxidation (mg/min)
Pre
Post
Difference Score

P Value
0.655

1743 ± 235
1735 ± 299
-8 ± 228

1753 ± 266
1776 ± 295
23 ± 257

31 (-1.7, 168)
0.512

59.4 ± 19.6
59.4 ± 21.7
-0.0 ± 26.6

58.6 ± 16.9
70.8 ± 23.7
12.2 ± 24.8

12.2 (-5.3, 29.7)
0.329

158.6 ± 47.7
157.6 ± 64.8
-0.9 ± 66.9

159.0 ± 47.8
138.3 ± 47.2
-21.6 ± 49.6
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-19.7 (-59.9, 20.6)

Central Blood Pressure
There were no significant group by time interactions present in any of the peripheral
blood pressure responses. Further, no group by time interactions were observed in any of
the central blood pressure measurements including augmentation index, augmentation
pressure or augmentation load. No group by time interactions were observed for pulse
wave velocity (Table 21).
Table 21. Haemodynamic and pulse wave analysis parameters for the CON and EX group
pre and post intervention
Variable
Peripheral SBP (mmHg)
Pre
Post
Difference Score
Peripheral DBP (mmHg)
Pre
Post
Difference Score
Peripheral MAP (mmHg)
Pre
Post
Difference Score
Central SBP (mmHg)
Pre
Post
Difference Score
Central DBP (mmHg)
Pre
Post
Difference Score

Control

Exercise

Treatment
effect (95% CI)

P Value
0.629

150 ± 23
145 ± 22
-5 ± 18

151 ± 20
148 ± 18
-3 ± 19

2 (-9, 15)
0.851

87 ± 14
83 ± 11
-4 ± 9

87 ± 10
83 ± 10
-4 ± 13

0 (-8, 7)
0.960

108 ± 17
105 ± 16
-3 ± 11

109 ± 13
106 ± 11
-3 ± 14

0 (-9, 8)
0.907

139 ± 25
135 ± 23
-4 ± 17

140 ± 19
137 ± 18
-3 ± 20

1 (-12, 13)
0.923

87 ± 14
84 ± 12
-3 ± 9

88 ± 10
84 ± 10
-4 ± 13
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-1 (-8, 7)

Central MAP (mmHg)
Pre
Post
Difference Score
Peripheral
Augmentation Index (%)
Pre
Post
Difference Score
Central Augmentation
Pressure (mmHg)
Pre
Post
Difference Score
Augmentation Load
Pre
Post
Difference Score
Central Augmentation
Index (%)
Pre
Post
Difference Score
Pulse Wave Velocity
Pre
Post
Difference Score

0.993
108 ± 17
105 ± 16
-3 ± 11

109 ± 13
106 ± 11
-3 ± 14

0 (-9, 9)
0.916

86.6 ± 17.0
84.7 ± 11.3
-1.9 ± 12.5

86.9 ± 12.2
84.5 ± 12.8
-2.4 ± 14.4

-0.5 (-9.3, 8.4)
0.842

16 ± 10
16 ± 8
0±9

16 ± 8
16 ± 9
0±9

0 (-5, 6)
0.544

15 ± 5
15 ± 6
0±6

13 ± 4
15 ± 4
2±4

2 (-2, 5)
0.397

145 ± 23
141 ± 18
-4 ± 18

142 ± 17
141 ± 17
-1 ± 19

3 (-9, 16)
0.510

9.9 ± 1.9
9.2 ± 1.4
-0.7 ± 1.9

10.3 ± 1.6
10.0 ± 1.4
-0.3 ± 1.6
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0.4 (-0.8, 1.3)

Muscular Strength & Endurance
There was a significant group by time interaction present for all 1-RMmaximal strength
variables (Table 22, Figure 5). This included the significant increases in chest press
(p=0.008), seated row (p=0.004), leg press (p=0.003) and leg extension (p=<0.001) for EX
group with no change in CON. This resulted in a moderate effect size for chest press (0.6),
leg press (0.7) and seated row (0.7) and a large effect size for leg extension (1.0).
Table 22. Maximal strength values for the CON and EX group pre and post intervention
Variable

Control

Exercise

Treatment effect
(95% CI)

Chest Press 1RM (kg)*
Pre
Post
Difference Score
Seated Row 1RM (kg)*
Pre
Post
Difference Score
Leg Press 1RM (kg)*
Pre
Post
Difference Score
Leg Extension 1RM (kg)*
Pre
Post
Difference Score

P Value
0.008

36.7 ± 12.4
35.8 ± 11.7
-0.9 ± 4.1

37.1 ± 11.1
39.8 ± 10.8
2.7 ± 6.6

3.6 (-1.0, -6.2)
0.004

67.7 ± 13.5
65.6 ± 11.6
-2.1 ± 9.4

69.7 ± 13.4
73.8 ± 13.6
4.1 ± 8.7

6.2 (-2.0, -10.3)
0.003

130.8 ± 57.1
134.1 ± 52.1
3.3 ± 22.0

134.5 ± 48.2
157.8 ± 58.9
23.3 ± 31.8

-0.0 (-7.0, -32.9)
<0.001

48.9 ± 16.0
48.7 ± 15.8
-0.2 ± 10.8

52.4 ± 16.9
62.4 ± 17.7
10.0 ± 9.8

10.2 (-5.4, -15.0)

Note: 1RM = one repetition maximum; * denotes significant time x group interaction
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Figure 5. Muscular Strength Effect Size

Note: 0.2 Small effect, 0.5 moderate effect, 0.8 large effect (Cohen, 1988)
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There was a significant group by time interaction present for the muscular endurance
variables assessed (Table 23, Figure 6) which included chest press endurance (p=<0.001)
and leg press endurance (p=0.001) with both endurance measures significantly increasing
in the EX vs. CON condition. An independent samples t-test did reveal a significant
difference between the CON and EX groups for chest press endurance when using the 6month 1RM value (p=0.032) with no difference was observed for the leg press.
Table 23. Muscular endurance values for the CON and EX group pre and post intervention
Variable

Control

Exercise

Treatment
effect (95% CI)

Chest Press 70%
Baseline 1RM reps*
Pre
Post
Difference Score
Leg Press 70% Baseline
1RM reps *
Pre
Post
Difference Score
Chest Press 70% 6
month 1RM reps ^
Pre
Post
Leg Press 70% 6 month
1RM reps ^
Pre
Post

P Value
<0.001

9.6 ± 3.3
8.4 ± 3.8
-1.2 ± 4.1

10.3 ± 4.0
14.1 ± 5.3
3.8 ± 5.3

5.0 (-2.4, -7.7)
0.001

15.6 ± 5.2
14.9 ± 4.9
-0.7 ± 5.8

15.2 ± 6.7
22.1 ± 8.5
6.9 ± 7.7

n/a
8.1 ± 4.3

n/a
11.0 ± 4.3#

n/a
14.4 ± 4.6

n/a
15.6 ± 6.4

7.7 (-3.4, -12.0)

Reps = number of repetitions; * denotes significant time x group interaction; N/A not applicable as
6 month 1RM required for test; ^ significant difference CONl vs. EX
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Figure 6. Muscular Endurance Effect Size

Note: 0.2 Small effect, 0.5 moderate effect, 0.8 large effect (Cohen, 1988)
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Physical Function
There was a significant group by time interaction for the time taken to complete the 400m
walk (p=0.010), indicating an improvement in the EX group (Table 24). No significant
differences were observed for the chair rise, stair climb or any of the 6m walk tests.
Table 24. Physical Function values for the CON and EX group pre and post intervention
Variable

Control

Exercise

Treatment
effect (95% CI)

400m walk (s)*
Pre
Post
Difference Score
Chair Rise (s)
Pre
Post
Difference Score
Stair Climb (s)
Pre
Post
Difference Score
6m normal pace walk (s)
Pre
Post
Difference Score
6m fast pace walk (s)
Pre
Post
Difference Score
6m backwards walk (s)
Pre
Post
Difference Score

P Value
0.010

272 ± 40
270 ± 44
-2 ± 19

269 ± 47
254 ± 41
-15 ± 22

13 (3, 23)
0.410

14.0 ± 3.5
13.3 ± 2.7
-0.7 ± 2.4

12.9 ± 2.5
11.8 ± 2.5
-1.1 ± 2.0

0.4 (-0.6, 1.4)
0.304

5.5 ± 1.3
5.6 ± 1.4
0.1 ± 0.6

5.0 ± 1.3
5.0 ± 1.1
0.0 ± 0.6

0.1 (-0.1, 0.4)
0.124

5.0 ± 0.7
4.6 ± 0.6
-0.4 ± 0.6

4.9 ± 0.8
4.7 ± 0.7
-0.2 ± 0.6

-0.2 (-0.5, 0.1)
0.629

3.6 ± 0.5
3.5 ± 0.4
0.1 ± 0.3

3.5 ± 0.6
3.4 ± 0.5
-0.1 ± 0.6

0.0 (-0.2, 0.1)
0.331

19.8 ± 7.5
18.6 ± 9.5
-1.2 ± 4.3

18.8 ± 4.7
16.6 ± 4.4
-2.2 ± 4.5

* denotes significant time x group interaction
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1.0 (-1.1, 3.1)

Metabolic Profile
There were no significant group by time interactions present in any of the blood
biomarkers measured (Table 25).

Table 25. Blood markers for the CON and EX group pre and post intervention
Variable

Control

Exercise

Treatment
effect (95% CI)

HbA1C (%)
Pre
Post
Difference Score
Testosterone (pg.mL-1)
Pre
Post
Difference Score
Prostate Specific Antigen
(ng.mL-1)
Pre
Post
Difference Score
Insulin (mU/L)
Pre
Post
Difference Score
Triglycerides (mmol/L)
Pre
Post
Difference Score
LDL Cholesterol
(mmol/L)
Pre
Post
Difference Score

P Value
0.457

6.0 ± 0.5
6.0 ± 0.7
0.0 ± 0.3

5.9 ± 0.6
5.8 ± 0.5
-0.1 ± 0.4

0.1 (-0.1, 0.2)
0.221

0.6 ± 1.0
1.8 ± 2.6
1.2 ± 2.8

1.5 ± 2.9
1.6 ± 2.1
0.1 ± 3.7

1.1 (-0.7 , 3.0)
0.551

0.8 ± 1.4
0.2 ± 0.4
-0.6 ± 1.1

0.8 ± 1.3
0.4 ± 1.4
-0.4 ± 1.8

-0.2 (-1.0, 0.5)
0.845

10.7 ± 5.3
10.9 ± 4.9
0.2 ± 4.8

8.8 ± 3.8
9.1 ± 3.9
0.3 ± 2.3

-0.2 (-2.0, 1.7)
0.131

1.2 ± 0.3
1.5 ± 0.5
0.3 ± 0.4

1.2 ± 0.5
1.3 ± 0.5
0.1 ± 0.5

0.2 (-0.1, 0.5)
0.641

2.8 ± 0.9
2.9 ± 0.7
0.1 ± 0.5

2.9 ± 0.8
2.9 ± 0.8
0.0 ± 0.5
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0.1 (-0.2, 0.3)

HDL cholesterol
(mmol/L)
Pre
Post
Difference Score
Total cholesterol
(mmol/L)
Pre
Post
Difference Score
Glucose (mmol/L)
Pre
Post
Difference Score
C Reactive Protein
(mg/L)
Pre
Post
Difference Score

1.2 ± 0.4
1.3 ± 0.2
0.1 ± 0.3

1.3 ± 0.4
1.3 ± 0.3
0.0 ± 0.2

0.897
0.1 (-1.3, 0.2)

0.444
4.6 ± 0.9
4.9 ± 1.2
0.3 ± 1.0

4.7 ± 1.2
4.9 ± 1.0
0.2 ± 1.0

0.2 (-0.3, 0.6)
0.073

5.3 ± 0.6
5.5 ± 0.8
0.2 ± 0.6

5.5 ± 1.1
5.3 ± 0.6
-0.2 ± 0.6

0.4 (0.0, 0.6)
0.202

1.6 ± 1.7
2.1 ± 1.7
0.5 ± 1.3

1.8 ± 2.2
1.6 ± 2.2
-0.2 ± 2.5
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0.7 (-0.4, 1.8)

DISCUSSION
This is the first study to utilise a 6-month, multi-centre, randomised controlled trial
to examine the influences of a combined aerobic and resistance training program on body
composition, cardiorespiratory capacity, resting metabolic rate, central blood pressure,
muscular strength and endurance, physical function and blood biomarkers in men
undergoing ADT for the treatment of prostate cancer. As a result of the intervention,
improvements were made in body composition, muscular strength and endurance and a
trend towards an increase in cardiorespiratory capacity.
Increases in fat mass and reductions in lean mass are common side effects of ADT
(Galvao, et al., 2008b; Smith, 2004; Smith, et al., 2002a; Smith, et al., 2006). In the present
study the EX intervention had a positive effect of significantly increasing lean mass
(treatment effect 0.8kg) and reducing total fat mass (treatment effect -1.1kg) with further
analysis revealing that specifically, trunk fat was favourably impacted (treatment effect 0.9kg) as well as overall percentage body fat (treatment effect 1.1%). Galvao et al. (2010)
have previously reported changes in lean body mass (0.8kg) in a 12-week combined
aerobic and resistance training intervention, however no changes were seen in whole
body fat, trunk fat or body fat percentage. It is thought the addition of a more substantial
aerobic training component (150 minutes/wk vs. 30-40 minutes/wk) combined with the
longer intervention (26 weeks vs. 12 weeks) brought about these previously unreported
changes. Galvao and colleagues (2011) have reported that longer term ADT (> 6 months)
patients may respond differently to an exercise program when compared to short term
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ADT (< 6 months). The authors reported that the shorter term ADT group increased total
body fat during the 12 week exercise intervention (0.9kg, p =0.018) when compared to the
longer term therapy group suggesting that the length of ADT duration may have impacted
the results in the current study.
Both upper body and lower body muscular strength were significantly improved as
a result of the EX intervention. Upper body strength improvements were represented by
an increase in chest press (treatment effect 3.6kg) and seated row (treatment effect 6kg)
whilst the lower body strength was represented by an increase in leg press (treatment
effect 20kg) and leg extension (treatment effect 10.2kg). These changes in strength were
supported by similar significant increases in upper body muscular endurance (treatment
effect 5 repetitions) and lower body muscular endurance (treatment effect 8 repetitions)
when compared to baseline load used post intervention. The changes observed in
muscular strength and endurance are similar to those seen by Galvao and colleagues
(2006) who employed a similar resistance training intervention in 10 men undergoing ADT.
Importantly, these muscular strength and endurance responses are also similar to those
seen in healthy men undertaking similar exercise interventions (Galvao, Newton, & Taaffe,
2005). Muscular strength has been demonstrated to contribute to the already established
protective effects of cardiorespiratory fitness against the risk of death in men (Ruiz, et al.,
2008), providing further justification for a combined aerobic and resistance training
intervention in this population.
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Whilst not statistically significant, maximal aerobic capacity did increase 5% in the
EX group with no change in the CON group. This is an important finding as no study has
previously utilised a direct assessment of maximal aerobic capacity in prostate cancer
patients undergoing ADT. Segal and colleagues (2009) have previously explored the effects
of either a resistance or aerobic exercise intervention for radiotherapy patients utilising
VO2peak as an outcome measure. They also reported a 5% advantage to either resistance or
aerobic training groups as a result of a 24-week intervention period, compared to a usual
care group. An interesting outcome of this study was that their resistance training group
also increased VO2peak with the authors reporting that although resistance training is not
generally considered a primary means for developing VO2peak, studies have shown circuit
weight training to increase VO2peak by 6% (Segal, et al., 2009; Thompson, et al., 2007).
Therefore, it is possible in this current study that the combined effects of aerobic and
resistance training led to greater improvements in VO2max than an exclusive aerobic
training intervention would have.
Aerobic functional walking capacity, as assessed by the long distance corridor walk
was significantly improved in the EX group following the 6-month intervention,
demonstrated by a reduced time to complete the given distance in the EX group when
compared to pre intervention values (treatment effect 13s). This is a significant outcome
given the long distance corridor walk has been shown to be a strong predictor of
mortality, cardiovascular disease and mobility limitations in older adults (Simonsick, Fan,
& Fleg, 2006). This current study demonstrates that walking endurance can be improved
in this population through appropriate exercise prescription.
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To date, no other study has investigated the impact of an exercise intervention on
resting metabolic rate (RMR) in men receiving ADT for the treatment of prostate cancer,
with only one study examining the effect that prostate cancer treatment has on RMR
(Reis, et al., 2009). In the current study, no differences were observed for RMR as a result
of the intervention. The secondary finding was that there was also no change in the CON
group suggesting ADT did not have an impact on RMR over the 6-month period. The
findings of the current study concur with the only other RMR related study conducted by
Reis et al. (2009) who found no differences in resting energy expenditure after 12 months
of ADT. Reis (2009) suggested the lack of differences may be a result of the small sample
size (n = 16), however, we employed a larger sample size (n = 76) in the current study and
the findings did not change. Reis et al. (2009) also identified a significant increase in
carbohydrate oxidation and a decrease in lipid oxidation although this was not the case in
our control group over the 6-month period. The exercise intervention did result in an
increase in fat oxidation rates by 21%; however, the large variation within our cohort
meant the change was not statistically significant. Similarly, carbohydrate oxidation rates
decreased by 14%, however, a similar variation amongst the participants led to a nonsignificant finding.
Serum testosterone and PSA did not change over the course of the intervention, as
has already been demonstrated by Galvao et al. (2006), providing further evidence that
exercise can be safely undertaken without compromising the purpose of reduced
androgen levels (Galvao, et al., 2006). Blood glucose levels, although statistically not
significant, did respond positively to the intervention with the EX group reducing blood
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glucose levels by approximately 0.2 mmol/L whilst the CON group had an increase of 0.2
mmol/L, a treatment effect of 0.4 mmol/L. Basaria et al. (2008) have previously described
that insulin resistance usually develops within a few months of ADT commencement,
however the resulting hyperinsulemia maintains glucose levels in the normal range until
such time that this compensatory mechanism fails during prolonged treatment resulting in
hyperglycemia. Our study found no such changes in insulin during the 6-month control
period or during the intervention; however the trend towards improved glucose control as
a result of the intervention is a positive outcome that has the potential to reduce the
likelihood of developing hyperglycemia during treatment, the defining characteristic of
diabetes mellitus.
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Conclusion
This study has shown that a 6-month combined aerobic and resistance exercise
program has a favourable impact on body composition, muscular strength and endurance,
physical function and a trend towards an increase in cardiorespiratory fitness. Of major
significance was the fact that total fat mass, trunk fat and body fat percentage can be
reduced in men undergoing ADT for the treatment of prostate cancer. Although previous
studies have found alterations in lean body mass (Galvao, et al., 2010) and total fat mass
when adjusting for ADT duration (Galvão, et al., 2011), this is the first study to report
favourable adaptations in overall fat mass in prostate cancer patients regardless of ADT
treatment time. The muscular strength and endurance outcomes combined with the trend
towards an increase in maximal aerobic capacity are of considerable significance in
reducing mortality (Ruiz, et al., 2008). The authors reported the age-adjusted death rate in
men with high levels of both muscular strength and cardiorespiratory fitness was 60%
lower than the death rate in the group of unfit men with the lowest levels of muscular
fitness. This study provides further justification that exercise, in particular combined
aerobic and resistance training, should be considered a key component of the course of
treatment in men undergoing ADT for the treatment of prostate cancer.
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CHAPTER 6

Concluding discussion and implications for clinical
guidelines and future research
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This chapter provides a generalised summary of the outcomes resulting from the
literature review and the results of the experimental chapters of this thesis. This chapter
also identifies the future research required in this field.
The literature review initially provided a background to cancer and identified the
most common forms of cancer which included breast, colorectal and prostate cancer. The
review explored the various cancer treatment options available which included active
surveillance, surgery, radiotherapy and systemic therapy (chemotherapy and hormonal
therapy) and the side effects associated with each form of treatment. It was identified
that the most common side effects of surgery were related to the actual surgical
procedure itself, comorbidities of the patients as well as preoperative therapy.
Radiotherapy side effects were dependent upon the location of the cancer whilst common
non site-specific side effects included fatigue, gastrointestinal issues and loss of appetite.
Systemic therapy included both chemotherapy and hormonal therapy with fatigue being
the most commonly reported side effect associated with chemotherapy. As hormonal
therapy takes numerous forms, the side effects are related to the actual type of hormonal
therapy employed. Side effects for third generation aromatase inhibitors used in the
treatment of breast cancer include osteoporosis and/or fracture as well as arthralgia,
skeletal and muscle pain whilst side effects associated with ADT for the treatment of
prostate cancer were categorised into cardiovascular and metabolic alterations.
Cardiovascular alterations were concerned with the increased risk of cardiovascular
disease found to be present in ADT treated patients whilst metabolic alterations were
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reported as increased abdominal circumference, obesity, insulin resistance, hyperglycemia
and dislipidemia.
The role of physical activity throughout the cancer continuum was explored with
research presented that supports the hypothesis that exercise may exert a protective
effect against the development of certain types of cancer, in particular breast and
colorectal cancer. Studies were also presented that support the link between physical
activity and improved survival rates in cancer patients. The majority of research has
focused on breast cancer patients with promising findings suggesting increased levels of
physical activity are associated with lower overall mortality rates and cancer recurrence.
The review of exercise and cancer studies focused on exercise interventions during cancer
treatment. Thirty-nine studies were reviewed in Table 1 (pages 40 - 48) that investigated
the role of an exercise intervention during cancer treatment. All cancer types were
included in the review with the most commonly investigated cancer being of the breast,
with others including prostate, leukaemia and mixed cancer populations. With regard to
the type of intervention, of the 39 studies reviewed, 24 were aerobic only, 6 were
resistance only, 8 were combined resistance and aerobic whilst the remaining study
compared the effectiveness of either a resistance or aerobic intervention. The most
common endpoints were physical function/ performance, physical fitness, fatigue, quality
of life, strength, body composition and psychological outcomes. Despite a variety of
intensities being prescribed, including self-selected intensities and an apparent lack of
experimental control in a number of the home based exercise interventions, the majority
of studies demonstrated positive outcomes as a result of exercise during cancer
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treatment. Exercise was determined to be a safe, effective and feasible strategy to employ
during cancer treatment to target the various side effects arising from treatments.
The first experimental chapter was undertaken to assess the feasibility and safety
of maximal exercise testing in ADT treated prostate cancer patients. One hundred and
twelve prostate cancer patients underwent a physician supervised multistage maximal
stress test (Bruce protocol) (Bruce, 1971) on a motorised treadmill. 85% of the
participants were able to meet the criteria established for the achievement of VO 2max and
only 3 positive tests (3.2%) were observed during the testing period. Apart from the
comparatively low cardiorespiratory capacity, when compared to healthy age-matched
controls the cardiovascular response to exercise was similar in this cancer population.
Overall, these results demonstrated that maximal exercise testing in prostate cancer
individuals was feasible and safe and provided a direct assessment of VO 2max that can be
used as a screening tool, for exercise prescription purposes and to track the effectiveness
of exercise interventions.
In the second experimental chapter a cross-sectional study was undertaken to
determine if the length of ADT treatment was linked to the development of additional risk
factors for cardiovascular disease and metabolic related toxicities. One hundred and seven
men undergoing ADT for the treatment of prostate cancer were stratified into two groups,
the acutely suppressed group (n= 57) had been exposed to ADT for less than 3 months
whilst the chronically suppressed group (n= 50) had been exposed to ADT for 3 months or
more. We found the chronically suppressed group to have a lower aerobic capacity and
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resting metabolic rate. The chronically suppressed group also possessed lower maximal
strength values and a corresponding decline in physical function. Whilst not statistically
significant, there was a trend towards a decrease in lean mass and an increase in fat mass
in the chronically suppressed group. It is thought that the combination of decreasing lean
mass and increasing fat mass would be a clinically meaningful body composition alteration
that resulted in a lower resting metabolic rate in the chronically suppressed group. Whilst
not measured in this study it is possible that physical activity levels may have declined as
treatment time progressed. The reduction in physical activity in cancer patients has been
previously demonstrated in breast cancer patients (Demark-Wahnefried, et al., 1997;
Irwin, et al., 2003) and this may have contributed to the difference observed in maximal
aerobic capacity and physical function outcomes.
In the third experimental chapter, a randomised controlled trial was conducted to
investigate the effects of a long term (6 months) combined aerobic and resistance training
intervention in patients receiving ADT for the treatment of prostate cancer. Participants
were randomly allocated to either an exercise group (n= 50) or a control group (n= 48).
The combined aerobic and resistance training program consisted of twice weekly clinic
based sessions as well as home based aerobic training. Primary endpoints assessed were
cardiorespiratory capacity, body composition, resting metabolic rate, central blood
pressure, metabolic profile and muscular strength and endurance. As a result of the
exercise intervention, there were significant improvements in body composition, muscular
strength and endurance and a trend towards an increase in cardiorespiratory capacity.
Whilst similar findings have been reported in smaller studies, this was the first study to
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demonstrate the effectiveness of a large scale, long term (6 month), multi-centre
randomised controlled trial. The extended duration of the exercise intervention is thought
to have led to the favourable adaptation in total fat mass that has not previously been
reported in this group of cancer patients. This trial further reiterated that exercise, in
particular combined aerobic and resistance training, is a safe and effective intervention
that should be considered a key component of the overall course of treatment for men
undergoing ADT for the treatment of prostate cancer.
This research has demonstrated that maximal exercise testing in ADT treated
prostate cancer patients is a feasible and safe method of testing. This research has also
demonstrated that additional therapy time exposure is associated with a number of
adverse cardiovascular and metabolic outcomes. Patients prescribed ADT for the
treatment of prostate cancer should be appropriately counselled as to the negative side
effects commonly associated with this form of treatment and be made aware of the
beneficial effects an appropriately administered exercise intervention can have on
reversing these negative alterations occurring throughout the course of treatment.
Further, these specifically designed exercise interventions should be commenced as soon
as practically possible post prostate cancer diagnosis and continue for the course of
treatment and ideally beyond.
Additional follow-up studies are required to determine if a supervised 6-month
exercise intervention does change physical activity behaviours in this population once the
supervised exercise sessions are concluded. These studies should focus on cardiovascular,
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metabolic and physical function outcomes whilst also considering post cancer survivorship
and quality of life outcomes. A potential limitation to this study was the inability to report
physical activity levels immediately post cancer diagnosis. This data would have provided a
clearer understanding of the causes of some of the declines in physical fitness and the
development of cardiovascular disease risk factors and treatment related toxicities. Whilst
specific intensities and dosages of the resistance training program used in this randomised
controlled trial have been well established, the aerobic training component of the study
requires further investigation. More research is required to examine the effects of
different aerobic exercise modes, durations and intensities required to significantly
influence cardiorespiratory fitness in this ADT treated prostate cancer population. The role
of high intensity interval training may be a more effective use of time and provide a more
optimal stimulus to elicit the desired changes in this population.
The effects of a combined diet and exercise program in prostate cancer patients
undergoing ADT is also yet to be examined in a large scale trial. It is thought that the
addition of a dietary intervention in this population would complement the existing body
of literature that focuses predominantly on physical activity prescription. Given that
common side effects of ADT include increased abdominal fat, loss of muscle mass,
increased risk of diabetes and cardiovascular disease, a dietary intervention that
specifically targets certain side effects (such as increases in body fat) would supplement
the physical activity interventions currently prescribed. The addition of a dietary
intervention may possibly result in even more favourable adaptations to those already
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seen though physical activity focused interventions, in particular body composition
alterations and diabetes related risk factors.
The field of exercise oncology despite being relatively young has experienced
significant growth in recent times. The studies presented in this thesis seek to add to the
body of knowledge and provide practical applications in the field of exercise oncology. In
particular this thesis expands the field of exercise and prostate cancer and provides
justification for oncologists and other health care professionals to encourage exercise to
be considered as a key component of the treatment process. The successfulness of the
multi-site exercise intervention utilised in this thesis should encourage prostate cancer
support networks to consider promoting and utilising community based exercise oncology
programs.
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APPENDICES
Appendix A Participant Letter

Dear Mr
Thank you for your interest in the study “A randomized controlled trial of exercise to
reduce treatment side-effects in men receiving therapy for prostate cancer.”
Please find attached:

1.
2.
3.
4.

A “Participant Information Sheet” outlining all aspects of the study;
A “Statement of Informed Consent” which you will be required to sign
before participating in the study;
A “Medical Doctor Consent Form” for your doctor; and
A map of the Joondalup Campus.

As previously mentioned, all volunteers are required to obtain their doctor’s approval
prior to participation – please take the Medical Doctor form to your doctor (GP) and have
them complete and sign the consent form (you may also want to show them the
Participant Information sheet). Following approval from your doctor, please contact me to
arrange a meeting where an orientation to the study will be provided and baseline
measurements will commence. At this meeting, please bring with you the “Medical Doctor
Consent Form” and “Statement of Informed Consent.”
If you have any questions, please don’t hesitate to contact me.

I look forward to hearing from you.
Best regards,
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Appendix B Participant Information Sheet
“A RANDOMIZED CONTROLLED TRIAL OF EXERCISE TO REDUCE TREATMENT SIDEEFFECTS IN MEN RECEIVING THERAPY FOR PROSTATE CANCER”
Researchers:
Professor Robert Newton, PhD, E-mail: r.newton@ecu.edu.au
Phone: 08 6304-5711
Dr. Dennis Taaffe, PhD,
E-mail: dtaaffe@hms.uq.edu.au Phone: 07 3346-7904
Dr. Daniel Galvão, PhD,
E-mail: d.galvao@ecu.edu.au
Phone: 08 6304-3420
Professor Nigel Spry, MBBS, Radiation Oncologist
Professor Frank Gardiner, MBBS, Urologist, E-mail: f.gardiner@uq.edu.au Phone: 07 3365-5237

Purpose of the Study
The usual treatments for prostate cancer may have side effects. Some of these side effects include
weight gain, loss of muscle and bone mass, tiredness which may affect a person’s quality of life.
However, exercise has been shown to be a safe and effective method for strength development in
older adults. Recently, resistance exercise has also been shown to safely increase muscle strength,
quality of life and decrease tiredness in men with prostate cancer. However, the effects of
combining weight bearing/impact loading activities and resistance and aerobic exercise on bone
strength, weight gain, muscle and physical function in prostate cancer patients undergoing
hormone therapy is unknown. Therefore, the purpose of this present study is to examine the
effects of different exercise modes (weight bearing/ impact loading, resistance and aerobic) on
weight gain, loss of muscle and bone mass, tiredness, physical function and quality of life in men
with prostate cancer. The findings from this study will allow health professionals to plan exercise
programs for men with prostate cancer to help decrease side effects and improve their quality of
life.

Participants Involvement
We require one hundred and ninety-five men undergoing treatment for prostate cancer to
suppress male hormones for at least 2 months to participate in this 12 months exercise study.
Participants are required to not have bone metastases because of concerns regarding bone
fragility and no musculo-skeletal, neurological or cardiovascular disorder that could inhibit them
from exercising, and to not have participated in regular (e.g. 2 to 3 times per week) resistance
training in the previous 12 months. In addition, volunteers will be required to obtain consent from
their doctor (GP) before participating in the study.
Participants will be randomly assigned into three groups:
(1) resistance/impact-loading exercise group
(2) usual care/delay exercise group
(3) resistance/cardiovascular exercise group
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Exercise Training Program
Resistance/impact-loading exercise program (group 1) - Sessions will take approximately 60
minutes (this includes the warm-up and cool-down periods) and will be conducted in the Exercise
and Sport Centre at Edith Cowan University (ECU) in Perth, and Bunbury and at the University of
Queensland (UQ) in Brisbane. Further, training sites in exercise clinics in Nedlands, Murdoch and
Mandurah will be available to participants. Twice weekly exercise sessions will commence with a
5-minute warm up comprising of low-level aerobic activity such as walking and stationary cycling,
as well as stretching. Six resistance exercises that target the major upper and lower body muscle
groups (chest press, seated row, leg press, leg extension, leg curl, lat pulldown) will be performed.
The rest period between sets will be 1-2 minutes. To ensure the progressive nature of the training
program, subjects will be encouraged to work past the specific RMs prescribed. The workload will
be increased by 5-10% increment for the next set/training session if subjects are able to perform
more repetitions than the RMs specified during a set. Intensity will be manipulated ranging from
6-12-RM using 1-4 sets per exercise.
The impact-loading regime involves several activities which we have previously used in a yearlong
training study in postmenopausal women. For the first 12 weeks, 2 rotations will be performed of
skipping (30 sec), bounding over soft hurdles (13-16 cm), and drop jumping (10-15 cm). In the
second 12 weeks, hopping on one leg (10 times) will be added, and 3 rotations of all activities will
be performed. In the third 12-week period, leaping (10 times) will replace skipping, and for the
remainder of the program 4 rotations will be performed of bounding (19-25 cm), drop jumping
(20-25 cm), hopping, and leaping. All exercise sessions will be conducted in small groups of up to
10 participants, with participants exercising in pairs or under direct supervision to ensure correct
technique and minimize the risk for injury. Each session will conclude with a 5-minute cool-down
period of stretching activities.
In addition to the clinic training, twice weekly home-based training will take place. As with the
clinic impact-loading program, the home exercise program will also follow a circuit routine and
comprise, in a progressive fashion, 2 to 4 rotations of skipping, hopping, leaping, and drop
jumping.
Usual care/delay exercise group (group 2) - This group will receive a printed booklet with
information about exercise but will not receive exercise training in the initial 6 months of the
study. In the second half of the study (month 7 to month 12) participants will undertake cycling
sessions twice a week. Further participants in this group will also be offered a 3-month resistance
training program following the 12-month intervention period. These sessions will be supervised
by an exercise leader and take place on campus at ECU and at UQ. Subjects will be monitored
during these sessions using the ratings of perceived exertion scale (RPE), and by heart rate
response.
Resistance/cardiovascular exercise group (group 3) - This group will undertake the same resistance
training regime as described above for group (1) that will include 6 exercises that target the major
198

upper and lower body muscle groups for the initial 6 months with a follow up home based
program for the remaining 6 months of the program. In addition, each clinic session will include 20
minutes of aerobic exercise using various modes such as walking or jogging on a treadmill, cycling
or rowing a stationary ergometer, or exercising on a cross training machine. Target intensity will
be 60%-85% estimated maximum heart (220 – age) with individual heart rate monitors (Polar
Electra Oy, Finland) provided for each participant. In addition to the clinic training, patients from
this group will be encouraged to undertake twice weekly home-based training incorporating
aerobic activity (e.g. walking, cycling) for the duration of the study.
All training will take place on Monday and Thursday or Tuesday and Friday at Edith Cowan
University Mount Lawley, Joondalup and Bunbury Campus or in Exercise Clinics in Nedlands,
Murdoch and Mandurah in WA, and The University of Queensland St Lucia Campus in Brisbane.
TEST MEASURES

Assessment at baseline, month 6 and month 12 (end of intervention) will contain all tests
as outlined below.
Body composition and bone density
x
x

Height and body weight.
Body composition (fat mass and lean mass) and bone density of the hip and spine sites will be
measured by dual x-ray absorptiometry (DXA), a routine technique for the measurement of
bone density. You will lie on a specially designed table for approximately 10 minutes and a
scanning arm will move above your total body and above your hip and spine (separate scans
for your whole body, hip and spine). A low-dosage x-ray will pass from underneath the table
to the scanning arm. The total radiation dose for all scans undertaken during the study is very
low only a little more than normal background radiation and much less than, for example, an
international flight.

Blood Pressure and Arterial Stiffness
x

The stiffness of your blood vessels and the blood pressure at the heart will be measured by a
procedure known as pulse wave analysis. This is a painless procedure that requires a small pen
like device to be placed on your wrist. Before and during the measurement you will be
required to lie on a bed in a semi recumbent position. The overall measure takes
approximately 15 minutes and also includes a normal blood pressure measure on the upper
arm.

Cardiorespiratory Capacity
x

Maximum oxygen uptake (measure of aerobic capacity) will be measured by expired air
analysis during a staged walking test on a motorized treadmill. Exercise capacity will be
determined on the basis of the speed and grade of the treadmill as well as direct expired air
gas analysis. Electrocardiogram will be recorded using a 4-lead monitoring system and blood
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pressure will be measured each testing minute by sphygmomanometer. You will be asked to
walk in a staged progressive walking test on a motorized treadmill under direct supervision of
a medical doctor and an exercise physiologist.
Muscle performance
x
x

Maximal muscle strength will be determined for each of the several upper and lower body
muscle exercises to be undertaken in the training program using weight-training machines.
The maximal strength is the most weight that can be lifted one time using correct technique.
To determine muscle endurance of the upper and lower body, the number of times you can lift
a weight that is 70% of your 1RM will be determined.

Functional performance
x
x

Stair climb: You will be asked to ascend a flight of stairs (11 stairs) as fast as possible.
6 metres backwards walk: As a test of balance, participants will place one foot will behind the
other and will be asked to walk backwards 6 metres.
x Chair rise: You will be seated in a chair and asked to rise and sit 5 consecutive times, without
the use of your arms for support, as fast as possible.
x 400 metres corridor walk: You will be asked to walk 20 meters in a corridor, turn and return to
the starting position and repeat another 9 times.
x Balance test: You will be asked to stand on a special platform under conditions of eyes open
and eyes closed. The platform will tilt slightly back and forth and the surrounding walls will
also move. You will be wearing a harness which will support your body weight if you lose
balance.
Note: before muscle performance and physical function tests are performed, demonstrations,
practice time, sufficient warm-up and stretching will be undertaken.
PSA, hormones and markers of cardiovascular disease and diabetes
x

PSA, hormones, and markers of cardiovascular disease and diabetes will be determined from
blood samples to assess any changes in these physiological markers. All the testing will take
place in the Exercise Physiology Research Laboratory at both ECU and UQ.

Lifestyle questionnaires
x
x
x

Quality of life will be assessed using a standardized questionnaire for prostate cancer patients
(EORTC QLQ-C30 and EORTC QLQ-PR25) that you can complete at home.
Psychological distress (e.g. Anxiety, Depression) will be assessed using a standardized
questionnaire (Brief Symptom Inventory 18).
Health history and Demographic information will be also assessed using standardized
questionnaires that you can complete at home. Self-reported physical activity will be also
assessed by the leisure score index from the Godin Leisure-Time Exercise Questionnaire
that you can complete at home.
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Risks
Resistance training may result in mild discomfort and muscle soreness, however, this will be
minimised by all sessions being supervised and commencing with a warm-up and concluding with
a cool-down period of mild stretching activities. It is also possible that some muscle soreness may
result from baseline performance testing, however, all participants will undertake a warm-up
period of stretching before beginning the full exercise program. The risk of discomfort and muscle
soreness will also be minimised by a gradual increase in exercise intensity. Lastly, risk of falling
may exist in the performance of some tasks, however, participants will be closely supervised and
spotted to prevent a fall from occurring. In the event that an emergency occurs, medical
assistance will be obtained from the University Health Service according to our established
emergency procedures.
Lastly, the discomforts associated with the blood drawing procedures are minimal. There is a risk
that sometimes bruising and infection may occur and that the arm might become sore. Risk of
bruising or infection from the blood draws will be minimized because all blood draws will be
performed by a trained phlebotomist (lab technician) with extensive experience in both research
and clinical settings. The total amount of blood drawn during each testing session will not exceed
10 ml. No syringes, lancets, needles or other devices capable of transmitting infection from one
person to another shall be reused. All of these items, which are disposable, will be destroyed after
each use. As an additional safeguard in preventing contamination new disposable gloves will be
required for all blood draws. All contaminated items will be disposed of promptly in sharps
containers.
All information will be strictly confidential and kept safely locked in a filing cabinet in the primary
investigators office. Should publications result from this study, no reference will be made to any
individuals.
On completion of the intervention and measurements, a summary of study and individual results
will be made available to all participants.
PARTICIPATION IS VOLUNTARY AND SUBJECTS ARE FREE TO WITHDRAW FROM THIS STUDY AT
ANY TIME.
The study has been approved by Human Research Ethics Committee at Edith Cowan University
subjects will be free to withdraw from the study at any time. Contact number, should there be any
concerns relating to the project, is (08) 6304 2170 or Email: research.ethics@ecu.edu.au.
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Appendix C Statement of Informed Consent
A RANDOMIZED CONTROLLED TRIAL OF EXERCISE TO REDUCE TREATMENT SIDE-EFFECTS IN MEN
RECEIVING THERAPY FOR PROSTATE CANCER
STATEMENT OF INFORMED CONSENT

1. I have read and understood the ‘Information Sheet’ for this study.
2. The nature and possible effects of the study have been explained to me.
3. I understand that the study involves the following procedures:
a. I will be required to obtain my doctors approval to undertake the study before any
measures or training can take place.
b. I will be randomly assigned to undertake one of the following three exercise programs for
12 months: (1) resistance/impact-loading exercise, (2) usual care/delay exercise group, or
(3) resistance/cardiovascular exercise.

c. I will be required to have my height, weight, body composition, blood analysis
(PSA, hormones, cholesterol), blood pressure, cardiorespiratory capacity, and bone
density taken before, at 6 months and after the study (month 12).
d. I will be required to complete a medical history before the training program
commences and a quality of life and fatigue questionnaire before, at 6 months and
after the study period (12 months).
e. I understand that my muscle strength will be assessed before, at 6 months and
after the study period (12 months).
f. I understand that the following measures of physical function: the time to climb a
flight of stairs, the time it takes to walk backwards 6 meters, the time it takes to
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rise from a chair and to walk 400 meters and my balance ability will be assessed
before, at 6 months and after the study period (12 months).
4 I understand that all research data will be treated as confidential.
5 Any questions that I have asked have been answered to my satisfaction.
6 I agree to participate in this study and understand that I can withdraw at any time
without prejudice.
7 I agree that research data gathered for the study may be published provided that I
cannot be identified as a subject.
This study has been approved by Human Research Ethics Committee at Edith Cowan University
contact number, should there be any concerns relating to the project, is (08) 6304 2170 or Email:
research.ethics@ecu.edu.au.

Name of subject (please Print) ______________________________________________
Signed _________________________________________

Date _________________

Contact Phone Number
____________________________________________________

Witness (Name, please print) _______________________________________________
Signed _________________________________________
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Date _________________

Appendix D Medical Doctor Consent Form
MEDICAL DOCTOR CONSENT FORM FOR EXERCISE STUDY
“A RANDOMIZED CONTROLLED TRIAL OF EXERCISE TO REDUCE TREATMENT
SIDE-EFFECTS IN MEN RECEIVING THERAPY FOR PROSTATE CANCER”

Researchers
Professor Robert Newton, PhD
E-mail: r.newton@ecu.edu.au
Phone: 08 6304- 5711
Dr. Dennis Taaffe, PhD
E-mail: dtaaffe@hms.uq.edu.au Phone: 07 3346-7904
Dr. Daniel Galvão, PhD
E-mail: d.galvao@ecu.edu.au
Phone: 08 6304-3420
Assoc/Professor Nigel Spry, MBBS, Radiation Oncologist E-mail: Nigel.Spry@health.wa.gov.au
Professor Frank Gardiner, MBBS, Medical Urologist
E-mail: f.gardiner@uq.edu.au

School of Exercise, Biomedical and Health Sciences, Edith Cowan University
and School of Human Movement Studies, The University of Queensland
Dear Doctor,
The School of Exercise, Biomedical and Health Sciences, Edith Cowan University and
School of Human Movement Studies, The University of Queensland are undertaking a
study into the effects of exercise in older adults undertaking ADT (Androgen Deprivation
Therapy) for prostate cancer. The intervention program will run for 12 months, entailing
various combinations of progressive resistance (strength/weight) training, weight
bearing/impact loading, stretching and aerobic exercises. Resistance exercise has been
shown to be a safe and effective method for enhancing muscle strength in older adults.
Preliminary studies have reported benefits from resistance exercise in prostate cancer
patients undertaking ADT. However, the combined effects of both aerobic and resistance
exercises and the inclusion of weight bearing/impact loading activities for this group of
patients are yet to be examined. Such strategies could counteract the musculoskeletal
treatment-related side effects (e.g. osteoporosis) and the newly reported adverse effects
from ADT on cardiovascular and glucose metabolism. We require one hundred and ninetyfive prostate cancer patients with at least 2 months past initiation of ADT and anticipated
to remain hypogonadal for the duration of the study. Participants are required to not have
bone metastases, musculo-skeletal, neurological or cardiovascular disorder that could
inhibit them from exercising and to not have participated in regular (e.g. 2 to 3 times per
week) resistance training in the previous 12 months. Participants will be randomly
assigned to one of three groups: (1) resistance/impact-loading exercise, (2) usual

204

care/delay exercise group, and (3) resistance/cardiovascular exercise groups. The
resistance exercise and major muscles used in the intervention will be:
1. Chest Press: Pectorals, Deltoid, Triceps Brachii
2.
3.
4.
5.
6.
7.

Seated Rows: Rhomboids, Latisimus Dorsi, Biceps Brachii
Biceps curl: Biceps Brachii, Brachialis
Triceps extension: Triceps Brachii
Leg Press: Quadriceps, Gluteals, Hamstrings
Leg Curls: Hamstrings
Leg Extensions: Quadriceps

Exercise sessions will commence with a 5-minute warm-up of aerobic activity and stretching and
conclude with a 5-minute cool-down period that includes exercises for the abdominal and
stretching. The exercise sessions will be undertaken at Edith Cowan University Sports and Exercise
Centre (Mount Lawley, Joondalup, or Bunbury Campus) and at The University of Queensland
(School of Human Movement Studies), using traditional resistance training machines to ensure
participant safety. The impact-loading regime involves several activities shown to be safe and
effective to maintain bone in older women, such as bounding and hopping. The aerobic
component of the training session will incorporate 20-30 minutes of aerobic exercise at an
intensity of 60-85% of heart rate maximum (a heart rate monitor will be worn). Exercise mode will
alternate between rowing, cycle and treadmill ergometers. All sessions will be conducted in small
groups of up to 10 participants under direct supervision to ensure proper technique and minimize
the risk for injury. The total time to complete the exercise session will be less than 60 minutes.
Outcome measures in the study include muscle strength and endurance, cardiorespiratory
capacity, blood pressure, body composition, hip and spine bone density, and functional abilities
(e.g. 400-metre walk, balance test, time to rise from a chair), which are all standard measures in
studies of older adults, as well as testosterone, PSA, cholesterol, insulin, glucose and quality of life.
Participants must meet all the following criteria to participate:
(1) Undertaking ADT for at least 2 months
(2) Non-bone metastases
(3) No established osteoporosis or undertaking medication known to affect bone metabolism, such
as bisphosphonates
(4) No musculo-skeletal, cardiovascular or neurological disorder that could inhibit them from
exercising
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The study has been approved by Human Research Ethics Committee at Edith Cowan
University and subjects will be free to withdraw from the study at any time. The concern
of the principle investigators are of past and/or present medical conditions that may
compromise the individual’s ability to participate in the intervention, whether they be
musculo-skeletal, neurological, cardiovascular, etc. in origin. For these reasons all
potential participants have been asked to seek their medical doctor’s approval prior to
involvement in the study.
Should you require further information, please feel free to contact us by phone or by e-mail.

Sincerely,

Robert Newton, Dennis Taaffe, Daniel Galvão, Nigel Spry and Frank Gardiner

_____________________________is in sufficient health to participate in the above
intervention study.
(Participant)

_________________________________

___________________________

(Doctor’s signature)

(Date)

_______________________________________

(Doctor’s name)
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Appendix E Urologist Letter
“A RANDOMIZED CONTROLLED TRIAL OF EXERCISE TO REDUCE TREATMENT
SIDE-EFFECTS IN MEN RECEIVING THERAPY FOR PROSTATE CANCER”
Dear Urologist,
This letter is to advise you that your patient is currently an active participant in a NHMRC
funded research study being conducted jointly by the School of Exercise, Biomedical and
Health Sciences, Edith Cowan University and the School of Human Movement Studies, The
University of Queensland. Your patient has been referred to us by our collaborative
researchers, Prof Nigel Spry and Prof David Joseph from Sir Charles Gardiner Hospital.
We are currently undertaking a study into the effects of exercise in older adults
undertaking ADT (Androgen Deprivation Therapy) for prostate cancer. The intervention
program runs for 12 months, entailing various combinations of progressive resistance
(strength/weight) training, weight bearing/impact loading, stretching and aerobic
exercises. Resistance exercise has been shown to be a safe and effective method for
enhancing muscle strength in older adults and previous work within our institutions has
reported benefits from resistance exercise and combined resistance and aerobic exercise
in prostate cancer patients undertaking ADT. Findings from our latest research, currently
in press in the Journal of Clinical Oncology, showed a significant decrease in typical side
effects associated with ADT such as reduced levels of fatigue, increased lean muscle mass,
and improved overall quality of life.
However, the combined effects of resistance exercises and the inclusion of weight
bearing/impact loading activities for this group of patients are yet to be examined. Such
strategies could counteract the musculoskeletal treatment-related side effects (e.g.
osteoporosis and premature sarcopenia). Furthermore, increased research into aerobic
the adaptations is necessary with new evidence that this can reduce adverse effects from
ADT on cardiovascular and glucose metabolism.
The concern of the principle investigators are of past and/or present medical conditions
that may compromise the individual’s ability to participate in the intervention, whether
they be musculo-skeletal, neurological, cardiovascular, etc. in origin. For these reasons all
potential participants have been asked to seek their medical doctor’s approval prior to
involvement in the study.
Should you require further information or wish to refer other existing patients, please feel
free to contact our research assistant and exercise physiologist Greg Levin by email
(g.levin@ecu.edu.au) or on our dedicated phone line (6304 2329).
Sincerely,
Robert Newton, Dennis Taaffe, Daniel Galvão, Nigel Spry and Frank Gardiner
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Appendix F Health History Questionnaire and Demographics
“A RANDOMIZED CONTROLLED TRIAL OF EXERCISE TO REDUCE
TREATMENT SIDE-EFFECTS IN MEN RECEIVING THERAPY FOR
PROSTATE CANCER”
Medical History and Medications Questionnaire
_____________________________________________________________________________________
Last Name
First Name
Middle Initial
_____________________________________________________________________________________
Date of Birth (Age)

Sex

Home Phone

_____________________________________________________________________________________
Address

City, state

Post code

_____________________________________________________________________________________
Family Physician
_____________________________________________________________________________________
Emergency Contact (Name)

Phone

Relationship

MEDICAL HISTORY
GENERAL
1) Smoking
(a) Are you or have you ever been a smoker? Yes / No.
(b) Past / Current smoker? ________________________
(c) Age you started smoking: _______________________
(d) Age you quit smoking (for past smokers only): _____________________
(e) Average number of cigarettes smoked per day: ______________________

2) Drinking (alcohol)
(a) How many drinks do you usually have per week? _____________________
3) Body weight
(a) Has your weight fluctuated more than a few kilos in the last 12 months? Yes / No.
(b) If ‘Yes’, approximately how many kilograms? ________________________
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4) Physical activity
(a) What is your current level of physical activity? Active/ Inactive. Details:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

5) Medical condition
(a) When were you diagnosed with prostate cancer?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

(b) Which types of treatments have you undertaken (or are currently undertaking),
example: Androgen deprivation therapy or hormonal therapy, radiation therapy, and/
or surgery? Please, specify the start date of each treatment and the duration treatment?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

(c) Do you know your PSA levels? When was the last time that your PSA levels were?
assessed?
______________________________________________________________________________________
______________________________________________________________________________________
(d) Do

you have any other medical conditions? (chronic or serious illness) Yes /No.
Details:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
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(e) Have you ever had any medical surgery? Yes /No. Details:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

6) Bones
(a) Have you been tested for osteoporosis before (DXA scan)? Yes / No
(b) What were the results? Normal bone density / Osteopenia / Osteoporosis
(c) Have you been placed on any medications to help strengthen your bones?
(i.e Fosamax, Actonel, Calcitriol) Yes / No (Include details of medications in
Medications Questionnaire.):_________________
(d) Has your doctor recommended you do anything else to improve your bone density?
(i.e. weight bearing exercise, calcium supplements) Yes /No. Details:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

(e) Have you ever broken a bone as a result of minor trauma? (including vertebral crush
fractures) Yes / No. Details:
_______________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________

AT THE PRESENT
(a) Do you experience shortness of breath while walking with others of your age?
Yes / No
(b) Do you experience sudden tingling, numbness, or loss of feeling in arms, hands, legs,
feet, or face?
Yes / No
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(c) Do you experience swelling of your feet and ankles?
Yes / No
(d) Do you get pains or cramps in your legs?
Yes / No
(e) Do you experience any discomfort in your chest?
Yes / No
(f) Have you ever been told that your blood pressure was abnormal? (If yes, do you
currently take any medication?)
Yes / No
(g) Have you ever been told that your serum cholesterol or triglyceride level was high?
Yes / No
(h) Do you have diabetes? (If yes, how is controlled?)
Yes / No. Details:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

MEDICATIONS
Please list below medications you are currently taking. Fill out every column for each
medication you list.
MEDICATION

DURATION

Reason for taking (which medical

(in months and years)

condition) and other comments
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A randomized control trial of exercise to reduce treatment side-effects in
men receiving therapy for prostate cancer
Demographic and Supplementary Medical Questionnaire
1. What is your current marital status?
Single
Married
Separated
Divorced

Defacto
Widowed

2. What is the highest level of education you have completed?
Primary
Secondary
Trade
Certificate/Diploma
Bachelor degree
Higher degree
Other ___________
3. Are you currently employed?
Yes / No
3b. If Yes:
Full Time / Part Time
What is your occupation? ____________________________
4. Have you previously been treated for Prostate Cancer?
Yes / No
4b. If Yes, which of these treatment options did you previously receive?
(please mark all appropriate options)
Radiation

Brachytheraphy

Chemotherapy

Surgery
Radical Prostatectomy
Orchidectomy

Hormone Therapy
Injection
Tablet

5. Do you know what your Gleason Score (prostate biopsy) is?
2

3

4

5

6

7

8
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9

10

Appendix G Training Day Log
Session
Day
Date
Upper body
Chest Press
Seated Row
Shoulder Press
Lat Pull
Triceps
extension
Biceps curl
Lower Body
Incline Leg
Press
Leg Curl
Leg Extension
Seated Calf
Raise
Trunk
Abdominal
Crunch
Other
Stretches
Warm-up
Cool-down
Aerobic
Bike
Heart Rate/RPE
Rowing
Heart Rate/RPE
Treadmill

1

2

3

4

Reps/Wt

Reps/Wt

Reps/Wt

Heart Rate/RPE
Training heart rate:
Observations:
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5

6

7

8

9

10

